---
document_datetime: 2025-04-10 14:24:37
document_pages: 83
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/darzalex-h-c-004077-ii-0076-epar-assessment-report-variation_en.pdf
document_name: darzalex-h-c-004077-ii-0076-epar-assessment-report-variation_en.pdf
version: success
processing_time: 121.4914352
conversion_datetime: 2025-12-24 05:10:11.886571
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

27 February 2025 EMA/CHMP/96363/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Darzalex

International non-proprietary name: Daratumumab

Procedure No. EMEA/H/C/004077/II/0076

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                      | ..................................................................................................7       |
| 1.2. Steps taken for the assessment of the product.........................................................8                |                                                                                                           |
| 2. Scientific discussion ................................................................................8                  |                                                                                                           |
| 2.1. Introduction.........................................................................................................8 |                                                                                                           |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................9             |
| 2.1.2. About the product............................................................................................11      |                                                                                                           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......11                                                                                                  |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................11                                               |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................12      |
| 2.3.1. Introduction....................................................................................................12   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................13      |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................21         |                                                                                                           |
| 2.3.4. Discussion on clinical                                                                                               | pharmacology...................................................................25                         |
| 2.3.5. Conclusions on clinical pharmacology.................................................................27              |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................27      |
| 2.4.1. Dose response study........................................................................................27        |                                                                                                           |
| 2.4.2. Main study......................................................................................................27   |                                                                                                           |
| 2.4.3. Discussion on clinical efficacy............................................................................53        |                                                                                                           |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................56          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................56    |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................75                          |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................76                            |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................76   |
| 2.6. Risk management plan........................................................................................77         |                                                                                                           |
| 2.7. Update of the Product information                                                                                      | ........................................................................79                                |
| 2.7.1. User consultation.............................................................................................79     |                                                                                                           |
| 3. Benefit-Risk Balance..............................................................................79                     |                                                                                                           |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................79             |
| 3.1.1. Disease or condition.........................................................................................79      |                                                                                                           |
| 3.1.2. Available therapies and unmet medical need.......................................................80                  |                                                                                                           |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................80               |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................80          |
| 3.3. Uncertainties and limitations about favourable effects.............................................81                  |                                                                                                           |
| 3.4. Unfavourable effects...........................................................................................81      |                                                                                                           |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................81                                                               |
| 3.6. Effects Table......................................................................................................81  |                                                                                                           |
| 3.7. Benefit-risk assessment and discussion.................................................................82              |                                                                                                           |
| 3.7.1. Importance of favourable and unfavourable effects..............................................82                    |                                                                                                           |
| 3.7.2. Balance of benefits and risks.............................................................................82         |                                                                                                           |
| 3.8. Conclusions                                                                                                            | .......................................................................................................82 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations .................................................................................  83 5. EPAR changes  ........................................................................................  83

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADAs         | anti-daratumumab antibodies                                             |
|--------------|-------------------------------------------------------------------------|
| ADR          | adverse drug reaction                                                   |
| AE           | adverse event                                                           |
| ALCYONE      | Study 54767414MMY3007                                                   |
| AL           | amyloidosis light chain amyloidosis                                     |
| ASCT         | autologous stem cell transplant                                         |
| ATC          | Anatomical Therapeutic Chemical                                         |
| CCDS         | Company Core Data Sheet                                                 |
| CCO          | clinical cutoff                                                         |
| CD38         | cluster of differentiation 38                                           |
| CEPHEUS      | Study 54767414MMY3019                                                   |
| CHMP         | Committee for Medicinal Products for Human Use                          |
| CI           | confidence interval                                                     |
| CL           | clearance                                                               |
| COVID-19     | Coronavirus disease 2019                                                |
| CR           | complete response                                                       |
| CSR          | clinical study report                                                   |
| Cmax         | maximum concentration                                                   |
| Cpeak,first  | predicted peak concentration after the first dose                       |
| Cpeak,max    | predicted maximum peak concentration                                    |
| Cpeak,q4w    | predicted peak concentration over the period of Cycle 9                 |
| Ctrough      | trough concentration                                                    |
| Ctrough,C3D1 | predicted trough concentration on Cycle 3 of Day 1                      |
| Ctrough,max  | predicted maximum trough concentration                                  |
| Ctrough,q4w  | predicted trough concentration in Cycle 9                               |
| DRd          | daratumumab- lenalidomide-dexamethasone                                 |
| D-VMP        | daratumumab-bortezomib-melphalan-prednisone                             |
| D-VRd        | daratumumab SC, bortezomib, lenalidomide, and dexamethasone             |
| ECOG         | Eastern Cooperative Oncology Group                                      |
| EHA-ESMO     | European Hematology Association - European Society for Medical Oncology |
| E-R          | exposure-response                                                       |
| FLC          | free light chain                                                        |

<div style=\"page-break-after: always\"></div>

| FOIA    | Freedom of Information Act                                                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------|
| GOF     | goodness-of-fit                                                                                                              |
| HBV     | hepatitis B virus                                                                                                            |
| HDT     | high-dose chemotherapy                                                                                                       |
| HRQoL   | health-related quality of life                                                                                               |
| IDMC    | Independent Data Monitoring Committee                                                                                        |
| ICH GCP | International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice |
| IgG     | immunoglobulin G                                                                                                             |
| IMWG    | International Myeloma Working Group                                                                                          |
| IRR     | injection-related reaction                                                                                                   |
| ISR     | injection site reaction                                                                                                      |
| ISS     | International Staging System                                                                                                 |
| MAIA    | Study 54767414MMY3008                                                                                                        |
| MAP     | maximum a posteriori                                                                                                         |
| MedDRA  | Medical Dictional for Regulatory Activities                                                                                  |
| MM      | multiple myeloma                                                                                                             |
| MPT     | melphalan, prednisone, and thalidomide                                                                                       |
| MRD     | minimal residual disease                                                                                                     |
| NCCN    | National Comprehensive Cancer Network                                                                                        |
| NDMM    | newly diagnosed multiple myeloma                                                                                             |
| NGS     | next generation sequencing                                                                                                   |
| OR      | odds ratio                                                                                                                   |
| ORR     | overall response rate                                                                                                        |
| OS      | overall survival                                                                                                             |
| pcVPC   | prediction-corrected visual predictive check                                                                                 |
| PD      | pharmacodynamics                                                                                                             |
| PERSEUS | Study 54767414MMY3014                                                                                                        |
| PFS     | progression-free survival                                                                                                    |
| PFS2    | progression-free survival on the next line of therapy                                                                        |
| PK      | pharmacokinetic                                                                                                              |
| PPK     | population pharmacokinetics                                                                                                  |
| Rd      | lenalidomide-dexamethasone                                                                                                   |

<div style=\"page-break-after: always\"></div>

| rHuPH20   | recombinant human hyaluronidase             |
|-----------|---------------------------------------------|
| RRMM      | relapsed/refractory multiple myeloma        |
| SAE       | serious adverse event                       |
| sARR      | systemic administration-related reaction    |
| SC        | subcutaneous                                |
| sCR       | stringent complete response                 |
| SOC       | system organ class                          |
| SMQ       | Standardized MedDRA Query                   |
| TEAE      | treatment-emergent adverse event            |
| TD        | transplant deferred                         |
| TIE       | transplant-ineligible                       |
| VGPR      | very good partial response                  |
| VMP       | bortezomib, melphalan, and prednisone       |
| VRd       | bortezomib, lenalidomide, and dexamethasone |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International N.V. submitted to the European Medicines Agency on 10 October 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma, to include also adult patients who are not eligible for stem cell transplant (SCT), based on the results of the final PFS analysis from Study CEPHEUS (54767414MMY3019), a randomised, open-label, active-controlled, multicenter phase 3 study in adult participants, comparing the clinical outcome of D-VRd with VRd in participants with untreated multiple myeloma for whom stem cell transplant is not planned as initial therapy, in terms of the primary endpoint of MRD negativity rate in participants with CR or better rate and major secondary endpoints of CR or better rate, PFS and sustained MRD negativity.

As a consequence, SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 are updated and the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representatives in the Package Leaflet.

An updated RMP version 11.1 has also been submitted.

## Information relating to orphan designation

Darzalex, was designated as an orphan medicinal EU/3/13/1153 on 17 July 2013. Darzalex was designated as an orphan medicinal product in the following indication:

- Treatment of plasma cell myeloma

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0264/2017 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## Protocol assistance

The MAH did not seek Protocol Assistance from the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Boje Kvorning Pires Ehmsen

Co-Rapporteur:

&lt;N/A&gt;

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 10 October 2024  |
| Start of procedure:                                  | 2 November 2024  |
| CHMP Rapporteur Assessment Report                    | 2 January 2025   |
| PRAC Rapporteur Assessment Report                    | 6 January 2025   |
| PRAC members comments                                | 8 January 2025   |
| PRAC Outcome                                         | 16 January 2025  |
| CHMP members comments                                | 20 January 2025  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 22 January 2025  |
| Request for supplementary information (RSI)          | 30 January 2025  |
| CHMP Rapporteur Assessment Report                    | 12 February 2025 |
| CHMP members comments                                | 17 February 2025 |
| Updated CHMP Rapporteur Assessment Report            | 20 February 2025 |
| Opinion                                              | 27 February 2025 |

## 2. Scientific discussion

## 2.1. Introduction

The MAH submitted an application to modify the approved indication of DARZALEX 1800 mg solution for injection in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) in adult patients who  are  eligible  for  autologous  stem  cell  transplant  (ASCT)  by  removing  the  transplant  eligibility requirement.

This  application  is  based  upon  the  results  of  the  final  PFS  analysis  from  the  pivotal  phase  3  study CEPHEUS (54767414MMY3019).

<div style=\"page-break-after: always\"></div>

## 2.1.1. Problem statement

## Claimed therapeutic indication

The newly proposed indication is: \"DARZALEX is indicated in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma\".

## Epidemiology

Multiple myeloma (MM), a malignant disorder of the plasma cells, characterized by uncontrolled and progressive proliferation of a plasma cell clone, is estimated to represent 1.0% to 1.8% of all new cancer cases worldwide and approximately 10% of hematological malignancies (Sung 2021; SEER 2022). In 2020, an estimated 176,404 patients were diagnosed with multiple myeloma globally, with a crude incidence rate of 2.3 cases per 100,000 persons and a world population age-standardized incidence rate of 1.8 cases per 100,000 persons (Ferlay 2020). In the EU-27 countries, the 2022 crude incidence rate was 7.9 cases per 100,000 persons, and the European population age-standardized incidence rate was 7.3 cases per 100,000 persons. The estimated number of new cases for the EU overall was 35,333 cases in  2022.  In  general,  Western  Europe  had  the  highest  incidence  rates  of  multiple  myeloma.  Crude incidence  rates  ranged  from  3.0 per  100,000  persons  in  Bulgaria  to  11.3  per  100,000  persons  in Denmark (European Cancer Information System 2023).

Despite  the  significant  improvement  in  patients'  survival  in  the  recent  decades,  only  10%-15%  of patients  achieve  expected  survival  compared  with  the  matched  general  population  (Usmani,  Blood Cancer J. 2018).

The median age at diagnosis of MM is approximately 70 years (Palumbo 2011).

## Biologic features

The proliferation of the malignant clonal plasma cells leads to subsequent replacement of normal bone marrow  hematopoietic  precursors  and  overproduction  of  monoclonal  proteins.  Multiple  myeloma  is characterized by osteolytic lesions, usually in the pelvis, spine, ribs, and skull. Lesions are caused by expanding  plasmacytomas  or  by  cytokines  secreted  by  myeloma  cells  that  activate  osteoclasts  and suppress  osteoblasts.  Increased  bone  loss  may  also  lead  to  hypercalcemia.  Solitary  extraosseous plasmacytomas are unusual but may occur in any tissue. In many patients, renal failure is present at diagnosis or develops during the course of the disorder and is caused by the deposition of light chains in the distal tubules or by hypercalcemia. Patients also often develop anaemia due to kidney disease or suppression of erythropoiesis by cancer cells. These signs and symptoms are commonly denoted by the mnemonic acronym CRAB: Calcemia, Renal damage, Anaemia, and Bone lesions (Palumbo 2011).

## Management

Different classes of drugs are approved for multiple myeloma (alkylators, steroids, proteasome inhibitors [PIs],  immunomodulatory  agents  [IMiDs],  histone  deacetylase  inhibitors  [HDACIs]  and  monoclonal antibodies).  Among  these  treatment  options,  lenalidomide  (an  IMiD)  and  bortezomib  (a  PI)  have  a prominent role. Both are approved and used as frontline treatment of multiple myeloma and used in combination with other drugs at relapse. Lenalidomide is also approved as maintenance therapy after ASCT in patients with NDMM.

<div style=\"page-break-after: always\"></div>

Treatment choices for multiple myeloma vary with age, performance status, comorbidity, aggressiveness of  the  disease,  and  related  prognostic  factors  (Palumbo  2011).  Patients  with  NDMM  are  typically categorized into 2 subpopulations: Eligible for ASCT or transplant ineligible. Eligibility is usually defined by age and suitability for intensive treatment. Patients will typically receive an induction regimen followed by treatment with ASCT, followed by consolidation therapy and maintenance treatment. For those not considered eligible for ASCT, longer-term treatment with multiagent combinations, including alkylators, steroids,  and  agents  such  as  PIs  (e.g.,  bortezomib)  and  IMiDs  (e.g.,  lenalidomide)  are  currently considered standards of care.

Over the past two decades, the introduction of new classes of drugs, such as PIs and IMiDs, have changed the management of frontline treatment in both transplant and nontransplant candidates (Kumar 2023 [NCCN  Guidelines];  Durie  2017;  Dimopoulos  2021  [ESMO  Guidelines];  Cavo 2011;  Palumbo 2014). Studies have indicated that multidrug combinations are superior to single- or double-agent combinations in treating multiple myeloma (Cavo 2012; van der Veer 2011).

The addition of new drugs to available regimens, or combinations of new drugs, improves depth of response, which in turn has been correlated with increased PFS and OS  (Lahuerta 2008; Harousseau 2010;  Chanan-Khan  2010;  Dingli  2007).  Contingent  on  the  premise  that  the  combined agents  have  nonoverlapping  and  synergistic  mechanisms  of  actions,  the  immediate  and  effective targeting of the tumours with multiple agents appears to be a successful strategy in improving the clinical outcome of multiple myeloma therapy.

The availability of different efficacious multiagent regimens has provided clinicians with the opportunity of tailoring treatment for each patient. Selection is based on patients' comorbidities and biologic age, as well  as  the  expected  toxicity  profiles  of  each  treatment  regimen  (Gay  2011).  However,  despite  the significant progress that has been made in the management of multiple myeloma, the disease relapses and it remains an incurable malignancy. Therefore, new treatment options and combinations directed at alternative mechanisms of action remain needed for these patients.

## Patients with NDMM ineligible for ASCT

Patients with NDMM are typically categorized as 'transplant-eligible' or 'transplant-ineligible' (TIE). For patients not considered eligible for high-dose chemotherapy and ASCT (TIE) or for whom transplant was not planned as initial therapy, the current standard of care is longer-term treatment with triplet or quadruplet combinations. Current frontline standards of care recommended for these patients in the EHA-ESMO Guideline include daratumumab plus Lenalidomide and dexamethasone D-Rd), bortezomib plus lenalidomide and dexamethasone (VRd), daratumumab plus bortezomib plus melphalan plus prednisone (D-VMP), bortezomib plus melphalan and prednisone, (VMP), and lenalidomide plus dexamethasone (Rd), commonly on a treat-to-progression or unacceptable toxicity basis (Dimopoulos 2021).

## Daratumumab in NDMM

Daratumumab has demonstrated efficacy when added to multiple combination regimens in the frontline setting, including in TIE patients in combination with Rd (Study 54767414MMY3008, hereafter referred to as MAIA) and VMP (Study 54767414MMY3007, hereafter referred to as ALCYONE). Data from MAIA and ALCYONE demonstrated a statistically significant improvement in PFS and OS with D-Rd (compared with Rd alone ([MAIA]) and D-VMP (compared with VMP alone [ALCYONE]).

Treatment  with  D-VRd  in  Study  54767414MMY3014  (hereafter  referred  to  as  PERSEUS)  resulted  in statistically significant improvements in PFS, overall CR or better rate, and overall MRD negativity rate compared with VRd alone in the NDMM-TE setting.

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

Daratumumab is a human mAb that binds with high affinity to CD38, a transmembrane glycoprotein expressed on tumour cells, and induces tumour-cell death through multiple mechanisms of action. These mechanisms of action include several immune-mediated activities, including complementdependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, antibody dependent cellular phagocytosis, and direct cytotoxicity by induction of apoptosis by Fc γ receptor-mediated crosslinking of tumour-bound mAbs (Overdijk 2016).

Daratumumab is approved as monotherapy in subjects with relapsed and refractory multiple myeloma and in combination with standard of care regimens for transplant-ineligible and transplant-eligible newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The sponsor sought Scientific Advice from CHMP on the design of the pivotal study of this application.

Key points regarding study MMY3016 are summarized here:

1. The MAH was asked about plans to stratify the study population. The MAH confirmed that patients would  be  stratified  for  age  and  ISS  and  an  additional  stratification  factor  would  also  be considered.
2. The SAWP expressed concerns about patients that are anticipated to refuse transplant in the proposed study. The MAH estimated that approximately 20% of patients, primarily from the US, would fall under this category but the percentage of European patients would be lower (although would vary between countries). To address this concern, the MAH considered stratifying patients and conducting subgroups analyses.
3. The primary endpoint for study MMY3019 (previously referred to as study MMY3016) was PFS at the time of SA. However, before enrolment of the first patient the protocol had been changed resulting in overall MRD negativity rate becoming the primary endpoint and PFS becoming a key secondary endpoint along with overall CR or better rate and sustained MRD negativity rate. The MAH did not seek new scientific advice regarding this change in trial design.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Daratumumab is a monoclonal antibody and is consequently classified as a naturally occurring substance . In accordance with the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00 Revision 1), the MAH submitted a justification for not submitting ERA studies and it was agreed that daratumumab is unlikely to pose a risk to the environment. Consequently, no Environmental Risk Assessment studies for daratumumab were required for this application.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

| Study ID EudraCT Number First Patient First Visit / Completion date (day Month year)       | Countries/ Territories: Number of                                                                                  | Phase Study Description/Design, Study Population, Primary Objective(s)                                                                                                                                                            | Total Number of Participants   | StudyDrug(s):Formulation(Route of Administration) Dose Regimen Duration of Treatment                                                                                                                                                                                                                                                                                                                                                                                                         | Number of Participants Treated (by Treatment Group)   | Type of StudyReport Issue Date Document ID Number CTD Location of Report or Publication                                                                |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Status 54767414MMY3019 (CEPHEUS) Synopsis 2018-001545-13 15 November 2018 NA Ongoing | Centers Brazil, Canada, Czechia, France, Germany, Israel, Japan, Netherlands, Poland, Spain, Turkey, UK, and US 98 | Phase 3 Randomized,open label, multicenter study Participants with NDMM for whom ASCT is not planned as initial therapy To determine if the addition of daratumumab toVRd improves overall MRD negativity compared with VRd alone | Randomized: 395 Treated: 392   | Treatment Am A (VRd): Bortezomib SC 1.3 mg/m² twice weckly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8 Lenalidomide PO at 25 mg daily on Days 1 through 14 of cach 21-day cycle for Cycles 1-8. During Cycles 9 and beyond, lenalidomide PO at 25 mg daily on Days 1 through 21 of each 28-day cycle Dexamethasone PO at 20 mg Days 1,2,4,5,8,9,11,12of each 21-day cycle for Cycles 1-8 In Cycle 9 and beyond, dexamethasone PO at 40 mg onDays1,8,15,22ofeach 28-day cycle | VRd: 195 D-VRd: 197                                   | Full Report (combined results of the primary MRD analysis, interim PFS analysis, and final PFS Analysis) 12 August 2024 EDMS-RIM-387751 Module 5.3.5.1 |
| Study Status 54767414MMY3019 (CEPHEUS) Synopsis 2018-001545-13 15 November 2018 NA Ongoing |                                                                                                                    |                                                                                                                                                                                                                                   |                                | Treatment Am B (D-VRd):                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                       |                                                                                                                                                        |

KEY:ASCT=autologous stem cell transplant;CTD=common technical document;D-VRd=daratumumab,bortezomib,lenalidomide,dexamethasone;MRD=minimal residual disease; NDMM= newly diagnosed multiple myeloma; PFS=progression-free survival; PO=per oral; SC=subcutaneous; VRd=bortezomib, lenalidomide, dexamethasone.

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

The clinical pharmacology of daratumumab SC has been well characterized as monotherapy and in combination with a variety of background therapies for participants with MM, with the PK and pharmacodynamics of daratumumab summarized in previous submissions. Clinical pharmacology information provided in the current submission focuses on evaluable data from participants treated with D-VRd in CEPHEUS in addition to PERSEUS data, to support a new indication of daratumumab SC in combination with VRd (D-VRd) for the treatment of patients with NDMM.

## Population PK

The  final  Population  PK  (PopPK)  dataset  contained  a  total  of  851  from  a  total  of  197  PK-evaluable participants from CEPHEUS.

A sensitivity analysis was performed to verify that PK values obtained after final DBL (05 June 2024) were consistent with PK values obtained from the DBL on 19 December 2022. The sensitivity analysis was based on 858 daratumumab serum PK samples from the 197 participants. 7 PK samples from later cycles were added in the dataset after final DBL (05 June 2024).

A previously developed IV/SC PopPK model for daratumumab using data from participants with NDMM is  used  in  the  current  PopPK  analysis  to  conduct  the  external  evaluation  to  verify  the  predictive performance of the previously developed PPK model with the current clinical SC PK data.

In the previously developed PPK model for NDMM, daratumumab was described by a 2-compartment PPK  model  with  first-order  absorption  and  parallel  linear  and  nonlinear  elimination  pathways. Daratumumab absorption was parameterized in terms of Ka and F1 for SC administration relative to IV administration. The PK parameters describing the daratumumab disposition were nonspecific linear CL, V1, Q, V2, Vmax, KDES, and Km. The interindividual variability in structural parameters was modelled with an exponential error model. The residual variability of daratumumab serum concentrations was modelled  on  the  log  scale  using  an  additive  residual  error  model.  The  corresponding  PK  parameter estimates of the final model are reported in Table 1 .

<div style=\"page-break-after: always\"></div>

Table 1. Parameter estimates of the PopPK model of daratumumab in participants with NDMM

| Parameter (Unit)   | Description                                                                                    |   Estimate | I0 %≤6                 |   %RSE | IIV (%CV)   | %RSE IIV   |
|--------------------|------------------------------------------------------------------------------------------------|------------|------------------------|--------|-------------|------------|
| CL (L/d)           | Linear clearance                                                                               |   0.103    | (0.0990; 0.107)        |  1.97  | 22.2        | 17.2       |
| ALB on CLa         | Effectofserumalbumin concentrationonlinearclearance                                            |  -0.232    | (-0.369; -0.0948)      | 30.2   |             |            |
| WT on CLa          | Effect of body weight on linear clearance                                                      |   1.04     | (0.888; 1.20)          |  7.59  |             |            |
| TPMC on CLa        | Effect of type of myeloma (IgG versus non-IgG) on linear clearance                             |   0.175    | (0.104; 0.245)         | 20.5   |             |            |
| V (L)              | Volumeofdistributioninthe central compartment                                                  |   6.71     | (6.44; 6.99)           |  2.12  | 19.1        | 18.4       |
| WT on V,b          | Effect of body weight on volume of distribution in the central compartment                     |   0.48     | (0.364; 0.596)         | 12.3   |             |            |
| SEX on V,b         | Effect of sex (female versus male) on volume of distribution in the centralcompartment         |  -0.098    | (-0.152; -0.0438)      | 28.3   |             |            |
| V2 (L)             | Volume of distribution in the peripheral compartment                                           |   3.84     | (3.62; 4.06)           |  2.89  |             |            |
| Q (L/d)            | Intercompartmentalclearance                                                                    |   0.0384   | (0.0360; 0.0409)       |  3.25  |             |            |
| Vmax (mg/h)        | Maximum velocity of the saturable clearance process                                            |   0.741    | (0.701; 0.782)         |  2.78  | 27.8        | 18.9       |
| KDes (L/h)         | First-order rate for decrease of maximum velocity of the saturable clearance process over time |   8.88e-05 | (0.0000820; 0.0000957) |  3.93  | 129         | 15.1       |
| Km (μg/mL)         | Michaelis-Menten constant                                                                      |   1.84     | (1.73; 1.96)           |  3.24  |             |            |
| Ka (L/h)           | First-order absorption rate                                                                    |   0.0176   | (0.0165; 0.0186)       |  3.11  | 54.2        | 13.0       |
| F1                 | Bioavailability for SC dose                                                                    |   0.591    | (0.572; 0.611)         |  1.71  | 44.0        | 16.9       |
| ADD ERR (%CV)      | Additive error term on the log- scale                                                          |  68.3      | (68.0 68.6)            |  0.412 |             |            |

- ADD ERR=additive error term on the log-scale; ALB=albumin; CI=confidence interval; CV=coefficient of variation; IgG=immunoglobulin G; IIV=interindividual variance; NDMM=newly diagnosed multiple myeloma; PK=pharmacokinetic(s); PPK=population pharmacokinetic(s); RSE=residual standard error; TPMCci=effect of value of volume of distribution; V1=central volume of distribution; WT=weight.
- TVCL = 0.103· W 1.04 ALB -0.232 · TPMCcL where TPMCcL is a shift factor of 1 for participants with non38 IgG multiple myeloma and 1 + 0.175 for participants with IgG multiple myeloma.
- 0.480 TVV1 = 6.71 · SEXv1, where SEXv1 is a shift factor of 1 for male and 1-0.0980 for female.

Note: Objective function value=-164.913. Condition number=18.7.

%RSE for IIV and ADD ERR are reported on the approximate standard deviation scale (standard error/variance estimate)/2.

%CV for IIV and ADD ERR are computed as sqrt(o²) and sqrt (o?), respectively.

- 95% CIs are calculated based on standard error from covariance matrix assuming PK parameters are normally distributed.

An external model evaluation was conducted to verify the predictive performance of the previous PopPK model in CEPHEUS participants with NDMM. The Goodness of Fit (GOF) plots and Prediction-Corrected Visual Predictive Checks (pcVPC) were used as external evaluation methods. GOF plots were generated by performing a maximum a posteriori (MAP) approach using current data with the previously estimated PPK model parameters as prior information ( Figure 1 ).

<div style=\"page-break-after: always\"></div>

Figure 1. GOF plots of the external validation model

<!-- image -->

Key:CONC=daratumumab serum concentration; CWRES=conditional weighted residuals; d=day: GOF=goodnessof-fit;IPRED=individual prediction of concentration;PRED=population model prediction.

Notes:Red solid line represents the data smoother.The blue and red dash line represent theprobability of95%and 99% cutoff,respectively.Blackline represents theline ofidentity for observed concentrations versus population prediction and individual prediction plots.For residual plots,blackline representshorizontal line crossing the y-axisatvalueofzero.

The evaluation with pcVPC was performed from 1,000 simulated replicates by using the previous PPK model parameters. Uncertainty in parameter estimates was excluded in these simulations ( Figure 2 ). The pcVPC stratified by body weight was reported to assess the adequacy of the model across this covariate  (data  not  shown). Figure  3 displays  a  forest  plot  of  subgroup  analysis  of  daratumumab Ctrough, C3D1 derived using MAP.

Figure 2. pcVPC of the external validation model

<div style=\"page-break-after: always\"></div>

<!-- image -->

Key:pcVPC=prediction-corrected visual predictive check.

Notes: Gray solid dots represent observations. The red solid and dashed lines represent the median and 5th and 95th percentiles of the observations; the black dashed lines represent the median and 5t and 95\" percentiles of the predictions; the shaded red and blue areas represent the 95% confidence interval of the median, 5t, and 95th percentiles predicted by the model, respectively.

Figure 3. Forest plot of subgroup analyses for daratumumab Cttough, C3D1 per the recommended dose schedule for D-VRd combination therapy

<!-- image -->

GeometricmeanratioforTroughConcentrationatCycle3Day1

Key: CI=confidence interval; Ctough,c3Di=predicted trough concentration on Cycle 3 of Day 1; D-VRd=daratumumab in combinationwithVELCADE?(bortezomib),Revlimid?(lenalidomide),and dexamethasone; ECOG=EastemCooperative OncologyGroup;GMR=geometricmeanratio;IgG=immunoglobulin G;

N=comparatornumberofparticipantsversusthereferencenumber ofparticipants.

Notes: Solid blue points represent GMR and short horizontal bars represent 90% CI. Dashed line represents reference value of 1. Shaded area spans represent the 80% to 125% range relative to the reference value. Values represent GMR and associated CI, adjusted for each covariate included in the analysis.

## Serum Daratumumab Concentrations Over Time

<div style=\"page-break-after: always\"></div>

The PK results from the D-VRd combination in CEPHEUS are summarised in Table 2 .

Table 2. Summary of Serum Daratumumab Concentration (µg/mL); PK-evaluable Analysis Set (MMY3019, CEPHEUS)

|                            | D-VRd        |
|----------------------------|--------------|
| Analysis set: PK-evaluable | 197          |
| Cycle 1 Day 1 (predose)    |              |
| N                          | 195          |
| Mean (SD)                  | BQL (-)      |
| Median                     | BQL          |
| Range                      | (BQL; BQL)   |
| CV (%)                     | -            |
| Geometric mean             | BQL          |
| Cycle 1 Day 4              |              |
| N                          | 180          |
| Mean (SD)                  | 93.8 (46.6)  |
| Median                     | 87.7         |
| Range                      | (BQL; 265)   |
| CV (%)                     | 49.6         |
| Geometric mean             | 79.6         |
| Cycle 3 Day 1 (predose)    |              |
| N                          | 178          |
| Mean (SD)                  | 407 (183)    |
| Median                     | 391          |
| Range                      | (9.39; 970)  |
| CV (%)                     | 45.0%        |
| Geometric mean             | 356          |
| Cycle 3 Day 4              |              |
| N                          | 169          |
| Mean (SD)                  | 524 (216)    |
| Median                     | 507          |
| Range                      | (BQL; 1163)  |
| CV (%)                     | 41.3%        |
| Geometric mean             | 438          |
| Cycle 9 Day 1 (predose)    |              |
| N                          | 141          |
| Mean (SD)                  | 289 (139)    |
| Median                     | 271          |
| Range                      | (BQL; 760)   |
| CV (%)                     | 48.0%        |
| Geometric mean             | 244          |
| Cycle 12 Day 1 (predose)   |              |
| N                          | 139          |
| Mean (SD)                  | 260 (121)    |
| Median                     | 239          |
| Range                      | (0.959; 708) |
| CV (%)                     | 46.4%        |
| Geometric mean             | 225          |
| Post-treatment Week 8      |              |
| N                          | 8            |
| Mean (SD)                  | 132 (231)    |
| Median                     | 18.8         |
| Range                      | (11.2; 682)  |
| CV (%)                     | 175.1%       |
| Geometric mean             | 42.3         |

Key: BQL=below quantification limit ( 0.2 μg/mL) ; CV=coefficient of variation; D-VRd=daratumumab in combination with bortezomib (VELCADE), lenalidomide, and dexamethasone; N=number of participants; PK=pharmacokinetic(s); QW=once every week; QxW=once per x weeks; SC=subcutaneous; SD=standard deviation.

Notes: Cycles 1 to 8 were 21 days in length while Cycle 9 and beyond are 28 days in length. Daratumumab 1800 mg SC was administered QW in Cycles 1 to 2, Q3W in Cycles 3 to 8, and Q4W thereafter. Geometric mean was calculated by using half of lowest quantifiable concentration in a sample (0.5*0.2 μg/mL) in place of BQL values (ie, 0.2 μg/mL).

<div style=\"page-break-after: always\"></div>

## Immunogenicity and PK

A low incidence (&lt;1%) of antibodies to daratumumab was reported in monotherapy and combination clinical  studies  of  daratumumab  SC  and  IV  in  participants  with  MM  to  date.  Consistent  with  other populations,  in  CEPHEUS,  1  (0.6%)  of  170  participants  in  the  daratumumab  SC  immunogenicityevaluable analysis set had treatment-emergent anti-daratumumab antibodies.

A  relatively  low  incidence  of  antibodies  to  rHuPH20  (&lt;10%)  was  reported  in  monotherapy  and combination clinical studies of daratumumab SC in participants with MM to date. In CEPHEUS, 12 (7.1%) of the 169 participants in the rHuPH20 immunogenicity-evaluable analysis set had treatment-emergent anti-rHuPH20 antibodies after the first administration of daratumumab SC. This is similar to previously reported incidence of anti-rHuPH20 antibodies for other therapeutic proteins administered with rHuPH20.

No clinically meaningful differences in the PK profiles of daratumumab SC were observed in participants who tested positive for anti-daratumumab and/or anti-rHuPH20 antibodies.

## Dose proportionality and time dependencies

Dose proportionality and time dependencies were evaluated in previous submissions. In this procedure, daratumumab is administered as a flat dose of 1800 mg in combination with rHuPH20 (2000 U/mL) and daratumumab drug substance (120 mg/mL) in a single vial.

## Special populations

## Serum Daratumumab Concentrations by Baseline Body Weight

The observed serum daratumumab concentrations were summarised by baseline body weight cutoffs (≤65 kg, &gt;65 to ≤85 kg, &gt;85 kg and ≤50 kg, &gt;50 to ≤85 kg, and &gt;85 kg) based on baseline body weight distribution in CEPHEUS and other daratumumab SC studies. In the PK evaluable population of CEPHEUS, the baseline body weight range was 40.4 to 125.0 kg, which was similar to that in other daratumumab  SC  studies.  Descriptive  statistics  for  serum  daratumumab  concentrations  at  various sampling  timepoints  for  PK-evaluable  participants  in  the  D-VRd  treatment  arm  are  summarized  by baseline body weight in

## Table 3 .

<div style=\"page-break-after: always\"></div>

Table  3 .  Summary  of  serum  daratumumab  concentration  (µg/mL)  following  SC  administration  of daratumumab in combination with VRd by body weight subgroups-CEPEUS; pK evaluable analysis set

|                           | D-VRd 1800 mg DaratumumabSC   | D-VRd 1800 mg DaratumumabSC   | D-VRd 1800 mg DaratumumabSC   | D-VRd 1800 mg DaratumumabSC   |
|---------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                           | Total                         | ≤50kg                         | >50t0≤85kg                    | >85kg                         |
| Analysis set: PK          | 197                           | 14                            | 145                           | 38                            |
| Cycle 1,Day 1 (Predose)   |                               |                               |                               |                               |
| N                         | 195                           | 14                            | 143                           | 38                            |
| Mean (SD)                 | BQL (-)                       | BQL (-)                       | BQL (-)                       | BQL (-)                       |
| Coefficient of variation  |                               |                               |                               |                               |
| Geometricmean             | BQL                           | BQL                           | BQL                           | BQL                           |
| Median                    | BQL                           | BQL                           | BQL                           | BQL                           |
| Range                     | (BQL; BQL)                    | (BQL; BQL)                    | (BQL; BQL)                    | (BQL; BQL)                    |
| Cycle 1, Day 4            |                               |                               |                               |                               |
| N                         | 180                           | 13                            | 132                           | 35                            |
| Mean (SD)                 | 93.8 (46.6)                   | 101 (58.8)                    | 98.2 (46.5)                   | 74.5 (37.3)                   |
| Coefficientofvariation    | 49.6%                         | 58.0%                         | 47.3%                         | 50.1%                         |
| Geometricmean             | 79.6                          | 87.1                          | 83.2                          | 65.1                          |
| Median                    | 87.7                          | 77.4                          | 91.1                          | 65.5                          |
| Range                     | (BQL; 265)                    | (42.0; 199)                   | (BQL; 265)                    | (14.4; 162)                   |
| Cycle 3, Day 1 (Predose)  |                               |                               |                               |                               |
| N                         | 178                           | 13                            | 130                           | 35                            |
| Mean (SD)                 | 407 (183)                     | 523 (200)                     | 425 (176)                     | 293 (152)                     |
| Coefficientofvariation    | 45.0%                         | 38.2%                         | 41.3%                         | 51.9%                         |
| Geometricmean             | 356                           | 491                           | 383                           | 240                           |
| Median                    | 391                           | 464                           | 404                           | 270                           |
| Range                     | (9.39; 970)                   | (262; 914)                    | (41.0; 970)                   | (9.39; 643)                   |
| Cycle 3, Day 4            |                               |                               |                               |                               |
| N                         | 169                           | 13                            | 124                           | 32                            |
| Mean (SD)                 | 524 (216)                     | 682 (237)                     | 543 (207)                     | 385 (175)                     |
| Coefficientofvariation    | 41.3%                         | 34.8%                         | 38.1%                         | 45.4%                         |
| Geometricmean             | 438                           | 643                           | 447                           | 347                           |
| Median                    | 507                           | 672                           | 521                           | 358                           |
| Range                     | (BQL;1163)                    | (332;1083)                    | (BQL;1163)                    | (83.9; 819)                   |
| Cycle 9,Day 1 (Predose)   |                               |                               |                               |                               |
| N                         | 141                           | 10                            | 102                           | 29                            |
| Mean (SD)                 | 289 (139)                     | 395 (138)                     | 301 (138)                     | 211 (104)                     |
| Coefficientofvariation    | 48.0%                         | 35.0%                         | 45.8%                         | 49.3%                         |
| Geometricmean             | 244                           | 374                           | 267                           | 152                           |
| Median                    | 271                           | 392                           | 285                           | 200                           |
| Range                     | (BQL; 760)                    | (230;641)                     | (30.2; 760)                   | (BQL; 433)                    |
| Cycle 12, Day 1 (Predose) |                               |                               |                               |                               |
| N                         | 139                           | 10                            | 103                           | 26                            |
| Mean (SD)                 | 260 (121)                     | 399 (163)                     | 264 (110)                     | 190 (94.4)                    |
| Coefficientofvariation    | 46.4%                         | 40.7%                         | 41.5%                         | 49.7%                         |
| Geometricmean             | 225                           | 364                           | 232                           | 167                           |
| Median                    | 239                           | 398                           | 258                           | 180                           |
| Range Post-treatmentWeek8 | (0.959; 708)                  | (125;708)                     | (0.959; 559)                  | (39.2; 415)                   |
| N                         | 8                             | 2                             | 4                             | 2                             |
| Mean (SD)                 | 132 (231)                     | 15.0 (5.35)                   | 206 (321)                     | 101 (116)                     |
| Coefficientofvariation    | 175.1%                        | 35.7%                         | 155.8%                        | 115.1%                        |
| Geometric mean            | 42.3 18.8                     | 14.5                          | 61.3                          | 58.6 101                      |
| Median Range              | (11.2; 682)                   | 15.0 (11.2;18.8)              | 65.1 (11.7; 682)              | (18.8;183)                    |

(VELCADE),lenalidomide, and dexamethasone;N number ofparticipants;PK=pharmacokinetic(s);

Key:BQL=belowquantificationlimit(O.2μg/mL);D-VRd=daratumumabincombinationwithbortezomib

QW=once every week; Q4W=once every 4 weeks; SC=subcutaneous;SD=standard deviation;

Notes:Daratumumab1800mgSCQWforCycles1to2,thenQ3WforCycles3to8.ForCycle9andbeyond Q4W.

VRd=VELCADE? (bortezomib), Revlimid? (lenalidomide), and dexamethasone.

Tableincludesparticipantswhoreceivedatleast1administrationofdaratumumabandhadatleast1PKsample concentrationvalueafterthefirstadministration.

A KM analysis was stratified by body weight in the daratumumab exposure Q1 subgroup, and shown in Figure 4.

<div style=\"page-break-after: always\"></div>

Figure 4. Kaplan-Meier Curves of PFS by Body Weight in Daratumumab Exposure Q1 Subgroup Population

<!-- image -->

Time from Randomization (months)

Key: Ctrough,max=predicted maximum trough concentration over the entire treatment period; PFS=progression-free survival; Q1=lowest exposure quartile (51.2-379 µg/mL).

## Race

Descriptive statistics for serum daratumumab concentrations at specified sampling timepoints for PKevaluable participants in the D-VRd treatment arm were calculated. The observed mean [SD] Ctrough, max of daratumumab at Cycle 3 Day 1 predose in black/African American participants (n=10) was 350 [154] μg/mL, 12.5% lower compared with white participants (400 [184] μg/mL, n=145). The observed mean [SD] Ctrough,max at Cycle 3 Day 1 predose in Asian participants (488 [178] μg/mL, n=10) was 22% higher compared to that of white participants. Given the small number of participants in the black or African American and Asian groups in this study and considerable overlap in daratumumab exposure across race, only limited conclusions regarding the effect of race/ethnicity on daratumumab SC PK can be made from the observed data for these subgroups. In the PPK analysis, race did not have a clinically meaningful effect on daratumumab PK (See Figure 3 in the popPK section).

## Pharmacokinetic interaction studies

No dedicated drug-drug interaction studies were performed for daratumumab SC.

As an IgG1қ mAb, the biotransformation of daratumumab is expected to be similar to endogenous IgG (i.e.,  degraded  into  small  peptides  and  amino  acids  via  catabolic  pathways)  and  subject  to  similar elimination  pathways  (Mascelli  2007;  Tabrizi  2006).  Renal  excretion  and  hepatic  enzyme  mediated metabolism of intact daratumumab are therefore unlikely to represent major elimination routes. Due to the high affinity to a unique epitope on CD38, daratumumab is also not anticipated to alter the activity of drug-metabolizing enzymes.

Because there is no overlapping pathway of elimination, no interactions are expected between daratumumab and small-molecule drugs including VRd.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Mechanism of action

Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein expressed on  the  surface  of  cells  in  a  variety  of  haematological  malignancies,  including  clonal  plasma  cells  in multiple myeloma and AL amyloidosis, as well as other cell types and tissues. CD38 protein has multiple functions such as receptor mediated adhesion, signalling, and enzymatic activity.

Daratumumab has been shown to potently inhibit the in vivo growth of CD38-expressing tumour cells. Based on in  vitro studies, daratumumab may utilise multiple effector functions, resulting in immune mediated tumour cell  death.  These  studies  suggest  that  daratumumab  can  induce  tumour  cell  lysis through  complement-dependent  cytotoxicity,  antibody-dependent  cell-mediated  cytotoxicity,  and antibody-dependent cellular phagocytosis in malignancies expressing CD38. A subset of myeloid derived suppressor  cells  (CD38+MDSCs),  regulatory  T  cells  (CD38+Tregs)  and  B  cells  (CD38+Bregs)  are decreased by daratumumab mediated cell lysis. T cells (CD3+, CD4+, and CD8+) are also known to express CD38 depending on the stage of development and the level of activation. Significant increases in  CD4+  and  CD8+  T  cell  absolute  counts,  and  percentages  of  lymphocytes,  were  observed  with daratumumab treatment in peripheral whole blood and bone marrow. In addition, T-cell receptor DNA sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immune modulatory effects that may contribute to clinical response.

Daratumumab induced apoptosis in  vitro after  Fc  mediated  cross-linking.  In  addition,  daratumumab modulated CD38 enzymatic activity, inhibiting the cyclase enzyme activity and stimulating the hydrolase activity. The significance of these in vitro effects in a clinical setting, and the implications on tumour growth, are not well-understood.

## Efficacy exposure-response analysis

A total of 392 participants (197 from the D-VRd arm and 195 from the VRd arm) from the intent-to-treat population were included in the dataset. All participants assigned to the D-VRd arm had received at least 1 dose of daratumumab with at least 1 evaluable PK sample post-dose and had PK exposure metrics (ie, Ctrough,max)  for  the  exposure-efficacy  analysis.  The  participants  in  the  VRd  arm  were  assigned  a daratumumab PK exposure of zero.

The  MRD  negativity  rate  in  the  E-R  analysis  set  was  60.9%  (n=120/197)  in  participants  randomly assigned to D-VRd and 40.0% (n=78/195) in participants randomly assigned to VRd treatment. MRD negativity rate showed a numerical increase as daratumumab Ctrough,max increased ( Figure 5 ).

<div style=\"page-break-after: always\"></div>

Figure 5. MRD negativity rate as function of Daratumumab Ctrough,max (µg/mL)

<!-- image -->

Daratumumab Ctrough.max (μg/mL)

Key: CI=confidence interval; C trough,max=predicted maximum trough concentration over the entire treatment period; D-VRd=daratumumab  in combination with VELCADE®  (bortezomib), Revlimid® (lenalidomide), and dexamethasone; MRD=minimum residual disease; OR=odds ratio; VRd=VELCADE® (bortezomib), Revlimid® (lenalidomide), and dexamethasone.

Notes: The upper and lower open circles represent the presence or absence of response across the range of daratumumab C trough,max. The purple dots depict the observed incidence for the exposure q uartile of participants receiving DVRd and the corresponding vertical bars represent the 95% CI. The red dot depicts the observed incidence of participants receiving VRd and the corresponding vertical bars represent the 95% CI. The full blue line and the associated shaded area represents the modelbased exposure -ef ficacy relationship and its 95% CI.

The relationship between MRD negativity rate and daratumumab Ctrough,max is shown in Figure 5 and was relatively shallow. The MRD negativity rate increased with higher daratumumab Ctrough,max as shown by an  OR  of  1.002  (95% CI:  1.001-1.003)  for  a  1 µg/mL  change  in  daratumumab  Ctrough,max  (pvalue &lt;0.001).

A statistically significant exposure-PFS relationship was found for daratumumab when categorized by quartiles of exposure ( Figure 6 ) or when used as a continuous variable in the univariate Cox regression model (p&lt;0.001) ( Table 4 ).

<div style=\"page-break-after: always\"></div>

Figure 6. Kaplan-Meier curves of PFS by daratumumab exposure subgroups in combination with VRd in  CEPHEUS

Daratumumab Ctrough,max (μg/mL)

<!-- image -->

Time from Randomization (months)

Key: C trough,max=predicted maximum trough concentration over the entire treatment period; PFS=progression -free survival; Q1=lowest exposure quartile; Q2=second exposure quartile; Q3=third exposure quartile; Q4=highest exposure quartile; VRd=VELCADE® (bortezomib), Revlimid® (lenalidomide), and dexamethasone.

Note: The quartiles for Ctrough,max were Q1 (51.2 -379 µg/mL), Q2 (381 -469 µg/mL), Q3 (471 -570 µg/mL), and Q4 ( 570 -872 µg/mL).

Table 4. Cox Proportional Hazard E-R Models for PFS

| Model   | Treatment or PK Metrics             |   N | Number of Events (%)   | HR    | 95% CI        | p-Value   |
|---------|-------------------------------------|-----|------------------------|-------|---------------|-----------|
| Model A | VRd                                 | 195 | 91 (46.7)              | -     | -             | -         |
|         | D-VRd                               | 197 | 63 (32 .0 )            | 0.592 | 0. 429,0.817  | 0.00126   |
| Model B | C trough,max (per 1 µg/mL increase) | 392 | 154 (39.3)             | 0.999 | 0.998,0.999   | 0.000107  |
| Model C | VRd                                 | 195 | 91 (46.7)              | -     | -             | -         |
|         | Q1 C trough,max 300 [51.2,379]      |  50 | 2 3 (46.0)             | 1.06  | 0.669,1.67    | 0. 814    |
|         | Q2 C trough,max 425 [381,469]       |  49 | 11 (2 2.4)             | 0.438 | 0.2 34,0.8 20 | 0.00981   |
|         | Q3 C trough,max 515 [471,570]       |  49 | 13 (26.5)              | 0.423 | 0.236,0.756   | 0.00371   |
|         | Q4 C trough,max 646 [570,872]       |  49 | 16 (32.7)              | 0.556 | 0.327,0.947   | 0.0307    |

Key: CI=confidence interval; C trough,max=predicted maximum trough concentration over the entire treatment period; DVRd=daratumumab  in combination with VELCADE®  (bortezomib), Revlimid® (lenalidomide), and dexamethasone; ER=exposure -response;  HR=hazard  ratio;  max=maximum;  min=minimum;  N=number  of participants; PFS=progression -free  survival;  PK=pharmacokinetic(s); Q1=lowest exposure quartile; Q2=second

<div style=\"page-break-after: always\"></div>

exposure quartile; Q3=third exposure quartile; Q4=highest exposure quartile; VRd=VELCADE® (bortezomib), Revlimid® (lenalidomide), and dexamethasone .

Note : The quartiles for Ctrough,max were Q1 (51.2 -379 µg/mL), Q2 (381 -469 µg/mL), Q3 (471 -570 µg/mL), and Q4 ( 570 -872 µg/mL). The median and range [min, max] of C trough,max for Model C are shown in the table .

A subgroup analysis for PFS, based on various baseline characteristic is shown in Figure 7.

Figure 7. Forest Plot of Subgroup Analyses on Progression-free Survival Based on Computerized Algorithm; Intent-to-treat Analysis Set; Final PFS Analysis (Study 54767414MMY3019)

<!-- image -->

|                                            |                      | VRd                  | VRd                  | D-VRd                | D-VRd                | Hazard Ratio         |
|--------------------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                                            | HazardRatioand95%Cl  |                      | EVT/N Median         |                      | EVT/N Median         | (95% CI)             |
| Sex                                        |                      |                      |                      |                      |                      |                      |
| Male                                       |                      | 53/111               | 49.2                 | 24/87                | NE                   | 0.46 (0.29, 0.75)    |
| Female                                     |                      | 38/87                | NE                   | 39/110               | NE                   | 0.73 (0.47, 1.15)    |
| Age                                        |                      |                      |                      |                      |                      |                      |
| <70years                                   |                      | 38/88                | NE                   | 30/88                | NE                   | 0.72 (0.44, 1.16)    |
| >=70years                                  |                      | 53/110               | 49.4                 | 33/109               | NE                   | 0.50 (0.33,0.78)     |
| Region                                     |                      |                      |                      |                      |                      |                      |
| Europe                                     |                      | 54/116               | 51.1                 | 37/120               | NE                   | 0.54 (0.36, 0.82)    |
| NorthAmerica                               |                      | 13/31                | 50.2                 | 10/37                | NE                   | 0.51 (0.22, 1.17)    |
| Other                                      |                      | 24/51                | NE                   | 16/40                | NE                   | 0.87 (0.46,1.64)     |
| Weight                                     |                      |                      |                      |                      |                      |                      |
| <=65kg                                     |                      | 24/63                | NE                   | 17/58                | NE                   | 0.62 (0.34,1.16)     |
| >65-85 kg                                  |                      | 40/88                | 51.1                 | 34/101               | NE                   | 0.65 (0.41, 1.02)    |
| >85kg                                      |                      | 27/47                | 41.9                 | 12/38                | NE                   | 0.46 (0.23, 0.91)    |
| Baseline International Staging System(ISS) |                      |                      |                      |                      |                      |                      |
| I                                          |                      | 28/68                | 60.6                 | 21/68                | NE                   | 0.66 (0.37,1.16)     |
| II                                         |                      | 37/75                | 45.6                 | 18/73                | NE                   | 0.36 (0.21, 0.64)    |
| IIII                                       |                      | 26/55                | 49.2                 | 24/56                | NE                   | 0.84 (0.48,1.46)     |
| Cytogenetic risk                           |                      |                      |                      |                      |                      |                      |
| High risk                                  |                      | 17/27                | 31.7                 | 13/25                | 39.8                 | 0.88 (0.42, 1.84)    |
| Standardrisk                               |                      | 60/149               | 60.6                 | 43/149               | NE                   | 0.61 (0.41, 0.91)    |
| BaselineECoGperformancescore               |                      |                      |                      |                      |                      |                      |
| 0                                          |                      | 30/84                | NE                   | 16/71                | NE                   | 0.53 (0.29, 0.97)    |
| >=1                                        |                      | 61/114               | 43.8                 | 47/126               | NE                   | 0.59 (0.40,0.86)     |
| ←FavorD-VRdFavorVRd→                       | ←FavorD-VRdFavorVRd→ | ←FavorD-VRdFavorVRd→ | ←FavorD-VRdFavorVRd→ | ←FavorD-VRdFavorVRd→ | ←FavorD-VRdFavorVRd→ | ←FavorD-VRdFavorVRd→ |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib- lenalidomide-dexamethasone; CI = confidence interval.

Note: Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as

the sole explanatory variable. A hazard ratio &lt;1 indicates an advantage for D-VRd.

Note: High risk is defined by FISH testing: t (4; 14), t (14; 16), and 17p deletion.

## Exposure safety analysis

The exposure-safety analysis for all selected TEAEs included 392 participants (D-VRd: 197, VRd: 195) who had evaluable daratumumab PK (ie, Cpeak,first for sARRs and Cpeak,max for other endpoints).

There was no apparent increase in TEAE rates with increasing exposure (Cpeak,first or Cpeak,max) for sARRs, thrombocytopenia, anemia, neutropenia, lymphopenia, or infections and infestations (all grades and Grades ≥3) within the studied drug concentration range in CEPHEUS ( Table 5 ). A decreasing trend in

<div style=\"page-break-after: always\"></div>

the event rate of thrombocytopenia (all grades and Grades ≥3) was observed based on Cpeak,max (ie, a higher rate of TEAEs was observed with the lower Cpeak,max). This could partially be due to the reason that participants with TEAEs may have dose interruption or delays, which led to lower concentrations in these participants.

Table 5. Comparison of TEAE rates across predicted daratumumab exposure subgroups in CEPHEUS

|                    | VRd %(95% CI)     | D-VRd Exposure Quartiles, %(95% CI)   | D-VRd Exposure Quartiles, %(95% CI)   | D-VRd Exposure Quartiles, %(95% CI)   | D-VRd Exposure Quartiles, %(95% CI)   |
|--------------------|-------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| TEAE               | N=195             | Q1 N=50                               | Q2 N=49                               | Q3 N=49                               | Q4 N=49                               |
| Neutropenia        | 39.0 (32.4, 46.0) | 60.0 (46.2, 72.4)                     | 59.2 (45.2, 71.8)                     | 63.3 (49.3, 75.3)                     | 40.8 (28.2, 54.8)                     |
| Grade ≥3           | 29.7 (23.8, 36.5) | 50.0 (36.6, 63.4)                     | 51.0 (37.5, 64.4)                     | 55.1 (41.3, 68.1)                     | 20.4 (11.5, 33.6)                     |
| Infections         | 85.6 (80.0, 89.9) | 90.0 (78.6, 95.7)                     | 85.7 (73.3, 92.9)                     | 98.0 (89.3, 99.6)                     | 93.9 (83.5, 97.9)                     |
| Grade ≥3           | 33.3 (27.1, 40.2) | 48.0 (34.8, 61.5)                     | 36.7 (24.7, 50.7)                     | 40.8 (28.2, 54.8)                     | 36.7 (24.7, 50.7)                     |
| Lymphopenia        | 17.4 (12.8, 23.4) | 18.0 (9.8, 30.8)                      | 22.4 (13.0, 35.9)                     | 12.2 (5.7, 24.2)                      | 20.4 (11.5, 33.6)                     |
| Grade ≥3           | 10.3 (6.7, 15.3)  | 14.0 (7.0, 26.2)                      | 12.2 (5.7, 24.2)                      | 8.2 (3.2, 19.2)                       | 14.3 (7.1, 26.7)                      |
| Anemia             | 31.8 (25.7, 38.6) | 38.0 (25.9, 51.8)                     | 42.9 (30.0, 56.7)                     | 38.8 (26.4, 52.8)                     | 28.6 (17.8, 42.4)                     |
| Grade ≥3           | 11.8 (8.0, 17.1)  | 18.0 (9.8, 30.8)                      | 12.2 (5.7, 24.2)                      | 12.2 (5.7, 24.2)                      | 10.2 (4.4, 21.8)                      |
| Thrombo- cytopenia | 33.8 (27.6, 40.7) | 66.0 (52.2, 77.6)                     | 49.0 (35.6, 62.5)                     | 36.7 (24.7, 50.7)                     | 34.7 (22.9, 48.7)                     |
| Grade ≥3           | 20.0 (15.0, 26.2) | 44.0 (31.2, 57.7)                     | 26.5 (16.2, 40.3)                     | 24.5 (14.6, 38.1)                     | 18.4 (10.0, 31.4)                     |
| sARRs              | 0                 | 0                                     | 4.1 (1.1, 13.7)                       | 4.1 (1.1, 13.7)                       | 6.1 (2.1, 16.5)                       |
| Grade ≥3           | 0                 | 0                                     | 0                                     | 0                                     | 2.0 (0.4, 10.7)                       |

Key: CI=confidence interval; C peak,first = predicted peak concentration after the first dose; Cpeak,max = predicted maximum peak concentration; DVRd=daratumumab in combination with VELCADE® (bortezomib), Revlimid® (lenalidomide), and dexamethasone; N=number of participants; Q1=lowest exposure quartile; Q2=second exposure quartile; Q3=third exposure quartile; Q4=highest exposure quartile; sARR=systemic administration -related reaction; TEAE=treatment -emergent adverse event; VRd=VELCADE® (bortezomib), Revlimid® (lenalidomide), and dexamethasone.

Notes: The relationship of sARRs was evaluated with Cpeak,first because this TEAE mainly occurs during the first dose, whereas the relationship with other safety endpoints was investigated using Cpeak,max. The quartiles for C peak,max were Q1 (106 -446 µg/mL), Q2 (448 -547 µg/mL), Q3 (548 -650 µg/mL), and Q4 (650 -997 µg/mL). The quartiles for Cpeak,first were Q1 (42.6 -99.5 µg/mL), Q2 (99.6 -114 µg/mL), Q3 (114 -135 µg/mL), and Q4 (136 -185 µg/mL).

## 2.3.4. Discussion on clinical pharmacology

## Pharmacokinetics

A previously developed 2-compartment IV/SC PPK model was used to fit CEPHEUS data by external validation.  Based on pcPVC and GOF plots the fit was considered reasonable, with no needs for reestimation.

Mean [SD] maximum Cmax at Cycle 3 Day 4 (524 [216] μg/mL) was 5.59-fold that of the Cmax at Cycle 1 Day 4 (93.8 [46.6] μg/mL), indicating systemic accumulation of serum daratumumab concentration following weekly daratumumab SC administrations during induction treatment. Mean [SD] Ctrough,max of daratumumab of 407 [183] μg/mL was observed immediately prior to dose administration at Cycle 3 Day 1 predose.

The  pharmacokinetics  of  daratumumab  as  observed  from  the  sampling  schedule  in  the  CEPHEUS MMY3019 study is consistent with  the  pharmacokinetics in  previous  studies.  This  was  confirmed  by external model validation using a PPK model build on data from the PERSEUS study. Direct tabular

<div style=\"page-break-after: always\"></div>

comparison of Cmax, Ctrough etc. for each cycle with other studies was not provided as the dosing schedule for the indication in scope of this application is new.

Mean maximum Ctrough is stated in SmPC section 5.2 for each individual indication. Mean maximum Ctrough is  slightly  lower  for  the  indication  in  scope  of  this  application  as  the  dosing  schedule  is  slightly  less frequent in the beginning as compared to the two other dosing schedules (6 weeks of weekly dosing as opposed to 8 weeks of weekly dosing). However, it is agreed that mean maximum Ctrough is similar to the other dosing schedule (407 vs 526or 537 µg/mL). The amendment to section 5.2 of the SmPC is accepted.

The incidence of immunogenicity towards daratumumab was very low as only 1 patient out of 170 was positive for treatment emergent neutralising anti-daratumumab antibodies. However, this patient had similar levels of exposure to daratumumab as patients negative for ADA. This is consistent with previous clinical studies with daratumumab, where Nabs have not been found to interfere with exposure. The incidence of immunogenicity towards rHuPH20 was higher, but still consistent with previous submissions for this excipient. Immunogenicity towards rHuPH20 is not expected to impact exposure to daratumumab or rHuPH20 due to its already very short half-life (6 minutes). The wording on immunogenicity in section 5.1 of the SmPC is still valid.

Dose  proportionality  and  time  dependencies  were  evaluated  in  previous  submissions.  The  dosing schedule is slightly different for the indication in the scope of this application (6 weeks of weekly dosing vs 8 weeks of weekly dosing). Therefore, the accumulation is expected to be slightly lower.

There was considerable overlap in serum daratumumab concentrations at PK sampling timepoints across body weight subgroups. However, consistent with a mAb administered SC by flat dose, higher serum daratumumab concentrations were observed in participants with lowest body weight (≤65 and ≤50 kg) and lower serum daratumumab concentrations were observed in participants with highest body weight (&gt;85 kg) at all PK sampling timepoints. For the lowest body weight subgroups (≤65 and ≤50 kg), mean Ctrough,max of daratumumab at Cycle 3 Day 1 predose was 9.8% and 23.1% higher, respectively, compared with that of the middle body weight subgroups (&gt;65 to ≤ 85 kg and &gt;50 to ≤ 85 kg). For the highest body weight subgroup (&gt;85 kg), mean Ctrough,max of daratumumab at Cycle 3 Day 1 predose was 43.0% and 45.1% lower, respectively, compared with that of the middle body weight subgroups (&gt;65 to ≤ 85 kg and &gt;50 to ≤ 85 kg). For the middle body weight subgroups (&gt;65 to ≤85 kg and &gt;50 to ≤85 kg), the mean concentration of daratumumab at Cycle 3 Day 1 predose was comparable to that of the total PK-evaluable analysis set.

Fourteen participants in the PK-evaluable analysis set had a body weight ≤ 50 kg and had mean (SD) maximum daratumumab Cmax at Cycle 3 Day 4 of 682 (237) µg/mL, which was within the range of maximum Cmax (Cycle  3  Day  4)  for  participants  in  the  total  PK-evaluable  analysis  set  (below  the quantification limit to 1,163 µg/mL).

The flat-dose administration of daratumumab SC 1800 mg achieved adequate systemic exposure for all body weight subgroups in the D-VRd treatment arm, i.e., the systemic exposure in the majority of participants exceeded the 236 µg/mL threshold previously established to be necessary for 99% modelpredicted target saturation.

Direct comparison of mean PK data from the CEPHEUS study and a POPPK model evaluation showed that race had no clinical meaningful effect on exposure.

Pharmacokinetic  drug-drug  interactions  were  not  submitted  as  these  are  not  expected  when daratumumab is co-administered with small molecule drugs.

## Pharmacodynamics

The MRD negativity rate increased with higher daratumumab Ctrough,max, but the relationship between between Ctrough,max and MRD negativity was not strong and the confidence intervals between all quartiles were overlapping.

<div style=\"page-break-after: always\"></div>

Kaplan-Meier stratified by body weight show slightly lower PFS in patients &gt;85 kg vs &lt;65 to 85 kg although differences were not statistically significant. This could be explained by the lower exposure observed and predicted in patients with body weight &gt;85 kg. To separate the body weight effect and the exposure effect on progression-free survival, Kaplan-Meier plot of PFS of the different weight groups with exposure in the lower quartile, showed that PFS was more or less comparable in patients of similar 'low' exposure and that the mean of the low and the high body weight group lies within the confidence interval of the middle weight group. Therefore, body weight in itself does not impact the survival, in patients within the lower exposure quartile.

The E-R analysis on efficacy data suggests that the daratumumab effect on PFS has been attained for the majority of the participants (&gt;75%, ie, participants with exposures greater than or equal to the first exposure quartile [Q1]) at the studied 1800 mg SC dose). This finding is consistent with observations in other studies (MMY3003, MMY3004, MMY3007, MMY3008, CANDOR, and APOLLO). The seemingly similar PFS between participants in daratumumab exposure Q1 and the VRd arm needs to be interpreted with caution, likely due to the imbalance of unknown confounders given the small sample size. A difference in PFS is observed when Q1 and Q4 are compared (2.15-fold increase in median Ctrough,max); however, no difference in PFS is seen when Q2 and Q4 are compared (1.52-fold increase in median Ctrough,max), suggesting  that  individual  variation  in  daratumumab  exposure  at  1800 mg  SC  is  not  expected  to introduce  clinically  meaningful  differences  in  PFS  in  participants  with  NDMM  for  whom  ASCT  is  not planned as initial therapy. In addition, the relatively narrow exposure range (1.42-, 1.72-, and 2.15-fold increase in median Ctrough,max when Q2, Q3, and Q4, respectively, are compared with Q1), due to the single dose level in CEPHEUS, limits the interpretation of the E-R relationship. Overall, these results support that the dose regimen provides efficacious exposure in the majority of participants with NDMM for whom ASCT is not planned as initial therapy .

The  exposure-safety  relationship  showed  no  apparent  increase  in  TEAE  rates  with  increasing daratumumab exposure for sARRs, anaemia, neutropenia, lymphopenia, or infections.

## 2.3.5. Conclusions on clinical pharmacology

The provided pharmacokinetics data, exposure-efficacy results and exposure-safety results support the approval of daratumumab SC at the recommended dose in combination with VRd in patients with NDMM who are ineligible for ASCT.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Not applicable. The present application concerns a fixed dose of daratumumab SC which has previously been established.

## 2.4.2. Main study

CEPHEUS (54767414MMY3019) : A Phase 3 Study comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in subjects with untreated Multiple Myeloma and for whom Hematopoietic Stem Cell Transplant is not planned as initial therapy

<div style=\"page-break-after: always\"></div>

## Methods

A diagrammatic representation of the study design is presented in Figure 8 .

Figure 8 . Schematic Overview of CEPHEUS

<!-- image -->

NDDM=newly diagnosed multiple myeloma; TIE=Transplant ineligible; D-VRd=daratumumab, bortezomib, lenalidomide, and dexamethasone; MRD=minimal residual disease; OS=overall survival; PFS=progression-free survival; VRd=bortezomib, lenalidomide, and dexamethasone

## Study participants

## Main inclusion criteria

1.  Newly  diagnosed  and  not  considered  candidate  for  high-dose  chemotherapy  with  stem  cell transplantation (SCT) due to:
- Being age ≥65 years

or

- age 18-65 years with presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with SCT or who refuse high-dose chemotherapy with SCT as initial treatment.
2. Diagnosis of multiple myeloma as documented per IMWG criteria: Monoclonal plasma cells in the bone marrow  ≥10%  or  presence  of  a  biopsy  proven  plasmacytoma  and  documented  multiple  myeloma satisfying at least one of the CRAB (calcium, renal, anaemia, bone) criteria or biomarkers of malignancy criteria:

## CRAB criteria:

1. Hypercalcemia: serum calcium &gt;0.25 mmol/L (&gt;1 mg/dL) higher than upper limit of normal (ULN) or &gt;2.75 mmol/L (&gt;11 mg/dL)
2. Renal insufficiency: creatinine clearance &lt;40mL/min or serum creatinine &gt;177 μmol/L (&gt;2 mg/dL)
3. Anaemia: haemoglobin &gt;2 g/dL below the lower limit of normal or haemoglobin &lt;10 g/dL
4.  Bone  lesions:  one  or  more  osteolytic  lesions  on  skeletal  radiography,  computed tomography (CT), or positron emission tomography (PET)-CT

## Biomarkers of Malignancy:

- a. Clonal bone marrow plasma cell percentage ≥60%

<div style=\"page-break-after: always\"></div>

- b. Involved: uninvolved serum free light chain (FLC) ratio ≥100
- c. &gt;1 focal lesion on magnetic resonance imaging (MRI) studies
3. Must have measurable disease, as assessed by central laboratory, defined by any of the following:
- IgG, IgA, IgM, IgD, or IgE multiple myeloma: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or
- Light chain multiple myeloma without measurable disease in serum or urine: Serum Ig FLC ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.
4. ECOG performance status score of 0, 1, or 2.
5.  Adequate Clinical laboratory values and organ function during the Screening Phase.
6. Female subjects must not be pregnant and avoid pregnancy through adequate means.

## Main exclusion criteria

1. Frailty index of ≥2 according to Myeloma Geriatric Assessment score.

2. Prior therapy for multiple myeloma other than a short course of corticosteroids (not to exceed 40 mg of dexamethasone, or equivalent per day, total of 160 mg dexamethasone or equivalent).

3.  Prior  or  concurrent  invasive  malignancy  (other  than  multiple  myeloma) within 5 years of date of randomization (exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in  situ of  the  cervix  or  breast,  or  other  non-invasive  lesion  that  in  the  opinion  of  the investigator, with concurrence with the sponsors medical monitor, is considered cured with minimal risk of recurrence within 3 years).

4.  Peripheral  neuropathy  or  neuropathic  pain  Grade  2  or  higher,  as  defined  by  the  National  Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.

5. Focal radiation therapy within 14 days of randomization with the exception of palliative radiotherapy for symptomatic pain management. Radiotherapy within 14 days prior to randomization on measurable extramedullary plasmacytoma is not permitted even in the setting of palliation for symptomatic management.

6. Plasmapheresis within 28 days of randomization.

7. Clinical signs of meningeal involvement of multiple myeloma.

8.  Chronic  obstructive  pulmonary  disease  (COPD)  with  a  FEV1  &lt;50%  of  predicted.  (FEV1  testing  is required for subjects suspected of having COPD).

9.  Moderate  or  severe  persistent  asthma  within  the  past  2  years,  uncontrolled  asthma  of  any classification. (Subjects who have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).

10. Known to be seropositive for human immunodeficiency virus (HIV) or active HBV or HCV infection.

11.  Concurrent  medical  or  psychiatric  condition  or  disease  (such  as  but  not  limited  to,  systemic amyloidosis, POEMS, active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease)  that  is  likely  to  interfere  with  study  procedures  or  results,  or  that  in  the  opinion  of  the investigator would constitute a hazard if enrolled in the study.

<div style=\"page-break-after: always\"></div>

12. Has clinically significant cardiac disease, including: Myocardial infarction within 6 months before signing the ICF, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV; Uncontrolled cardiac arrhythmia or clinically  significant  ECG  abnormalities  Screening  12-lead  ECG  showing  a  baseline  QT interval as corrected by Frederica ' s formula (QTcF) &gt;470 msec.

13. Received a strong CYP3A4 inducer within 5 half-lives prior to randomization.

14. Allergy, hypersensitivity, or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients, or sensitivity to mammalian-derived products or lenalidomide.

## Treatments

The study consisted of 3 phases: A Screening Phase, a Treatment Phase (Intervention Phase), and a Follow-up Phase (Postintervention Phase). The Screening Phase was up to 28 days before randomization. Subjects received either D-VRd or VRd for 8 cycles. No subject received bortezomib after completion of the first 8 cycles of VRd. After completing 8 cycles of therapy, subjects continued with DRd or Rd until disease progression or unacceptable toxicity.

Participants assigned to the D-VRd treatment arm were to receive daratumumab SC administered at 1800 mg weekly in Cycles 1 and 2, every 3 weeks in Cycles 3 through 8, and every 4 weeks in Cycle 9 and beyond until the participant had disease progression or experienced an unacceptable toxicity. Cycles 1-8 were 21 days in length, and Cycles 9 and beyond were 28 days in length.

Participants in both treatment arms were to receive bortezomib, lenalidomide, and dexamethasone as stated below:

Bortezomib : 1.3 mg/m2 administered as an SC injection twice a week (Days 1, 4, 8, and 11) for Cycles 1-8. For participants who experienced injection-site reactions, bortezomib could have been administered by IV injection (per local prescribing information). Per protocol, bortezomib was a fixed dose for the first 8 cycles of treatment only.

Lenalidomide : administered PO at 25 mg on Days 1 to 14 in Cycles 1-8 for participants with CrCl ≥ 60 mL/min. During Cycles 9 and beyond, lenalidomide 25 mg was administered daily on Days 1 through 21 of each 28-day cycle. Lenalidomide was taken (with or without food) as a single dose at the same time daily. Lenalidomide dosing continued until disease progression or unacceptable toxicity.

Dexamethasone (or an equivalent corticosteroid): administered PO at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. For participants who were older than 75 years of age or participants who were underweight (BMI &lt;18.5), dexamethasone could have been administered at a dose  of  20  mg  on  Days  1,  4,  8,  and  11.  In  Cycles  9  and  beyond,  dexamethasone  40  mg  PO  was administered  on  Days  1,  8,  15,  22  of  each  28-day  cycle.  For  participants  older  than  75  years  or underweight (BMI &lt;18.5), the dexamethasone dose could have been administered at a dose of 20 mg weekly.

For participants in the D-VRd arm, the dexamethasone PO or IV dose administered as a pre-injection medication  on  daratumumab  injection  days  replaced  the  PO/IV  dexamethasone  dose  for  that  day. Dexamethasone was administered until the participant experienced disease progression or unacceptable toxicity during the treatment phase.

<div style=\"page-break-after: always\"></div>

For participants potentially planning an SCT at a later time, stem cell harvest following mobilization with G-CSF, plerixafor, or cyclophosphamide (or any combination of the 3) was permitted after Cycle 4 while on study treatment.

## Pre-administration Medication

To decrease the risk of IRRs, all subjects received the following medications 1 to 3 hours prior to each study drug administration:

- Paracetamol (acetaminophen) 650-1000 mg IV or orally (PO).
- An antihistamine: diphenhydramine 25-50 mg IV or PO, or equivalent.
- Dexamethasone 20 mg Cycles 1-8 and 40 mg for Cycle 9 and beyond IV or PO on injection days. For subjects older than 75 years or underweight (body mass index [BMI] &lt;18.5), dexamethasone 20 mg may be administered as appropriate. An equivalent intermediate-acting or long-acting corticosteroid may substitute.
- Montelukast 10 mg (or equivalent) is recommended on Cycle 1 Day 1 only up to 24 hours prior to daratumumab injection.

## Objectives

## Primary objective

The primary objective is to determine if the addition of daratumumab to VRd will improve overall MRD negativity rate compared with VRd alone.

## Secondary Objectives (selection)

The secondary objectives are:

To determine if the addition of daratumumab to VRd will improve clinical outcome as measured by:

- PFS
- MRD negativity rate at 1 year
- Durability of MRD negativity
- ORR, rate of very good partial response (VGPR) or better, and rate of CR or better
- Time to response
- Duration of response
- Time to next treatment

- Progression-free survival on the next line of therapy (PFS2; defined as time from randomization to progression on the next line of therapy or death, whichever comes first)

- OS

## Outcomes/endpoints

## Primary Endpoint

Overall MRD negativity rate, which is defined as the proportion of subjects who have achieved MRD negative status (at 10 -5 ) by bone marrow aspirate after randomization and prior to progressive disease (PD) or subsequent anti-myeloma therapy.

Subjects who have achieved MRD negative status on or after PD or after the switch to subsequent antimyeloma therapy before PD, were not considered MRD negative in the primary endpoint analysis. MRD positive  subjects  included  subjects  of  which  all  tested  samples  were  found  to  be  MRD  positive  or indeterminate. For subjects with missing MRD samples, failure to calibrate baseline MRD, or otherwise unevaluable samples, MRD status were considered as MRD positive.

The primary estimand, the main clinical quantity of interest to be estimated in the study, was defined by the following 5 components:

<div style=\"page-break-after: always\"></div>

- Treatments:

- Daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd, investigational treatment) for eight 21-day cycles followed by daratumumab, lenalidomide, and dexamethasone (VRd) therapy until disease progression or unacceptable toxicity

- Bortezomib, lenalidomide and dexamethasone (VRd) for eight 21-day cycles followed by lenalidomide and dexamethasone (Rd, control treatment) until disease progression or unacceptable toxicity

· Population: subjects with untreated multiple myeloma and for whom hematopoietic stem cell transplant was not planned as initial therapy

· Variable: MRD negativity status (yes or no, yes defined as achieving CR or better response and MRD negative status (at 10-5) by bone marrow biopsy/aspirate any time after treatment assignment but prior to either of the intercurrent events: subsequent antimyeloma therapy or progressive disease)

- Population-level summary: odds ratio (OR) of D-VRd vs. VRd
- Intercurrent events:
- Subsequent antimyeloma therapy
- Progressive disease

Composite strategy was used to count for the intercurrent events as reflected in the variable definition.

## Major Secondary Endpoints

## CR or better rate

CR or better rate is defined as the proportion of subjects achieving CR or sCR prior to subsequent antimyeloma therapy in accordance with the IMWG criteria during or after the study treatment.

The estimand corresponding to the major secondary endpoint, CR or better rate, in the study, was defined as:

· Variable: CR or better response (yes or no, yes defined as achieving CR or better response any time after treatment assignment but prior to subsequent antimyeloma therapy)

- Intercurrent events: - Subsequent antimyeloma therapy

Composite strategy was used to count for the intercurrent events as reflected in the variable definition.

## PFS

PFS is defined as the duration from the date of randomization to either progressive disease (PD) or death due  to  any  cause,  whichever  comes  first.  Disease  progression  was  determined  according  to  the International Myeloma Working Group (IMWG) criteria. Subjects who started subsequent anti-myeloma therapies  for  multiple  myeloma  without  disease  progression  were  censored  at  the  last  disease assessment before the start of subsequent therapies. Subjects who withdrew consent from the study before disease progression were censored at the last disease assessment. Subjects who were lost to follow-up were censored at the last disease assessment before subjects were lost to follow-up. Subjects who had not progressed and were still alive at the cutoff date for analysis were censored at the last disease assessment. Subjects without any post-baseline disease assessment were censored at the date of randomization.

Determination of dates of PFS event and dates for censoring is summarized in Table 6 as follows.

<div style=\"page-break-after: always\"></div>

Table 6 . PFS event and censoring method

| Situation                                                                                                                                                      | Outcome   | Date of Event or Censoring                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Disease progression prior to start of subsequent antimyeloma therapy                                                                                           | PFS event | Earliest date that indicates disease progression                                                                                                  |
| Death (due to any cause) *                                                                                                                                     | PFS event | Date of death                                                                                                                                     |
| Disease progression or death immediately preceded by 2 or more consecutive missed disease assessments                                                          | Censored  | At the last adequate disease assessment before the consecutive missed disease assessments                                                         |
| No postbaseline disease assessment                                                                                                                             | Censored  | Date of randomization                                                                                                                             |
| Other, such as: Withdrawal of consent to study participation + Lost to follow-up Start of subsequent antimyeloma therapy prior to disease progression or death | Censored  | Date of last disease assessment prior to withdrawal of consent to study participation, lost to follow-up, start of subsequent antimyeloma therapy |

*Subjects who died after consent withdrawal will be censored at the date of consent withdrawal for PFS analysis

The estimand corresponding to the major secondary endpoint PFS for this study was defined by the following 5 components:

- Treatments:

- Daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd, investigational treatment) for eight 21-day cycles followed by daratumumab, lenalidomide, and dexamethasone (VRd) therapy until disease progression or unacceptable toxicity

- Bortezomib, lenalidomide and dexamethasone (VRd, control treatment) for eight 21-day cycles followed by lenalidomide and dexamethasone (Rd) until disease progression or unacceptable toxicity

- Population: subjects with untreated multiple myeloma and for whom hematopoietic stem cell transplant was not planned as initial therapy
- Variable: progression-free survival
- Population-level summary: hazard ratio (HR) of D-VRd vs. VRd
- Intercurrent events:
- Start of subsequent antimyeloma therapy prior to disease progression or death
- COVID-19 infection with the outcome of death prior to disease progression.

Hypothetical strategy was applied to the intercurrent events of subsequent antimyeloma therapy prior to disease progression or death, as if the subjects would not had experienced such an intercurrent event. Treatment  policy  was  used  for  COVID-19  infection  with  the  outcome  of  death  prior  to  disease progression, whether such an intercurrent event occurred or not was irrelevant.

## Sustained MRD negativity rate

Sustained MRD negativity rate is defined as the proportion of subjects who achieve CR or better response and have achieved MRD negative status (at 10-5) at two bone marrow biopsy/aspirate examinations that are a minimum of one year apart (and the two examinations should be prior to progressive disease (PD), subsequent anti-myeloma therapy, or both), without any examination showing MRD positive status in between.

The estimand corresponding to the major secondary endpoint, durable MRD negativity rate, in the study, was defined as:

· Variable: durable MRD negativity status (yes or no, yes defined as achieving CR or better response and MRD negative status (at 10-5) at two bone marrow biopsy/aspirate examinations that are a minimum of

<div style=\"page-break-after: always\"></div>

one year apart without any examination showing MRD positive status in between, and prior to either of the intercurrent events: subsequent antimyeloma therapy or progressive disease).

## Other secondary endpoints

MRD negativity rate at one year is defined as the  proportion of subject who achieved CR or better response and MRD negative status (at 10-5) by bone marrow biopsy/aspirate at 12 months after the first dose of study treatment and prior to progressive disease (PD), subsequent anti-myeloma therapy, or both. But the subjects who had achieved MRD negative status on or after PD or the start of subsequent anti-myeloma  therapy,  were  not  considered  as  MRD  negative.  Similar  definitions  apply  to  the  MRD negativity rates at other scheduled time points, which were 18, 24, 30, or 36 months after the first dose of study treatment.

Overall response rate (ORR) is defined as the proportion of subjects who achieve PR or better responses (i.e., PR, VGPR, CR, or sCR) based on the computerized algorithm, in accordance with the IMWG criteria, during or after the study treatment but before the start of subsequent anti-myeloma therapy.

VGPR or better rate is defined as the proportion of subjects achieving VGPR, CR, and sCR based on the computerized algorithm, in accordance with the IMWG criteria, during or after the study treatment but before the start of subsequent anti-myeloma therapy.

Progression-free survival on the next line of therapy (PFS2) is defined as the time from randomization to progression on the next line of treatment or death (due to any cause), whichever comes first. Disease progression was based on investigator judgment. Subjects who were still alive and not yet progressed on the next line of treatment were censored on the last date of follow-up. Subjects who withdraw consent or lost to follow-up prior to any subsequent antimyeloma therapy were censored at the date of last disease  assessment  during  the  course  of  study.  Subjects  without  any  post-baseline  follow-up  were censored at the randomization.

Overall survival (OS) is defined as the time from the date of randomization to the date of the subject's death due to any cause. Subjects who were lost to follow-up were censored at the time of lost to followup. Subjects who died after consent withdrawal were considered as having an OS event. If the subject was alive at the cutoff date for the analysis or the survival status was unknown, then the subject's data was censored at the date the subject was last known to be alive. The date of last known alive was determined by the maximum collection/assessment date from among selected data domains within the clinical database.

Time to response (TTR, i.e., time to the first response) is defined as the time between the randomization and the first efficacy evaluation at which the subject meets all criteria for PR or better based on the computerized algorithm, according to IMWG response criteria.

## Sample size

Based on the available data from studies CASTOR, POLLUX, and ALCYONE, approximately 64% of MRD negative subjects at a threshold of 10 -4 were also MRD negative at a threshold of 10 -5 . The IFM2009-TE NDMM  study  showed  a  49%  overall  MRD  negativity  rate  at 10 -4 for  all  the  VRd  subjects  without transplant. Thus, the anticipated overall MRD negativity rate ( 10 -5 ) for the control arm in this study is estimated to be at most 35%. This study assumes that the addition of daratumumab to VRd would lead to a 15% absolute increase in overall MRD negativity rate (50% D-VRd vs. 35% VRd alone). A sample size of 360 subjects (180 each arm) is needed to achieve a power of 80% to detect such a treatment difference at a 2-sided alpha of 0.05.

<div style=\"page-break-after: always\"></div>

This sample size was to provide approximately 80% power to detect a 37% reduction in the risk of progression or death (HR=0.63, translating to an improvement in median PFS from 43 months to 68 months) with a log-rank test at a 2-sided alpha of 0.05. To ensure adequate power for PFS, an adaptive approach may be used to determine the timing of the final PFS analysis (162 events). If the observed HR for PFS at the interim analysis (i.e., 60% of events) was higher than expected, the final analysis of PFS may be delayed until approximately 205 events have been observed (roughly 3 years later). If the HR of 0.7 was observed for PFS at the interim, 205 events were to provide approximately 80% conditional power (CP) for the final analysis of  PFS. The event size for the final analysis of PFS was not to be decreased from 162. The ADDPLAN ®2  targeting the CP=80% subject to the maximum number of events 205 has been used to plan the adaptive design. To maintain a strong control of the type I error rate for the PFS analysis, an inverse normal p-value combination method was used if the number of events for the final analysis increased to approximately 205. The method allows flexible adaptations at an IA and creates a valid test that controls the type I error rate in a strong sense analytically. In this proposed design, the adaptation is the potential adjustment of the required number of events for the final analysis.

## Randomisation

Central randomization was implemented in this study. Eligible subjects were stratified by ISS (Stage I, II, or III, based on β-2 microglobulin and albumin by central laboratory), and age/transplant eligibility (&lt;70 years ineligible, or age &lt;70 years and refusal to transplant, or age ≥70 years), and then assigned randomly to 1 of 2 treatment groups in a 1:1 ratio based on an algorithm implemented in the interactive web response system (IWRS) before the study. The randomization was balanced by using randomly permuted blocks. Based on the randomization code, the IWRS assigned a unique intervention code, which dictated the intervention assignment and matching study drug kit for the subject.

## Blinding (masking)

This was an open label study.

## Statistical methods

## Primary endpoint

For this study, threshold value of 10 -5  was used for the primary MRD negativity analysis. Other threshold values (10 -4  and 10 -6 ) could also be explored.

MRD negativity on or after disease progression or switch to subsequent anti-myeloma therapy without confirmed progression on study treatment, were not considered as MRD negative in the analysis.

The overall MRD negativity rate was calculated for each treatment group based on the ITT analysis set. The corresponding 95% exact CI was provided. Reasons for missing or unevaluable MRD status were tabulated by treatment group.

The stratified Cochran Mantel Haenszel (CMH) estimate of odds ratio and its 95% confidence interval and p-value from Fisher's exact test were used to test if the MRD negativity rate is the same between the two treatment groups. Stratification factors used in the analysis include ISS staging (I, II, III) and age/transplant eligibility (&lt;70 years ineligible, &lt;70 years and refusal to transplant, ≥70 years).

Following supplementary analyses may be performed in a similar manner as described above:

- Overall MRD negativity rate based on the 'modified ITT' analysis set (if ≥10% subjects who have discontinued study treatment/ study or died due to COVID-19)

- Overall MRD negativity rate based on the CR or better subjects only.

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

CR or better responses after switch to subsequent anti-myeloma therapy were not counted as CRs in the analysis. The CR or better rate were calculated for each treatment group based on the ITT analysis set. The corresponding 95% exact CI was provided. The stratified CMH estimate of odds ratio and its 95% confidence interval and p-value for testing treatment difference was reported. Stratification factors used in the analysis was the same as for the primary endpoint.

Analysis of PFS were based on the ITT analysis set. The Kaplan-Meier method was used to estimate the distribution of overall PFS for each treatment group. The median PFS with 95% CI was provided. In addition, the number and percentage of subjects who had a PFS event or were censored was reported. The reasons for PFS censoring were summarized accordingly. The Kaplan-Meier PFS curve was plotted by treatment group. The treatment comparison of the distribution of overall PFS was based on a stratified log-rank  test.  The  p-value  from  a  stratified  log-rank  test  was  reported.  Hazard  ratio  and  its  95% confidence interval was estimated based on a stratified Cox's regression model with treatment as the sole explanatory variable. Stratification factors used in the analyses aligned with those for the primary endpoint.  In  addition,  landmark  PFS  rate  with  95%  CI  was  estimated  by  Kaplan-Meier  method  and reported for each treatment group. The proportional hazard (PH) assumption of the PFS analysis was examined graphically (log-log plot of S(t)) and/or numerically (e.g., good of fitness test by Schoenfeld residual). If the PH assumption was not met, additional analyses may be performed to address the issue, such as the Inverse probability of censoring weighting (IPCW) analysis to take the confounding factors (e.g., daratumumab-containing subsequent therapy) into account because non-PH may be caused by potential treatment change (or crossover). Additionally, following sensitivity or supplementary analyses may be performed in a similar manner as described above: Sensitivity · Unstratified analysis of PFS · Progressive  disease  is  based  on  investigator  assessment  according  to  the  IMWG  response  criteria Supplementary · Not censor the events after the start of subsequent antimyeloma therapies · Censor the death due to COVID-19 · Censor the subjects who permanently discontinue treatment/study due to COVID-19 (censor at last disease evaluation before treatment/study discontinuation).

The durable MRD negativity rate was calculated for each treatment group based on the ITT analysis set. The corresponding 95% exact CI was also provided. Chi-square estimate of the common odds ratio with 95% confidence interval and p-value from Fisher's exact test for treatment difference was reported.

The analysis of MRD negativity rate at 1 year and other timepoints (i.e., 18, 24, 30, or 36 months), ORR and VGPR or better rate was performed in a similar manner as for CR or better response. The analysis of OS, PFS2, time to subsequent antimyeloma therapy, and DOR was performed in a similar manner as for PFS. At the primary MRD analysis, OS analysis was exploratory and descriptive. The Kaplan-Meier curves of OS were also provided by treatment group. Time to first response was analyzed for subjects who achieved a response (PR or better) and descriptive statistics (N, mean, SD, median, and range) was provided.

## Interim analysis and Multiplicity

There was no interim analysis planned for the overall MRD negativity rate. After the primary analysis of MRD negativity  rate,  disease  assessment  continued  for  the  secondary  endpoint  PFS,  for  which  one interim analysis was planned after approximately 98 events (i.e., 60% of the total 162 events) have been accumulated. The significance levels at this interim analysis of PFS to establish the superiority (or declare the futility) of daratumumab plus VRd over VRd alone were determined based on the observed number of PFS events at this analysis using the O'Brien-Fleming boundaries as implemented by the LanDeMets alpha- and beta-spending method.

If the primary endpoint of overall MRD negativity rate was statistically significant, the key secondary endpoints (i.e., CR or better rate, PFS, and durable MRD negativity rate) were sequentially tested, each with an overall two-sided alpha of 0.05, by utilizing a hierarchical testing approach as proposed by Tang and Geller (1999) that strongly controls family wise Type I error rate.

<div style=\"page-break-after: always\"></div>

Due to the short follow-up time at the primary MRD data cut, PFS and durable MRD negativity data were premature, hence hierarchical test starting at the interim PFS data cut (98 events occurred) could be performed. The final PFS analysis (162 events occurred) was skipped if the PFS interim result crosses the pre-specified stopping boundary. The significance level at each data cut was determined by the alpha-spending function specific to endpoints:

- For CR or better rate, the information fraction is expected to be 80% at the primary MRD cut. The O'Brien-Fleming alpha-spending function as implemented by the Lan-DeMets method was used for alpha spending: 0.0244 (two-sided) at the primary MRD cut and 0.0428 (two-sided) at the interim PFS cut.
- For PFS, the exact significance level at the interim analysis and final PFS analysis was determined by the observed number of events per the O'Brien-Fleming alpha spending function. Assuming 98 PFS events are observed at the interim analysis, the alpha to be spent was 0.0076 (2-sided) for the interim analysis and 0.0476 (2-sided) for the final PFS analysis (162 PFS events occur).

To ensure adequate power for PFS, an adaptive approach may be used to determine the timing of the final PFS analysis. If the observed HR for PFS at the interim analysis (i.e., 60% of events) is  higher than expected (e.g., 0.7 or higher), the final analysis of PFS may be delayed until approximately 205 events have been observed. To control the overall type I error rate, the inverse normal test with the same fixed weights (i.e., information fractions of interim and final analyses) as originally planned was used to combine the log-rank statistics before and after the interim analysis.

- For durable MRD negativity rate, the information fraction is expected to be 80% at the interim PFS  cut.  The  O'Brien-Fleming  alpha-spending  function  as  implemented  by  the  Lan-DeMets method was used for alpha spending: 0.0244 (two-sided) at the interim PFS cut and 0.0428 (two-sided) at the final PFS cut.

If the null hypothesis for any of these endpoints failed to be rejected at the interim analysis, then any subsequent endpoint(s) listed above were not tested until the next analysis time point (e.g., final PFS analysis), if applicable. If the null hypothesis for an endpoint was rejected at any interim analysis, it remained being rejected and would not be re-tested at any subsequent time points, if any.

## Results

## Participant flow

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Recruitment

Study Initiation Date:  15 November 2018 (Date first participant was screened)

Primary MRD Analysis Clinical Cutoff: 08 April 2021 (Date of the last observation recorded as part of the database for the primary analysis)

Final PFS Analysis Clinical Cutoff: 07 May 2024 (Date of last observation recorded as part of the database for final PFS analysis)

## Conduct of the study

The protocol was amended 6 times as summarised below.

## Amendment 1 (10 September 2018)

To add language describing hepatitis testing, which is now required across daratumumab studies for subjects who are positive for anti-HBc and/or anti-HBs.

## Amendment 2 (18 January 2019)

The overall reason for the amendment was in response to identification of a new important risk (hepatitis B virus [HBV] reactivation). Additionally, revisions and clarifications were made to considerations for

<div style=\"page-break-after: always\"></div>

lenalidomide  use,  sequence  of  secondary  endpoints,  as  well  as  other  measurement  parameters throughout the Protocol.

## Amendment 3 (19 November 2019)

The overall reason for the amendment was to expand the scope of efficacy review by Independent Data Monitoring Committee (IDMC) at different stages in the study. Additionally, to ensure that the subjects continue to receive treatment with other components of study treatment even if any one component is held,  discontinued  or  reduced,  to  clarify  that  subsequent  anti-myeloma  therapies  should  not  be administered until disease progression and in subjects who discontinue study treatment for reasons other than disease progression, should be monitored and subsequent treatment should not be started until documented disease progression.

## Amendment 4 (1 October 2020)

To update the timeframes and landmark analyses for primary analysis of minimal residual disease (MRD) negativity rate. Primary endpoint of MRD negativity remains unchanged, but primary analysis will now occur at approximately 18 months in order to maximize MRD samples available for primary analysis, to ensure the maturity of MRD negativity at the primary analysis, and to mitigate the impact of Coronavirus Disease 2019 (COVID-19) pandemic on MRD sample collection.

## Amendment 5 (24 March 2022)

To mitigate the impact of Coronavirus Disease 2019 (COVID-19) pandemic.

## Amendment 6 - 14 March 2024

The overall rationale for the amendment was to continue the study with limited data collection after the planned final PFS analysis. Subjects benefitting from treatment with daratumumab could have continued access to study treatment after the end of data collection.

## Protocol deviations

Major protocol deviations are summarised in Table 7 .

Table 7 . Summary of Major Protocol Deviations; Intent-to-treat Analysis Set; Final PFS Analysis (Study 54767414MMY3019)

| Analysisset:intent-to-treat                         | VRd n (%) 198   | D-VRd n (%) 197   | Total n (%) 395   |
|-----------------------------------------------------|-----------------|-------------------|-------------------|
| Total number ofsubjectswith majorprotocol deviation | 13 (6.6%)       | 8 (4.1%)          | 21 (5.3%)         |
| Type of major protocol deviation                    |                 |                   |                   |
| Entered but did not satisfy criteria                | 2 (1.0%)        | 3 (1.5%)          | 5 (1.3%)          |
| Receivedadisallowedconcomitanttreatment             | 8 (4.0%)        | 3 (1.5%)          | 11 (2.8%)         |
| Other                                               | 3 (1.5%)        | 3 (1.5%)          | 6 (1.5%)          |
| Other-COv1D-19related                               | 1 (0.5%)        | 0                 | 1 (0.3%)          |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomidedexamethasone; COVID-19 = Coronavirus Disease 2019.

Note: Percentages calculated with the number of subjects in each treatment group as denominator.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 8. Summary of demographics and baseline characteristics; Intent-to-treat Analysis Set; Final PFS analysis (Study 54767414MMY3019)

|                                 | VRd            | D-VRd          | Total          |
|---------------------------------|----------------|----------------|----------------|
| Analysis set: intent-to-treat   | 198            | 197            | 395            |
| Age, years N                    |                |                |                |
|                                 | 198            | 197            | 395            |
| Category, n (%)                 |                |                |                |
| 65                              | 35 (17.7%)     | 36 (18.3%)     | 71 (18.0%)     |
| 65-<70                          | 53 (26.8%)     | 52 (26.4%)     | 105 (26.6%)    |
| ≥70                             | 110 (55.6%)    | 109 (55.3%)    | 219 (55.4%)    |
| Mean (SD)                       | 68.9 (7.31)    | 69.0 (7.01)    | 69.0 (7.15)    |
| Median                          | 70.0           | 70.0           | 70.0           |
| Range                           | (31; 80)       | (42; 79)       | (31; 80)       |
| Sex                             |                |                |                |
| N                               | 198            | 197            | 395            |
| Female                          | 87 (43.9%)     | 110 (55.8%)    | 197 (49.9%)    |
| Male                            | 111 (56.1%)    | 87 (44.2%)     | 198 (50.1%)    |
| Race                            |                |                |                |
| N                               | 198            | 197            | 395            |
| White                           | 156 (78.8%)    | 162 (82.2%)    | 318 (80.5%)    |
| Black or African American       | 9 (4.5%)       | 10 (5.1%)      | 19 (4.8%)      |
| Asian                           | 14 (7.1%)      | 11 (5.6%)      | 25 (6.3%)      |
| Native Hawaiian or otherPacific |                |                |                |
| Islander                        | 1 (0.5%)       | 0              | 1 (0.3%)       |
| Other                           | 2 (1.0%)       | 1 (0.5%)       | 3 (0.8%)       |
| Not reported                    | 16 (8.1%)      | 13 (6.6%)      | 29 (7.3%)      |
| Ethnicity                       |                |                |                |
| N                               | 198            | 197            | 395            |
| Hispanic or Latino              | 35 (17.7%)     | 31 (15.7%)     | 66 (16.7%)     |
| Not Hispanic or Latino          | 147 (74.2%)    | 154 (78.2%)    | 301 (76.2%)    |
| Not reported                    | 16 (8.1%)      | 12 (6.1%)      | 28 (7.1%)      |
| Weight, kg                      |                |                |                |
| N                               | 198            | 197            | 395            |
| Category, n (%)                 |                |                |                |
| 595                             | 63 (31.8%)     | 58 (29.4%)     | 121 (30.6%)    |
| >65 and≤ 85                     | 88 (44.4%)     | 101 (51.3%)    | 189 (47.8%)    |
| >85                             | 47 (23.7%)     | 38 (19.3%)     | 85 (21.5%)     |
| Mean (SD)                       | 74.35 (15.770) | 73.92 (16.342) | 74.14 (16.039) |
| Median                          | 72.55          | 73.60          | 73.00          |
| Range                           | (38.0; 125.0)  | (40.4; 125.0)  | (38.0; 125.0)  |
|                                 | VRd            | D-VRd          | Total          |
| Baseline ECOG score             |                |                |                |
| N                               | 198            | 197            | 395            |
| 0                               | 84 (42.4%)     | 71 (36.0%)     | 155 (39.2%)    |
| 1                               | 100 (50.5%)    | 103 (52.3%)    | 203 (51.4%)    |
| 2                               | 14 (7.1%)      | 23 (11.7%)     | 37 (9.4%)      |
| Total Additive (Frailty) Score  |                |                |                |
| N                               | 198            | 197            | 395            |
| Fit (score=0)                   | 132 (66.7%)    | 124 (62.9%)    | 256 (64.8%)    |
| Inteimediate-fitness (score=1)  | 66 (33.3%)     | 73 (37.1%)     | 139 (35.2%)    |
| Frail (score>=2)                | 0              | 0              | 0              |

Key:VRd=bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone; BSA

=Body Surface Area; ECOG = Eastern Cooperative Oncology Group.

Note: Subjects reporting multiple races are included under other.

Note: Percentages calculated with the number of subjects in cach treatment group with available data as denominator.

<div style=\"page-break-after: always\"></div>

Table 9. Summary of baseline disease characteristics; Intent-to-treat Analysis Set; Final PFS analysis (Study 54767414MMY3019)

|                                                      | VRd          | D-VRd        | Total        |
|------------------------------------------------------|--------------|--------------|--------------|
| Analysis set: intent-to-treat                        | 198          | 197          | 395          |
| Type of myeloma by immunofixation or serum FLC assay |              |              |              |
| N                                                    | 198          | 197          | 395          |
| IgG                                                  | 114 (57.6%)  | 130 (66.0%)  | 244 (61.8%)  |
| IgA                                                  | 52 (26.3%)   | 38 (19.3%)   | 90 (22.8%)   |
| IgM                                                  | 0            | 0            | 0            |
| IgD                                                  | 3 (1.5%)     | 2 (1.0%)     | 5 (1.3%)     |
| IgE                                                  | 0            | 0            | 0            |
| Light chain                                          | 25 (12.6%)   | 22 (11.2%)   | 47 (11.9%)   |
| Kappa                                                | 15 (7.6%)    | 10 (5.1%)    | 25 (6.3%)    |
| Lambda                                               | 9 (4.5%)     | 11 (5.6%)    | 20 (5.1%)    |
| FLC-Kappa t                                          | 0            | 1 (0.5%)     | 1 (0.3%)     |
| FLC-Lambda f                                         | 1 (0.5%)     | 0            | 1 (0.3%)     |
| Biclonal                                             | 3 (1.5%)     | 5 (2.5%)     | 8 (2.0%)     |
| Negative Immunofixation                              | 0            | 0            | 0            |
| Unknown                                              | 1 (0.5%)     | 0            | 1 (0.3%)     |
| Type of measurable disease                           |              |              |              |
| N                                                    | 198          | 197          | 395          |
| Serum only                                           | 108 (54.5%)  | 120 (60.9%)  | 228 (57.7%)  |
| IgG                                                  | 76 (38.4%)   | 89 (45.2%)   | 165 (41.8%)  |
| IgA                                                  | 31 (15.7%)   | 27 (13.7%)   | 58 (14.7%)   |
| Other b                                              | 1 (0.5%)     | 4 (2.0%)     | 5 (1.3%)     |
| Serum and urine                                      | 45 (22.7%)   | 41 (20.8%)   | 86 (21.8%)   |
| Urine only                                           | 24 (12.1%)   | 20 (10.2%)   | 44 (11.1%)   |
| Serum FLC                                            | 21 (10.6%)   | 16 (8.1%)    | 37 (9.4%)    |
| ISS Staging *                                        |              |              |              |
| N                                                    | 198          | 197          | 395          |
| 1                                                    | 68 (34.3%)   | 68 (34.5%)   | 136 (34.4%)  |
| I1                                                   | 75 (37.9%)   | 73 (37.1%)   | 148 (37.5%)  |
| III                                                  | 55 (27.8%)   | 56 (28.4%)   | 111 (28.1%)  |
| Time since initial MM diagnosis, months              |              |              |              |
| N                                                    | 198          | 197          | 395          |
| Mean (SD)                                            | 1.60 (1.100) | 1.49 (1.028) | 1.54 (1.065) |
| Median                                               | 1.26         | 1.15         | 1.18         |
| Range                                                | (0.3; 8.0)   | (0.4; 5.8)   | (0.3; 8.0)   |
| Number of lytic bone lesions                         |              |              |              |
| N                                                    | 198          | 197          | 395          |
| None                                                 | 49 (24.7%)   | 34 (17.3%)   | 83 (21.0%)   |
| 1-3                                                  | 51 (25.8%)   | 43 (21.8%)   | 94 (23.8%)   |
| 4-10                                                 | 34 (17.2%)   | 44 (22.3%)   | 78 (19.7%)   |
| More than 10                                         | 64 (32.3%)   | 76 (38.6%)   | 140 (35.4%)  |
| Presence of extramedullary plasmacytomas             |              |              |              |
| N                                                    | 198          | 197          | 395          |
| Yes                                                  | 13 (6.6%)    | 11 (5.6%)    | 24 (6.1%)    |
| No                                                   | 185 (93.4%)  | 186 (94.4%)  | 371 (93.9%)  |
| Presence of evaluable bone marrow assessment         |              |              |              |
| N                                                    | 198          | 197          | 395          |
| Yes                                                  | 198 (100.0%) | 196 (99.5%)  | 394 (99.7%)  |
| No                                                   | 0            | 1 (0.5%)     | 1 (0.3%)     |

<div style=\"page-break-after: always\"></div>

| % Plasma cells, bone marrow biopsy/aspirate   | 198         | 196         | 394         |
|-----------------------------------------------|-------------|-------------|-------------|
| N ≤10                                         | 7 (3.5%)    | 6 (3.1%)    | 13 (3.3%)   |
| 10-30                                         | 102 (51.5%) | 82 (41.8%)  | 184 (46.7%) |
| >30-60                                        | 48 (24.2%)  | 60 (30.6%)  | 108 (27.4%) |
| >60                                           | 41 (20.7%)  | 48 (24.5%)  | 89 (22.6%)  |
| % Plasma cells, bone marow biopsy             |             |             |             |
| N                                             | 86          | 89          | 175         |
| <10                                           | 3 (3.5%)    | 4 (4.5%)    | 7 (4.0%)    |
| 10-30                                         | 27 (31.4%)  | 26 (29.2%)  | 53 (30.3%)  |
| >30-60                                        | 31 (36.0%)  | 25 (28.1%)  | 56 (32.0%)  |
| >60                                           | 25 (29.1%)  | 34 (38.2%)  | 59 (33.7%)  |
| % Plasma cells, bone marrow aspirate          |             |             |             |
| N                                             | 187         | 183         | 370         |
| ≤10                                           | 15 (8.0%)   | 21 (11.5%)  | 36 (9.7%)   |
| 10-30                                         | 107 (57.2%) | 86 (47.0%)  | 193 (52.2%) |
| >30-60                                        | 40 (21.4%)  | 52 (28.4%)  | 92 (24.9%)  |
| >60                                           | 25 (13.4%)  | 24 (13.1%)  | 49 (13.2%)  |
| Bone marrow cellularity by biopsy             |             |             |             |
| N                                             | 70          | 73          | 143         |
| Hypercellular                                 | 30 (42.9%)  | 32 (43.8%)  | 62 (43.4%)  |
| Normocellular                                 | 29 (41.4%)  | 24 (32.9%)  | 53 (37.1%)  |
| Hypocellular                                  | 5 (7.1%)    | 6(8.2%)     | 11 (7.7%)   |
| Indeteminate                                  | 6 (8.6%)    | 11 (15.1%)  | 17 (11.9%)  |
| Bone marrow cellularity by aspirate           |             |             |             |
| N                                             | 27          | 39          | 66          |
| Hypercellular                                 | 10 (37.0%)  | 8 (20.5%)   | 18 (27.3%)  |
| Normocellular                                 | 16 (59.3%)  | 18 (46.2%)  | 34 (51.5%)  |
| Hypocellular                                  | 1 (3.7%)    | 8 (20.5%)   | 9 (13.6%)   |
| Indeteminate                                  | 0           | 5 (12.8%)   | 5 (7.6%)    |
| Cytogenetic risk                              |             |             |             |
| N                                             | 198         | 197         | 395         |
| Standard risk d                               | 149 (75.3%) | 149 (75.6%) | 298 (75.4%) |
| High risk d                                   | 27 (13.6%)  | 25 (12.7%)  | 52 (13.2%)  |
| del(17p)                                      | 14 (7.1%)   | 12 (6.1%)   | 26 (6.6%)   |
| t(4; 14)                                      | 13 (6.6%)   | 12 (6.1%)   | 25 (6.3%)   |
| t(14; 16)                                     | 2 (1.0%)    | 4 (2.0%)    | 6 (1.5%)    |
| Un-evaluable or missing                       | 22 (11.1%)  | 23 (11.7%)  | 45 (11.4%)  |

Key:VRd=bortezomib-lenalidomide-dexamethasone; D-VRd =daratumumab-bortezomib-lenalidomide-dexamethasone; FLC = free light chain; ISS = International Staging System; MM = multiple myeloma; NE = not evaluable.

b Includes IgD, IgM, IgE and biclonal.

* Includes subjects without measurable disease in serum and urine.

* ISS staging is derived based on the combination of serum β2-microglobulin and albumin.

d Standard risk includes subjects who are negative for del17p, t(14;16), or t(4;14) by FISH. High risk includes the subjects who are positive for any of del17p, t(14;16), or t(4;14)by FISH.

Includes subjects without a positive immunofixation but with evidence of free light chain kappa by FLC testing.

Note: Percentages calculated with the number of subjects in cach dose level with available data as denominator.

f Includes subiects without a positive immunofixation but with evidence of free light chain lambda by FLC testing.

<div style=\"page-break-after: always\"></div>

Table 10 . Summary of subsequent antimyeloma therapy by therapeutic class, pharmacologic class, and drug; Safety Analysis Set; Final PFS Analysis (Study 54767414MMY3019)

|                                                                                       | VRd        | D-VRd      | Total      |
|---------------------------------------------------------------------------------------|------------|------------|------------|
| Analysis sct: safety                                                                  | n(%) 195   | n (%) 197  | n (%) 392  |
| Total number of subjects with 1 or more subsequent antimycloma theapics *             | 65 (33.3%) | 22 (11.2%) | 87 (22.2%) |
| Total number of subjects with 1 or more subsequent autologous stem cell transplants * | 4 (2.1%)   | 0          | 4 (1.0%)   |
| Therapeutic class/phamacologic class/drug                                             |            |            |            |
| Antincoplastic agents                                                                 | 54 (83.1%) | 21(95.5%)  | 75 (86.2%) |
| Other antincoplastic agents                                                           | 52 (80.0%) | 20 (90.9%) | 72 (82.8%) |
| Daratumumab                                                                           | 34 (52.3%) | 1(4.5%)    | 35 (40.2%) |
| Bortezomib                                                                            | 19 (29.2%) | 9 (40.9%)  | 28 (32.2%) |
| Carfilzomib                                                                           | 13 (20.0%) | 9 (40.9%)  | 22 (25.3%) |
| Monoclonal antibodies                                                                 | 5 (7.7%)   | 2(9.1%)    | 7 (8.0%)   |
| Isatuximab                                                                            | 5 (7.7%)   | 1(4.5%)    | 6 (6.9%)   |
| lxazomib                                                                              | 2 (3.1%)   | 2(9.1%)    | 4 (4.6%)   |
| Cisplatin                                                                             | 2 (3.1%)   | 1(4.5%)    | 3 (3.4%)   |
| Other antincoplastic agcnts                                                           | 1 (1.5%)   | 1(4.5%)    | 2 (2.3%)   |
| Bclantamab mafodotin                                                                  | 0          | 1(4.5%)    | 1 (1.1%)   |
| Car t-cells nos                                                                       | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Cc 92480                                                                              | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Elotuzumab                                                                            | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Isatuximab irfc                                                                       | 0          | 1(4.5%)    | 1 (1.1%)   |
| Ixazomib citate                                                                       | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Panobinostat                                                                          | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Venetoclax                                                                            | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Alkylating agents                                                                     | 16 (24.6%) | 5 (22.7%)  | 21 (24.1%) |
| Cyclophosphamide                                                                      | 14 (21.5%) | 3 (13.6%)  | 17 (19.5%) |
| Melphalan                                                                             | 5 (7.7%)   | 1(4.5%)    | 6 (6.9%)   |
| Bendamustine                                                                          | 0          | 1(4.5%)    | 1 (1.1%)   |
| Cyclophosphamide monohydate                                                           | 0          | 1(4.5%)    | 1 (1.1%)   |
| Lomustine                                                                             | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Plant alkaloids and other natual products                                             | 3 (4.6%)   | 2(9.1%)    | 5 (5.7%)   |
| Etoposide                                                                             | 2 (3.1%)   | 1(4.5%)    | 3 (3.4%)   |
| Vineristine                                                                           | 1 (1.5%)   | 1(4.5%)    | 2 (2.3%)   |
| Cytotoxie antibiotics and related substances                                          | 2 (3.1%)   | 2(9.1%)    | 4 (4.6%)   |
| Doxonbicin                                                                            | 2 (3.1%)   | 1(4.5%)    | 3 (3.4%)   |
| Doxonbicin hydrochloride                                                              | 0          | 1(4.5%)    | 1 (1.1%)   |
| Antimetbolites                                                                        | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Fludarabine                                                                           | 1 (1.5%)   | 0          | 1 (1.1%)   |
| Corticosteroids for systemic usc                                                      | 54 (83.1%) | 17(77.3%)  | 71 (81.6%) |
| Corticosteroids for systemic use, plain                                               | 54 (83.1%) | 17(77.3%)  | 71 (81.6%) |
| Dexamcthasone                                                                         | 51 (78.5%) | 17(77.3%)  | 68 (78.2%) |
| Prednisone                                                                            | 6 (9.2%)   | 1(4.5%)    | 7 (8.0%)   |
| Methylprednisolone sodium succinate                                                   | 1(1.5%)    | 0          | 1 (1.1%)   |

<div style=\"page-break-after: always\"></div>

| Immunosuppressants                         | 38 (58.5%)   | 11 (50.0%)   | 49 (56.3%)   |
|--------------------------------------------|--------------|--------------|--------------|
| Immunosuppressants                         | 38 (58.5%)   | 11 (50.0%)   | 49 (56.3%)   |
| Pomalidomide                               | 21 (32.3%)   | 7 (31.8%)    | 28 (32.2%)   |
| Lenalidomide                               | 17 (26.2%)   | 4 (18.2%)    | 21 (24.1%)   |
| Thalidomide                                | 3 (4.6%)     | 1(4.5%)      | 4 (4.6%)     |
| Iberdomide                                 | 1 (1.5%)     | 0            | 1 (1.1%)     |
| Investigational drug                       | 4 (6.2%)     | 0            | 4 (4.6%)     |
| Uncoded                                    | 4 (6.2%)     | 0            | 4 (4.6%)     |
| Investigational dng                        | 4 (6.2%)     | 0            | 4 (4.6%)     |
| All other therapcutic products             | 1 (1.5%)     | 0            | 1 (1.1%)     |
| All other therpeutie products              | 1 (1.5%)     | 0            | 1 (1.1%)     |
| All other therpeutie products              | 1 (1.5%)     | 0            | 1 (1.1%)     |
| Blood substitutes and perfiusion solutions | 1(1.5%)      | 0            | 1 (1.1%)     |
| Blood and related products                 | 1 (1.5%)     | 0            | 1 (1.1%)     |
| Ciherhlnnd nrnhcta                         | 1/15%1       | n            | 1111%1       |

Key: VRd = bortezomib-lenalidomidedexamethasone; D -VRd = daratumumab-bortezomib-lenalidomidedexamethasone.

a Percentages calculated with the number of subjects in each treatment group as denominator.

b Percentages are calculated with the number of subjects who received subsequent antimyeloma therapies in each group as denominators.

## Numbers analysed

Table 11. Summary of subjects per analysis aet; (Study 54767414MMY3019)

|                            | VRd   | D-VRd   | Total   |
|----------------------------|-------|---------|---------|
| Study population           |       |         |         |
| Subjects screened          |       |         | 499     |
| Intent-to-treat(ITT)       | 198   | 197     | 395     |
| Safety                     | 195   | 197     | 392     |
| Pharmacokinclic cvaluable  |       | 197     | 197     |
| Daratumumab immunogenicity |       | 170     | 170     |
| rHuPH20 immunogenicity c   |       | 169     | 169     |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomidedexamethasone.

a Includes subjects assigned to D-VRd group who received at least 1 administration of daratumumab and have at least 1 pharmacokinetic sample concentration value after the first injection.

b Includes subjects assigned to D-VRd group who received at least 1 dose of daratumumab and have appropriate serum samples for detection of antibodies to daratumumab (i.e., subjects with at least 1 sample obtained after their first dose daratumumab).

c Includes subjects assigned to D-VRd group who received at least 1 dose of daratumumab and have at least 1 serum sample for detection of antibodies to anti-rHuPH20 either pre- or post- treatment.

## Outcomes and estimation

Primary efficacy endpoint: Overall MRD negativity rate

Table 12 . Summary of MRD negativity Rate at 10 -5  in Bone Marrow; Intent-to-treat Analysis Set; Primary MRD Analysis-data cut off: 08 April 2021 (Study 54767414MMY3019)

<div style=\"page-break-after: always\"></div>

|                               | VRd            | D-VRd             |
|-------------------------------|----------------|-------------------|
| Analysis set: intent-to-treat | 198            | 197               |
| MRD negativity rate (10-5)    | 70 (35.4%)     | 105 (53.3%)       |
| 95% CI of MRD negativity rate | (28.7%, 42.4%) | (46.1%, 60.4%)    |
| Odds ratio with 95% CIb       |                | 2.07 (1.38, 3.10) |
| P-valuec                      |                | 0.0004            |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide- dexamethasone; CI = confidence interval; CR = complete response.

a Exact 95% confidence interval.

b Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are: ISS staging (I,

II, III), age/transplant eligibility (&lt;70 years ineligible, or age&lt;70 years and refusal to transplant, or age ≥70 years) as randomized. An odds ratio &gt; 1 indicates an advantage for D-VRd.

c P-value from Fisher's exact test.

## Key secondary endpoint: PFS

Table 13. Summary of progression-free survival based on computerised algorithm; Intent-to treat Analysis Set; Interim PFS Analysis-data cut off: 08 September 2022 (Study 54767414MMY3019)

|                                 | VRd                  | D-VRd             |
|---------------------------------|----------------------|-------------------|
| Analysis set: intent-to-treat   | 198                  | 197               |
| Progression-free survival (PFS) |                      |                   |
| Number of events (%)            | 67 (33.8%)           | 46 (23.4%)        |
| Number of censored (%)          | 131 (66.2%)          | 151 (76.6%)       |
| Kaplan-Meier estimate (months)  |                      |                   |
| 25% quantile (95% CI)           | 25.53 (18.69, 31.41) | NE (22.74, NE)    |
| Median (95% CI)                 | NE (NE, NE)          | NE (NE, NE)       |
| 75% quantile (95% CI)           | NE (NE, NE)          | NE (NE, NE)       |
| P-valuea                        |                      | 0.0104            |
| Hazard ratio (95% CI)b          |                      | 0.61 (0.42, 0.90) |
| 12-month PFS rate % (95% CI)    | 89.6 (84.2, 93.3)    | 89.6 (84.3, 93.2) |
| 18-month PFS rate % (95% CI)    | 82.2 (75.7, 87.0)    | 86.4 (80.7, 90.5) |
| 24-month PFS rate % (95% CI)    | 76.9 (70.0, 82.5)    | 80.5 (74.1, 85.4) |
| 30-month PFS rate % (95% CI)    | 72.2 (65.0, 78.2)    | 77.2 (70.5, 82.6) |
| 36-month PFS rate % (95% CI)    | 62.2 (54.6, 69.0)    | 75.5 (68.7, 81.1) |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide- dexamethasone; CI = confidence interval; COVID-19 = Coronavirus Disease 2019.

a p-value is based on the log-rank test stratified with ISS staging (I, II, III), and age/transplant eligibility (&lt;70 years ineligible, or age&lt;70 years and refusal to transplant, or age ≥70 years) as randomized.

b Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), and age/transplant eligibility (&lt;70 years ineligible, or age&lt;70 years and refusal to transplant, or age ≥70 years) as randomized. A hazard ratio &lt;1 indicates an advantage for D-VRd.

Note: Subjects who had disease progression or death immediately preceded by 2 or more consecutive missed disease assessments would be censored at the last adequate disease assessment before the consecutive missed disease assessments.

Note: Subjects who died due to COVID-19 without progression are considered as having PFS events.

<div style=\"page-break-after: always\"></div>

Figure 9. Kaplan-Meir plot for progression-free survival based on computerised algorithm; Intent-to treat Analysis Set; Interim PFS Analysis-data cut off: 08 September 2022 (Study 54767414MMY3019)

<!-- image -->

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomidedexamethasone.

## Key secondary endpoint: Overall CR or better rate

Table 14 . Summary of overall best confirmed response based on computerised algorithm; Intent-totreat Analysis Setdata cut off: 08 April 2021 (Study 54767414MMY3019)

| TEFRESP01PA:                      | SummaryofOverallBestConfirmedResponseBasedonComputerizedAlgorithm;Intent-to-treatAnalysisSet(Study 54767414MMIY3019)   | SummaryofOverallBestConfirmedResponseBasedonComputerizedAlgorithm;Intent-to-treatAnalysisSet(Study 54767414MMIY3019)   | SummaryofOverallBestConfirmedResponseBasedonComputerizedAlgorithm;Intent-to-treatAnalysisSet(Study 54767414MMIY3019)   | SummaryofOverallBestConfirmedResponseBasedonComputerizedAlgorithm;Intent-to-treatAnalysisSet(Study 54767414MMIY3019)   | SummaryofOverallBestConfirmedResponseBasedonComputerizedAlgorithm;Intent-to-treatAnalysisSet(Study 54767414MMIY3019)   | SummaryofOverallBestConfirmedResponseBasedonComputerizedAlgorithm;Intent-to-treatAnalysisSet(Study 54767414MMIY3019)   |
|-----------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
|                                   | VRd                                                                                                                    | VRd                                                                                                                    | D-VRd                                                                                                                  | D-VRd                                                                                                                  |                                                                                                                        |                                                                                                                        |
|                                   | n (%)                                                                                                                  | 95% CI for %                                                                                                           | n (%)                                                                                                                  | 95%CI for%                                                                                                             | OddsRatio (95% CI)                                                                                                     | P-valueb                                                                                                               |
| Analysisset:intent-to-treat       | 198                                                                                                                    |                                                                                                                        | 197                                                                                                                    |                                                                                                                        |                                                                                                                        |                                                                                                                        |
| Response category                 |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |                                                                                                                        |
| Stringentcompleteresponse(sCR)    | 71 (35.9%)                                                                                                             | (29.2%,43.0%)                                                                                                          | 102 (51.8%)                                                                                                            | (44.6%, 58.9%)                                                                                                         | 1.94 (1.29, 2.92)                                                                                                      | 0.0015                                                                                                                 |
| Completeresponse (CR)             | 46 (23.2%)                                                                                                             | (17.5%, 29.7%)                                                                                                         | 49 (24.9%)                                                                                                             | (19.0%, 31.5%)                                                                                                         |                                                                                                                        |                                                                                                                        |
| Very good partial response (VGPR) | 52 (26.3%)                                                                                                             | (20.3%,33.0%)                                                                                                          | 30 (15.2%)                                                                                                             | (10.5%, 21.0%)                                                                                                         |                                                                                                                        |                                                                                                                        |
| Partial response (PR)             | 12 (6.1%)                                                                                                              | (3.2%, 10.3%)                                                                                                          | 11 (5.6%)                                                                                                              | (2.8%, 9.8%)                                                                                                           |                                                                                                                        |                                                                                                                        |
| Stable disease (SD)               | 10 (5.1%)                                                                                                              | (2.4%, 9.1%)                                                                                                           | 4 (2.0%)                                                                                                               | (0.6%, 5.1%)                                                                                                           |                                                                                                                        |                                                                                                                        |
| Progressive disease (PD)          | 0                                                                                                                      | (NE, NE)                                                                                                               | 0                                                                                                                      | (NE, NE)                                                                                                               |                                                                                                                        |                                                                                                                        |
| Not evaluable (NE)                | 7 (3.5%)                                                                                                               | (1.4%, 7.1%)                                                                                                           | 1 (0.5%)                                                                                                               | (0.0%, 2.8%)                                                                                                           |                                                                                                                        |                                                                                                                        |
| Overallresponse(sCR+CR+VGPR+PR)   | 181 (91.4%)                                                                                                            | (86.6%, 94.9%)                                                                                                         | 192 (97.5%)                                                                                                            | (94.2%,99.2%)                                                                                                          | 3.52(1.28,9.67)                                                                                                        | 0.0090                                                                                                                 |
| VGPRorbetter(sCR+CR+VGPR)         | 169 (85.4%)                                                                                                            | (79.6%, 90.0%)                                                                                                         | 181 (91.9%)                                                                                                            | (87.1%, 95.3%)                                                                                                         | 1.92 (1.01,3.66)                                                                                                       | 0.0430                                                                                                                 |
| CR or better (sCR + CR)           | 117 (59.1%)                                                                                                            | (51.9%, 66.0%)                                                                                                         | 151 (76.6%)                                                                                                            | (70.1%, 82.4%)                                                                                                         | 2.31 (1.48, 3.60)                                                                                                      | 0.0002                                                                                                                 |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomidedexamethasone; CI = confidence interval.

<div style=\"page-break-after: always\"></div>

a Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are: ISS staging (I, II, III), age/transplant eligibility (&lt;70 years ineligible, or age&lt;70 years and refusal to transplant, or age ≥70 years) as randomized. An odds ratio &gt; 1 indicates an advantage for D-VRd.

b P-value from the Cochran Mantel-Haenszel Chi-Squared test.

Note: Response was assessed by computerized algorithm, based on International Uniform Response Criteria Consensus Recommendations.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Key secondary endpoint: Sustained MRD negativity

Table 15 . Summary of Durable MRD-negative Rate at 10 -5  in Bone Marrow; Intent-to-treat Analysis Set- data cut off: 08 September 2022 (Study 54767414MMY3019)

| Analysis set: intent-to-treat        | VRd 198        | D-VRd 197        |
|--------------------------------------|----------------|------------------|
| Durable MRD-negativity rate (10-5) a | 50 (25.3%)     | 84 (42.6%)       |
| Exact 95% CI of MRD negativity rate  | (19.4%, 31.9%) | (35.6%, 49.9%)   |
| Odds 1atio with 95% CI               |                | 2.18 (1.42,3.34) |
| P-valued                             |                | 0.0003           |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomidedexamethasone; CI = confidence interval.

a Durable MRD-negative is defined as MRD negative and confirmed by at least 1 year apart without MRD positive in between.

b Exact 95% confidence interval.

c Chi-square estimate of the common odds ratio is used. An odds ratio &gt; 1 indicates an advantage for D-VRd. d P-value from Fisher's exact test.

Note: Subjects who had negative or positive MRD assessment are considered as having MRD assessment. Note: Durable MRD negativity rate is defined as the proportion of subjects who achieve CR or better response and have achieved MRD negative status (at 10 -5) at 2 bone marrow aspirate examinations that are a minimum of 1 year apart (and the 2 examinations should be prior to progressive disease (PD), subsequent anti-myeloma therapy, or both), without any examination showing MRD positive status in between.

## Secondary endpoint: Overall survival

Table 16 . Summary of Overall Survival; Intent-to-treat Analysis Set- data cut-off: 07 May 2024 (Study 54767414MMY3019)

|                                   | VRd                  | D-VRd             |
|-----------------------------------|----------------------|-------------------|
| Analysis set: intent-to-treat     | 198                  | 197               |
| Overall survival (OS)             |                      |                   |
| Number of events (%)              | 60 (30.3%)           | 51 (25.9%)        |
| Number of censored (%)            | 138 (69.7%)          | 146 (74.1%)       |
| Kaplan-Meier estimate (months)    |                      |                   |
| 25% quantile (95% CI)             | 42.02 (31.31, 60.58) | 52.04 (28.94, NE) |
| Median (95% CI)                   | NE (61.86, NE)       | NE (NE, NE)       |
| 75% quantile (95% CI)             | NE (NE, NE)          | NE (NE, NE)       |
| P-valuea                          |                      | 0.3950            |
| Hazard ratio (95% CI)b            |                      | 0.85 (0.58, 1.24) |
| 12-month survival rate % (95% CI) | 92.7 (88.0, 95.6)    | 90.8 (85.7, 94.1) |
| 18-month survival rate % (95% CI) | 88.0 (82.4, 91.8)    | 88.7 (83.3,92.4)  |
| 24-month survival rate % (95% CI) | 85.8 (80.0, 90.1)    | 83.9 (77.9, 88.4) |
| 30-month survival rate % (95% CI) | 82.6 (76.4, 87.3)    | 79.7 (73.2,84.7)  |
| 36-month survival rate % (95% CI) | 77.7 (71.1, 83.0)    | 78.6 (72.1, 83.8) |
| 48-month survival rate % (95% CI) | 71.8 (64.8, 77.7)    | 75.9 (69.1, 81.3) |
| 54-month survival rate % (95% CI) | 69.6 (62.5, 75.7)    | 74.2 (67.3, 79.8) |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomidedexamethasone; CI = confidence interval.

a - p-value is based on the log-rank test stratified with ISS staging (I, II, III), and age/transplant eligibility (&lt;70 years

<div style=\"page-break-after: always\"></div>

ineligible, or age&lt;70 years and refusal to transplant, or age ≥70 years) as randomized.

b - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), and age/transplant eligibility (&lt;70 years ineligible, or age&lt;70 years and refusal to transplant, or age ≥70 years) as randomized. A hazard ratio &lt;1 indicates an advantage for D-VRd.

Figure 10. Kaplan-Meier Plot for Overall Survival; Intent-to-treat Analysis Set; Final PFS Analysis-data cut-off: 07 May 2024 (Study 54767414MMY3019)

<!-- image -->

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomiblenalidomide-dexamethasone.

## Ancillary analyses

Figure 11. Forest Plot of subgroup analyses on MRD Negativity Rate at 10-5 in Bone Marrow; Intentto-treat Analysis Set; Final PFS Analysis- data cut-off: 07 May 2024 (Study 54767414MMY3019)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomiblenalidomidedexamethasone;

CI = confidence interval; N = number of subjects; n = number of subjects with negative MRD at 10 -5 ; CR = complete response; sCR = stringent complete response; ECOG = Eastern Cooperative Oncology Group; FISH = fluorescence in situ hybridization.

Note: High risk is defined by FISH testing: t (4; 14), t (14; 16), and 17p deletion.

Note: Mantel-Haenszel estimate of the common odds ratio for un-stratified tables is used. An odds ratio &gt; 1 indicates an advantage for D-VRd.

<div style=\"page-break-after: always\"></div>

Figure 12. Forest plot of sensitivity and supplementary analyses for Progression-free Survival based on computerised algorithm; Final PFS Analysis- data cut-off: 07 May 2024 (Study 54767414MMY3019)

<!-- image -->

|                                                         | Events Number(%)    | Hazard Ratio     | 2-sidedp-value   |
|---------------------------------------------------------|---------------------|------------------|------------------|
|                                                         | VRd D-VRd           | (95%CI)          |                  |
| SensitiveandsupplementaryanalysistoPFs                  |                     |                  |                  |
| Un-stratified PFS                                       | 91(46.0%)63(32.0%)  | 0.59(0.43-0.82)  | 0.0013           |
| Censored forDeathdue to COVID-19                        | 85(42.9%)51(25.9%)  | 0.49(0.34-0.69)  | <0.0001          |
| CensoredSubjectsWhoDiscontinueTRT/StudyduetoCOVID-19    | 85(42.9%)51(25.9%)  | 0.49 (0.34-0.69） | <0.0001          |
| NotCensoredforSubsequentAntinyelomaTherapy              | 94（47.5%)63(32.0%6) | 0.55(0.4-0.76)   | 0.0003           |
| NotCensored forDeathorPDafter2orMoreConsecutiveMissedDE | 97(49.0%)65(33.0%)  | 0.55(0.4-0.76)   | 0.0002           |
| Progression-freeSurvivalBasedon InvestigatorAssessment  | 90（45.5%)63(32.0%)  | 0.57(0.42-0.79)  | 0.0007           |

Figure 13. Forest Plot of subgroup analyses on progression-free survival based on computerised algorithm; Intent-to-treat Analysis Set; Final PFS Analysis data cut-off: 07 May 2024 (Study 54767414MMY3019)

|                                             |                         | VRd    | VRd    | D-VRd   | D-VRd        | Hazard Ratio      |
|---------------------------------------------|-------------------------|--------|--------|---------|--------------|-------------------|
|                                             | Hazard Ratio and 95% Cl | EVT/N  | Median |         | EVT/N Median | (95% CI)          |
| Sex                                         |                         |        |        |         |              |                   |
| Male                                        |                         | 53/111 | 49.2   | 24/87   | NE           | 0.46 (0.29, 0.75) |
| Female                                      |                         | 38/87  | NE     | 39/110  | NE           | 0.73 (0.47, 1.15) |
| Age                                         |                         |        |        |         |              |                   |
| <70 years                                   |                         | 88/8   | NE     | 30/88   | NE           | 0.72 (0.44, 1.16) |
| >=70 years                                  |                         | 53/110 | 49.4   | 33/109  | NE           | 0.50 (0.33, 0.78) |
| Region                                      |                         |        |        |         |              |                   |
| Europe                                      |                         | 54/116 | 51.1   | 37/120  | NE           | 0.54 (0.36, 0.82) |
| North America                               |                         | 13/31  | 50.2   | 10/37   | NE           | 0.51 (0.22, 1.17) |
| Other                                       |                         | 24/51  | NE     | 16/40   | NE           | 0.87 (0.46, 1.64) |
| Weight                                      |                         |        |        |         |              |                   |
| <=65 kg                                     |                         | 24/63  | NE     | 17/58   | NE           | 0.62 (0.34, 1.16) |
| >65 - 85 kg                                 |                         | 40/88  | 51.1   | 34/101  | NE           | 0.65 (0.41, 1.02) |
| >85 kg                                      |                         | 27/47  | 41.9   | 12/38   | NE           | 0.46 (0.23, 0.91) |
| Baseline Internatlonal Staging System (ISS) |                         |        |        |         |              |                   |
| I                                           |                         | 28/68  | 60.6   | 21/68   | NE           | 0.66 (0.37, 1.16) |
| II                                          |                         | 37/75  | 45.6   | 18/73   | NE           | 0.36 (0.21, 0.64) |
| IIII                                        |                         | 26/55  | 49.2   | 24/56   | NE           | 0.84 (0.48, 1.46) |
| Cytogenetic risk                            |                         |        |        |         |              |                   |
| High risk                                   |                         | 17/27  | 31.7   | 13/25   | 39.8         | 0.88 (0.42, 1.84) |
| Standard risk                               |                         | 61/09  | 60.6   | 43/149  | NE           | 0.61 (0.41, 0.91) |
| Baseline ECOG performance score             |                         |        |        |         |              |                   |
| Q                                           |                         | 30/84  | NE     | 16/71   | NE           | 0.53 (0.29, 0.97) |
| >=1                                         |                         | 61/114 |        | 47/126  | NE           | 0.59 (0.40, 0.86) |

+Favor D-VRd Favor VRd→

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomidedexamethasone; CI = confidence interval.

Note: Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable. A hazard ratio &lt;1 indicates an advantage for D-VRd.

Note: High risk is defined by FISH testing: t (4; 14), t (14; 16), and 17p deletion.

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 17. Summary of Efficacy for trial MMY3019 (Cepheus)

| Myeloma and for Study identifier   | VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Study Number: 54767414MMY3019 (Cepheus) EudraCT Number: 2018-001545-13   | VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Study Number: 54767414MMY3019 (Cepheus) EudraCT Number: 2018-001545-13   | VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Study Number: 54767414MMY3019 (Cepheus) EudraCT Number: 2018-001545-13                                                                                                                                                                                                          |
|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Myeloma and for Study identifier   | NCT Number: NCT03652064 A randomized (1:1), open-label, multicenter, Phase 3 study comparing D-VRd vs. VRd in patients with NDMM who are ineligible for treatment with ASCT                                                           |                                                                                                                                                                                                                                       | 15 November 2018 (first participant screened) Starts up to 28 days before randomization Extends from C1D1 to discontinuation of all study treatment                                                                                                                                                                                                                                                                                          |
| Hypothesis                         | treatment discontinuation Superiority of D-VRd over VRd                                                                                                                                                                               | treatment discontinuation Superiority of D-VRd over VRd                                                                                                                                                                               | treatment discontinuation Superiority of D-VRd over VRd                                                                                                                                                                                                                                                                                                                                                                                      |
| Treatments groups                  | VRd                                                                                                                                                                                                                                   | VRd                                                                                                                                                                                                                                   | Bortezomib s.c. 1.3 mg/m2 (Days 1, 4, 8, and 11) for Cycles 1-8. Fixed duration of 8 cycles. Lenalidomide 25 mg PO - D1 to D14 in cycles 1-8. Cycle 9 and beyond 25mg PO D1- D21 until PD or unacceptable toxicity. Dexamethasone 20mg PO Days 1, 2, 4, 5, 8, 9, 11, 12 in Cycles 1-8. In Cycles 9 and beyond, 40 mg PO on Days 1, 8, 15, 22, until PD or unacceptable toxicity Cycles 1-8: 21D in length Cycles 9 and beyond: 28D in length |
| Treatments groups                  | D-VRd                                                                                                                                                                                                                                 | D-VRd                                                                                                                                                                                                                                 | VRd as above Daratumumab SC 1800 mg weekly in Cycles 1- 2, every 3 weeks in Cycles 3-8, and every 4 weeks in Cycle 9 and beyond until PD or unacceptable toxicity                                                                                                                                                                                                                                                                            |
| Endpoints and definitions          | Primary endpoint                                                                                                                                                                                                                      | Overall MRD negativity rate                                                                                                                                                                                                           | The proportion of ITT subjects who have achieved MRD negative status (at 10 -5 ) by bone marrow aspirate after randomization and prior to progressive disease (PD) or subsequent anti- myeloma therapy.                                                                                                                                                                                                                                      |
| Endpoints and definitions          | Key Secondary endpoint                                                                                                                                                                                                                | PFS by computerised algorithm                                                                                                                                                                                                         | Time from the date of randomization to the date of PD (assessed by 2011 IMWG criteria) or death                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                 | Key Secondary endpoint                                                                                                                                                                                                                   | Overall CR or better rate                                                                                                                                                                                                                | The percentage of ITT participants who achieved CR or sCR status anytime during the                                                                                                                                                      | The percentage of ITT participants who achieved CR or sCR status anytime during the                                                                                                                                                      |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Key Secondary endpoint                                                                                                                                                                                                                   | Sustained MRD negativity rate                                                                                                                                                                                                            | study per the 2011 IMWG criteria The proportion of ITT participants who achieved CR or better response and maintained MRD-negative status for at least 12 months, without any MRD-positive results in between.                           | study per the 2011 IMWG criteria The proportion of ITT participants who achieved CR or better response and maintained MRD-negative status for at least 12 months, without any MRD-positive results in between.                           |
|                                                 | Secondary endpoint                                                                                                                                                                                                                       | Overall survival                                                                                                                                                                                                                         | Measured from the date of randomization to the date of the participant's death                                                                                                                                                           | Measured from the date of randomization to the date of the participant's death                                                                                                                                                           |
| Database lock                                   | 05 June 2024                                                                                                                                                                                                                             |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                     |
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                         |
| Analysis population and time point description  | Intent to treat, n = 395 Median follow-up of 22.3 months at primary MRD analysis (08 APR 2021) Median follow-up of 39.9 months at interim PFS analysis (08 SEP 2022) Median follow-up of 58.7 months at final PFS analysis (07 MAY 2024) | Intent to treat, n = 395 Median follow-up of 22.3 months at primary MRD analysis (08 APR 2021) Median follow-up of 39.9 months at interim PFS analysis (08 SEP 2022) Median follow-up of 58.7 months at final PFS analysis (07 MAY 2024) | Intent to treat, n = 395 Median follow-up of 22.3 months at primary MRD analysis (08 APR 2021) Median follow-up of 39.9 months at interim PFS analysis (08 SEP 2022) Median follow-up of 58.7 months at final PFS analysis (07 MAY 2024) | Intent to treat, n = 395 Median follow-up of 22.3 months at primary MRD analysis (08 APR 2021) Median follow-up of 39.9 months at interim PFS analysis (08 SEP 2022) Median follow-up of 58.7 months at final PFS analysis (07 MAY 2024) |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                          | Treatment group                                                                                                                                                                                                                          | D-VRd                                                                                                                                                                                                                                    | VRd                                                                                                                                                                                                                                      |
|                                                 | Number of subjects                                                                                                                                                                                                                       | Number of subjects                                                                                                                                                                                                                       | N = 197                                                                                                                                                                                                                                  | N = 197                                                                                                                                                                                                                                  |
|                                                 | Overall MRD negativity rate, n (%)                                                                                                                                                                                                       | Overall MRD negativity rate, n (%)                                                                                                                                                                                                       | 105 (53.3%)                                                                                                                                                                                                                              | 70 (35.4%)                                                                                                                                                                                                                               |
|                                                 | %(95% CI) PFS event by                                                                                                                                                                                                                   | %(95% CI) PFS event by                                                                                                                                                                                                                   | (46.1%, 60.4%) 46                                                                                                                                                                                                                        | (28.7%, 42.4%) 67                                                                                                                                                                                                                        |
|                                                 | computerised algorithm, n                                                                                                                                                                                                                | computerised algorithm, n                                                                                                                                                                                                                | 23.4%                                                                                                                                                                                                                                    | 33.8%                                                                                                                                                                                                                                    |
|                                                 | % Overall CR or better rate, n (%) %(95% CI)                                                                                                                                                                                             | % Overall CR or better rate, n (%) %(95% CI)                                                                                                                                                                                             | 151 (76.6%) (70.1%, 82.4%)                                                                                                                                                                                                               | 117 (59.1%) (51.9%, 66.0%) 50 (25.3%)                                                                                                                                                                                                    |
|                                                 | Sustained MRD negativity rate, n (%)                                                                                                                                                                                                     | Sustained MRD negativity rate, n (%)                                                                                                                                                                                                     | 84 (42.6%)                                                                                                                                                                                                                               | (19.4%, 31.9%)                                                                                                                                                                                                                           |
|                                                 | %(95% CI)                                                                                                                                                                                                                                | %(95% CI)                                                                                                                                                                                                                                | (35.6%, 49.9%)                                                                                                                                                                                                                           |                                                                                                                                                                                                                                          |
|                                                 | Overall survival events, n                                                                                                                                                                                                               | Overall survival events, n                                                                                                                                                                                                               | 51                                                                                                                                                                                                                                       | 60                                                                                                                                                                                                                                       |
|                                                 |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          | (25.9%)                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                          |
|                                                 | %                                                                                                                                                                                                                                        | %                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                          | (30.3)                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  | Primary endpoint - Overall MRD negativity rate                                                                                                                                                                                           | Comparison groups                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                        | D-VRd vs VRd                                                                                                                                                                                                                             |
| Effect estimate per comparison                  | Primary endpoint - Overall MRD negativity rate                                                                                                                                                                                           | Odds ratio a 95% CI                                                                                                                                                                                                                      | Odds ratio a 95% CI                                                                                                                                                                                                                      | 2.07 (1.38, 3.10)                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | Secondary endpoint - PFS by computerised algorithm                                                                                                                                                                                       | P-value Comparison groups HR c 95% CI P-value d                                                                                                                                                                                          | P-value Comparison groups HR c 95% CI P-value d                                                                                                                                                                                          | D-VRd vs VRd 0.61 (0.42, 0.90) 0.0104                                                                                                                                                                                                    |
| Effect estimate per comparison                  | Secondary endpoint - Overall CR or                                                                                                                                                                                                       | Comparison groups Odds ratio a                                                                                                                                                                                                           | Comparison groups Odds ratio a                                                                                                                                                                                                           | D-VRd vs VRd 2.31                                                                                                                                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          | 95% CI e                                                                                                                                                                                                                                 | 95% CI e                                                                                                                                                                                                                                 | (1.48, 3.60)                                                                                                                                                                                                                             |
| Effect estimate per comparison                  | better Secondary                                                                                                                                                                                                                         | P-value                                                                                                                                                                                                                                  | P-value                                                                                                                                                                                                                                  | 0.0002                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  | endpoint - Sustained MRD negativity rate                                                                                                                                                                                                 | Comparison groups f                                                                                                                                                                                                                      | Comparison groups f                                                                                                                                                                                                                      | D-VRd vs VRd 2.18                                                                                                                                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          | Odds ratio                                                                                                                                                                                                                               | Odds ratio                                                                                                                                                                                                                               |                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          | (1.42, 3.34)                                                                                                                                                                                                                             |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          | 95% CI                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          | P-value b                                                                                                                                                                                                                                | P-value b                                                                                                                                                                                                                                | 0.0003                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                       |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          | D-VRd vs VRd                                                                                                                                                                                                                             |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                        |                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          | 0.85                                                                                                                                                                                                                                     |
| Effect estimate per comparison                  | - Overall survival g                                                                                                                                                                                                                     | HR c                                                                                                                                                                                                                                     | HR c                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          | 95% CI                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                   | (0.58, 1.24)                                                                                                                                                                                                                             |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          | P-value d (nominal)                                                                                                                                                                                                                      | P-value d (nominal)                                                                                                                                                                                                                      |                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          | 0.395                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Notes   | All results mentioned are from CCO at primary MRD analysis (08 APR 2021) except PFS results and sustained MRD rate results which are from CCO at interim PFS analysis (08 SEP 2022), and OS results which are from CCO at final PFS analysis (07 MAY 2024). a - Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are: ISS staging (I, II, III), age/transplant eligibility (<70 years ineligible, or age<70 years and refusal to transplant, or age ≥70 years) as randomized. b - P-value from Fisher's exact test. c - Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), and age/transplant eligibility (<70 years ineligible, or age<70 years and refusal to transplant, or age ≥70 years) as randomized. d - p-value is based on the log-rank test stratified with ISS staging (I, II, III), and age/transplant eligibility (<70 years ineligible, or age<70 years and refusal to transplant, or age ≥70 years) as randomized. e - P-value from the Cochran Mantel-Haenszel Chi-Squared test. f - Chi-square estimate of the common odds ratio is used. g - All OS analyses are descriptive   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

CEPHEUS is a randomised (1:1), open-label, multicentre, Phase 3 study that evaluated the efficacy and safety of daratumumab SC in combination with D-VRd vs VRd in participants with NDMM for whom ASCT was not planned as initial therapy.  At randomization, participants were stratified by ISS stage (I, II, or III) and age/transplant eligibility (&lt;70 years ineligible, or &lt;70 years and refusal to transplant [meaning transplant was not planned as initial therapy], or ≥70 years).

The stratification factors have prognostic implications in this setting and are deemed appropriate.

## Study participants

Inclusion and exclusion criteria are overall acceptable. The trial allowed for inclusion of patients who refused ASCT as initial therapy but in fact were eligible for such treatment. It can be assumed that patients who are eligible for treatment with ASCT but refuse that treatment option are more fit and less comorbid than patients who are 'truly' ineligible and this could potentially affect efficacy and safety outcomes of the trial. This potentially hampers the generalisability of study results to a truly ineligible population.

The diagnostic criteria for multiple myeloma are acceptable and widely recognized (Monoclonal plasma cells in the bone marrow ≥10% or presence of a biopsy proven plasmacytoma and presence of at least one CRAB or SLiM CRAB criteria). However, it should be noted that a screening period of 28 days before randomisation to treatment excluded patients with NDMM who needed acute or sub-acute anti-myeloma treatment with more than just 40mg x 4 of dexamethasone to alleviate severe kidney disease, severe hypercalcemia or significant bone disease. Early death in multiple myeloma is, among other factors, correlated  with  hypercalcemia,  fractures  and  impaired  renal  function  (Augustson,  JCO,  2005).  The exclusion of NDMM patients with an acute or sub-acute presentation at diagnosis can be considered justifiable as management of acutely ill NDMM patients in the strict framework of a clinical trial can be complicated. However, the exclusion of NDMM patients with a more acute presentation should be kept in mind when extrapolating trial results to non-trial settings. Patients with active systemic infection were also excluded from the trial. Infection is common in NDMM patients and is one of the leading causes of early death in NDMM. It is acceptable to exclude such patients in a trial where the main goal is to

<div style=\"page-break-after: always\"></div>

investigate  long-term  efficacy  of  an  anti-myeloma  agent.  Importantly,  the  included  patients  were randomised and patients with bad prognostic markers such as ISS stage III and high-risk cytogenetics were also included.

## Treatments

Treatment regimens were standard and acceptable.

## Objectives/endpoints

The primary endpoint was overall MRD negativity rate defined as the proportion of ITT subjects who have achieved MRD negative status (at 10 -5 ) by bone marrow aspirate after randomization and prior to progressive disease (PD) or subsequent anti-myeloma therapy. The key secondary endpoints were PFS by computerised algorithm (assessed by 2011 IMWG criteria), overall CR or better rate and sustained MRD negativity rate. Overall survival analyses were not type 1 error controlled.

The Scientific Advice given in November 2017 recommended that PFS was a preferable endpoint to MRD negativity rate. Despite the SA, the primary endpoint for study MMY3019 was changed from PFS to overall MRD negativity rate and PFS was downgraded to a key secondary endpoint before enrolment began.

## Statistical methods

This was an open-label trial in which the endpoints, including PFS, were assessed by investigators rather than through an IBCR. EMA guidelines recommend the use of IBCR in open-label trials to ensure objective and consistent evaluation of endpoints like PFS. The absence of IBCR in this study represents a potential limitation, as investigator-based assessments are inherently prone to bias due to knowledge of treatment assignments. While an IDMC was established to review safety and efficacy during the trial, its role does not include assessing individual endpoints such as PFS.

The primary endpoint of MRD negativity was analysed using a 10 -5  threshold on the ITT analysis set, with 95% CI calculated. MRD negativity after progression or subsequent therapy was excluded. Odds ratios and p-values were estimated using the stratified Cochran Mantel Haenszel method, stratified by ISS stage and age/transplant eligibility.

Censoring rules for PFS primarily involved administrative censoring at the study cut-off, which accounted for the majority of censored cases in both arms (73.8% in VRd vs. 89.6% in D-VRd). Non-administrative censoring, such as withdrawal of consent, initiation of subsequent anti-myeloma therapy, or missed assessments,  occurred  less  frequently  in  the  D-VRd  arm  (8  participants  withdrew,  3  missed  two assessments or experienced death, and 1 was lost to follow-up in the D-VRd arm compared to 9, 11, 6, and 1, respectively, in the VRd arm), indicating a lower likelihood of bias arising from these factors in the treatment group. Given the minimal impact of non-administrative censoring in the D-VRd arm and the lower frequency of such cases compared to the VRd arm, conducting additional sensitivity analyses may not be necessary to confirm the robustness of the PFS results. PFS was analysed using the ITT analysis set. Kaplan-Meier curves were plotted, and hazard ratios with 95% CIs were estimated using a stratified Cox proportional hazards model, with treatment as the sole explanatory variable. Treatment differences were tested using a stratified log-rank test, and landmark PFS rates with 95% CIs were estimated by the Kaplan-Meier method.

No interim analysis was conducted for the primary endpoint (MRD negativity), so no alpha adjustment was required. For PFS, a single interim analysis was planned after 60% of events, using O'Brien-Fleming boundaries with the Lan-DeMets alpha-spending method to control type I error. The amendment in Protocol 2 clarified the hierarchical testing approach for key secondary endpoints to ensure control of the family-wise Type I error rate. This update was made well before the primary MRD analysis and interim PFS analysis. While the timing of these amendments raises theoretical concerns about procedural bias,  this  is  mitigated  by  the  fact  that  the  primary  endpoint  and  all  key  secondary  endpoints  were statistically significant, indicating robust results.

<div style=\"page-break-after: always\"></div>

## Study conduct

Protocol  amendments  have  been  appropriately  justified  and  are  not  believed  to  have  affected  trial integrity.  Enrolment  began  before  the  COVID-19  pandemic,  but  much  of  the  study  was  conducted through the main waves of the COVID-19 pandemic and this is likely to have affected trial conduct but it is not believed to invalidate trial results. In particular, many deaths due to COVID-19 in Brazil was observed.

Major protocol deviations were few and mostly balanced between study arms. Receiving a disallowed concomitant  treatment  happened  more  frequently  in  the  VRd  arm  than  the  D-VRd  arm  (8  vs  3, respectively).  The  majority  of  these  events  in  both  arms  were  due  to  administration  of  subsequent anticancer treatment before progressive disease being confirmed.

Protocol deviations are believed not to have had major impact on trial conduct or study results.

## Baseline characteristics

The demographic and clinical characteristics of the patients at baseline were generally balanced in the two groups and reflect a rather fit patient population with NDMM that could go up to 28 days without initiation  of  anti-myeloma  treatment  other  than  4  x  40mg  of  dexamethasone  and  thus  selecting  a population with less aggressive debut of multiple myeloma without immediate need of treatment.

The median age was 70.0 (range: 31 to 80) years. Half of the participants were female (49.9%). The proportion of participants with an ECOG performance score of 0, 1 and 2 was 39.2%, 51.4%, and 9.4%, respectively. More participants in the VRd arm had an ECOG performance score of 0 (D-VRd: 36.0%; VRd: 42.4%), while more participants in the D-VRd arm had an ECOG performance score of 2 (D-VRd: 11.7%; VRd: 7.1%). Based on total frailty scores at baseline, 64.8% of participants were fit (score of 0), 35.2% had intermediate fitness (score of 1), and per protocol no participant was frail (score of 2).

Of the 350 participants who had evaluable baseline cytogenetic data reported, 52 (14.9%) participants had  a  high-risk  cytogenetic  abnormality  (presence  of  del[17p]  [7.4%],  t[4;14]  [7.1%]  or  t[4;16] [1.7%]). Cytogenetic risk factors were overall balanced between study arms.

The median time from initial diagnosis of MM to randomization was 1.18 months across both arms.

Stratification factors of ISS stage and age or transplant eligibility were balanced between study arms. A total of 106 (26.8%) patients were considered eligible for ASCT but refused this treatment option. The remaining 289 (73.2%) patients were in fact ineligible for ASCT due to age or comorbidities. They reflect the target population that is the basis for this application for extension of indication. The efficacy and safety of daratumumab in combination with VRd has already been assessed and is considered established in the transplant eligible population on basis of study MMY3014 (PERSEUS); EMEA/H/C/004077/II/0072.

## Efficacy data and additional analyses

At the primary MRD analysis (08 April 2021), with a median follow-up of 22.3 months, the addition of daratumumab SC to VRd resulted in a statistically significant improvement  in  the  primary  endpoint overall MRD negativity rate as measured by NGS for participants achieving CR or better compared with VRd alone, with an absolute increase of 17.9% favoring D-VRd (D-VRd: 105 (53.3%); VRd: 70 (35.4%); OR=2.07 with 95% CI: 1.38, 3.10; 2-sided p=0.0004). Treatment effect on overall MRD negativity rate (D-VRd over VRd) was generally consistent across the pre-specified subgroups with the exception of high risk cytogenetics.

As of the interim PFS analysis cutoff date (08 SEP 2022), with a median follow-up of 39.0 months, a total  of  113  PFS  events  were  observed (D-VRd: 46 [23.4%]; VRd: 67 [33.8%]) corresponding to a maturity of 28.6% PFS events (113/395). The addition of daratumumab to VRd resulted in a statistically significant improvement in the key secondary endpoint of PFS with a HR of 0.61 (95% CI: 0.42, 0.90; 2-sided p=0.0104) crossing the prespecified 2-sided stopping boundary of 0.0145 in favor of the D-VRd arm).  The  median  PFS  was  not  reached  in  either  treatment  arm.  Prespecified  sensitivity  and

<div style=\"page-break-after: always\"></div>

supplementary  analyses  were  consistent  with  the  final  PFS  result  per  the  computerized  algorithm supporting results of the interim PFS analysis.

This  improvement  in  a  time-to-event  endpoint  is  an  important  finding  that  supports  the  primary response-based  endpoint  (overall  MRD  negativity  rate)  and  reinforces  efficacy  claims  of  adding daratumumab to VRd in  NDMM patients  who  are  ineligible  for  treatment  with  ASCT.  Whether  MRD negativity can be considered a validated trial level surrogate marker for PFS in NDMM is yet to be robustly confirmed (Landgren, Blood, 2024; Paiva, Blood Adv, 2023; Ficek, Clin lymp myel leuk, 2023). However, in study MMY3019 the positive results from the primary endpoint of MRD negativity rate are supported by PFS results.

At the primary MRD analysis cutoff (08 April 2021), the addition of daratumumab to VRd resulted in a statistically significant improvement in the key secondary endpoint of overall CR or better rate compared with  VRd  alone,  with  an  absolute  increase  of  17.5%  favoring  D-VRd  (D-VRd:  76.6%;  VRd:  59.1%; OR=2.31 with 95% CI: 1.48, 3.60, 2-sided p=0.0002), crossing the prespecified stopping boundary of p=0.0244 in favor of the D-VRd arm.

As of the interim PFS analysis cutoff (08 SEP 2022), the key secondary endpoint of sustained MRD negativity rate was 42.6% (n=84) in the D-VRd arm vs 25.3% (n=50) in the VRd arm. The common odds ratio from Chi-square estimate was 2.18 (95% CI: 1.42, 3.34) and the 2-sided p-value was 0.0003, crossing the prespecified boundary of 2-sided p=0.0244 in favor of the D-VRd arm.

At the final PFS analysis CCO (07 MAY 2024) with a median follow-up of 58.7 months, OS data were still not mature, with a total of 111 deaths [D-VRd: 51/197 (25.9%); VRd: 60/198 (30.3%)]. The median OS was not reached for either treatment arm. The hazard ratio for death (D-VRd vs. VRd) was 0.85 (95% CI: 0.58, 1.24). All OS analyses in study MMY3019 are descriptive. There seems to be no obvious OS detriment by adding daratumumab to VRd in NDMM patients who are ineligible for treatment with ASCT.

## 2.4.4. Conclusions on the clinical efficacy

Results  from  the  study  MMY3019  showed  a  statistically  significant  improvement  in  the  event-based endpoint PFS from the addition of daratumumab to VRd in patients with NDMM who are ineligible for treatment with ASCT. This improvement is considered clinically significant and is consistent with the effect seen on the primary endpoint of the trial, overall MRD negativity rate, and the improvements in overall CR or better rate and sustained MRD negativity rate.

OS data are immature but do not show any sign of detriment in the experimental arm.

## 2.5. Clinical safety

## Patient exposure

The Safety Analysis Set includes all patients that received at least one dose of any study treatment in study 54767414MMY3019 corresponding to a total of 392 participants (D-VRd: 197; VRd: 195). It also includes patients that were eligible for ASCT but opted out (n=53 in each arm corresponding to 27%). A summary of the duration of treatment in that trial is presented in Table 18 .

<div style=\"page-break-after: always\"></div>

Table 18 . Summary of Duration of Treatment, by Treatment Phase; Safety Analysis Set (Study 54767414MMY3019)

|                                                       | VRd              | D-VRd             |
|-------------------------------------------------------|------------------|-------------------|
| Analysis set: safety                                  | 195              | 197               |
| Duration of study treatment(months)                   |                  |                   |
| N                                                     | 195              | 197               |
| Mean (SD)                                             | 35.11 (22.063)   | 42.83 (21.341)    |
| Median                                                | 34.33            | 56.28             |
| Range                                                 | (0.5; 63.8)      | (0.1; 64.6)       |
| Bortezomib dose intensity (mg/m²/cycle) a             |                  |                   |
| N                                                     | 195              | 197               |
| Mean (SD)                                             | 4.22 (0.863)     | 4.28 (0.864)      |
| Median                                                | 4.41             | 4.51              |
| Range                                                 | (1.7; 5.3)       | (1.3; 5.4)        |
| Lenalidomide dose intensity (mg/cycle) b              |                  |                   |
| N                                                     | 195              | 197               |
| Mean (SD)                                             | 291.27 (117.375) | 291.68 (124.463)  |
| Median                                                | 291.50           | 270.00            |
| Range                                                 | (60.0; 504.1)    | (45.0; 504.7)     |
| Lenalidomide dose intensity (Cycle 1-8, mg/cycle) b   |                  |                   |
| N                                                     | 195              | 197               |
| Mean (SD)                                             | 258.53 (90.879)  | 259.41 (91.097)   |
| Median                                                | 291.25           | 297.50            |
| Range                                                 | (60.0; 350.0)    | (45.0; 371.9)     |
| Lenalidomide dose intensity (Cycle 9+, mg/cycle) b    |                  |                   |
| N                                                     | 167              | 169               |
| Mean (SD)                                             | 319.86 (130.271) | 319.77 (139.006)  |
| Median                                                | 305.38           | 289.47            |
| Range                                                 | (70.0; 525.0)    | (30.0; 525.0)     |
| Dexamethasone dose intensity (mg/cycle) b             |                  |                   |
| N                                                     | 195              | 197               |
| Mean (SD)                                             | 106.86 (38.549)  | 95.02 (44.841)    |
| Median                                                | 101.59           | 87.62             |
| Range                                                 | (17.5; 160.0)    | (11.4; 160.0)     |
| Dexamethasone dose intensity (Cycle 1-8, mg /cycle) b |                  |                   |
| N                                                     | 195              | 197               |
| Mean (SD)                                             | 129.91 (36.514)  | 128.11 (39.017)   |
| Median                                                | 150.00           | 150.00            |
| Range                                                 | (40.0; 160.0)    | (18.8; 177.5)     |
| Dexamethasone dose intensity (Cycle 9+, mg /cycle) b  |                  |                   |
| N                                                     | 158              | 173               |
| Mean (SD)                                             | 88.62 (41.356)   | 82.95 (48.329)    |
| Median                                                | 80.00            | 77.50             |
| Range                                                 | (10.0; 160.0)    | (10.0; 160.0)     |
| Daratumumab dose intensity (mg/cycle) c               |                  |                   |
| N                                                     |                  | 197               |
| Mean (SD)                                             |                  | 2106.08 (532.170) |
| Median                                                |                  | 1918.03           |
| Range                                                 |                  | (1800.0; 5400.0)  |

<div style=\"page-break-after: always\"></div>

|                                                  | VRd   | D-VRd             |
|--------------------------------------------------|-------|-------------------|
| Daratumumab dose intensity (Cycle 1-2, mg/cycle) |       |                   |
| N                                                |       | 197               |
| Mean (SD)                                        |       | 4981.52 (780.805) |
| Median                                           |       | 5400.00           |
| Range                                            |       | (1800.0; 5700.0)  |
| Daratumumab dose intensity (Cycle 3-8, mg/cycle) |       |                   |
| N                                                |       | 191               |
| Mean (SD)                                        |       | 1803.40 (43.449)  |
| Median                                           |       | 1800.00           |
| Range                                            |       | (1800.0; 2400.0)  |
| Daratumumab dose intensity (Cycles 9+, mg/cycle) |       |                   |
| N                                                |       | 175               |
| Mean (SD)                                        |       | 1800.13 (0.835)   |
| Median                                           |       | 1800.00           |
| Range                                            |       | (1800.0; 1806.3)  |
| Number of daratumumab injections                 |       |                   |
| N                                                |       | 197               |
| Mean (SD)                                        |       | 49.1 (22.85)      |
| Median                                           |       | 61.0              |
| Range                                            |       | (1; 75)           |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone.

a Dose intensity (mg/m²/cycle) is calculated as the sum of total doses (mg/m²) received in all cycles divided by the number of treatment cycles on bortezomib.

- Dose intensity (mg /cycle) is calculated as the sum of total doses (mg) received in all cycles divided by the number of treatment cycles on daratumumab.
- b Dose intensity (mg/cycle) is calculated as the sum of total doses (mg) received in all cycles divided by the mumber of treatment cycles on lenalidomide and dexamethasone, respectively.

## Adverse events

An overview of the treatment emergent adverse events (TEAEs) reported Study 54767414MMY3019 is summarised in Table 19.

<div style=\"page-break-after: always\"></div>

Table 19 . Overview of Treatment-emergent Adverse Events; Safety Analysis Set (Study 54767414MMY3019)

|                                                     | VRd          | D-VRd        |
|-----------------------------------------------------|--------------|--------------|
| Analysis set: safety                                | n (%) 195    | n (%) 197    |
| Any TEAE                                            | 195 (100.0%) | 197 (100.0%) |
| At least one relateda                               | 190 (97.4%)  | 195 (99.0%)  |
| Maximum toxicity grade                              |              |              |
| Grade 1                                             | 1 (0.5%)     | 0            |
| Grade 2                                             | 26 (13.3%)   | 15 (7.6%)    |
| Grade 3                                             | 113 (57.9%)  | 88 (44.7%)   |
| Grade 4                                             | 34 (17.4%)   | 61 (31.0%)   |
| Grade 5                                             | 21 (10.8%)   | 33 (16.8%)   |
| Any serious TEAE                                    | 131 (67.2%)  | 142 (72.1%)  |
| At least one relateda                               | 82 (42.1%)   | 74 (37.6%)   |
| TEAE leading to discontinuation of bortezomib       | 32 (16.4%)   | 25 (12.7%)   |
| At least one related to bortezomib                  | 24 (12.3%)   | 18 (9.1%)    |
| TEAE leading to discontinuation of lenalidomide     | 48 (24.6%)   | 63 (32.0%)   |
| At least one related to lenalidomide                | 24 (12.3%)   | 30 (15.2%)   |
| TEAEleading to discontinuationof dexamethasone      | 69 (35.4%)   | 47 (23.9%)   |
| At least one related to dexamethasone               | 32 (16.4%)   | 14 (7.1%)    |
| TEAE leading to discontinuation of daratumumab      |              | 34 (17.3%)   |
| At least onerelated todaratumumab                   |              | 7 (3.6%)     |
| TEAE leading to discontinuation of study treatmentb | 31 (15.9%)   | 15 (7.6%)    |
| Adverse event (COVID-19)                            | 51 (26.2%)   | 81 (41.1%)   |
| Serious adverse event (COVID-19)                    | 20 (10.3%)   | 30 (15.2%)   |
| AE leading to death (COVID-19)                      | 6 (3.1%)     | 12 (6.1%)    |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone;

TEAE = treatment-emergent adverse event; COVID-19 = Coronavirus Disease 2019.

a TEAEs related to at least 1 of the 4 components of study treatment: bortezomib, lenalidomide, dexamethasone, daratumumab.

b Includes those subjects indicated as having discontinued treatment due to an adverse event on the end of treatment CRF page.

Note: Adverse events are reported using MedDRA version 23.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

The most commonly reported TEAEs (≥10% in either treatment arm) and Grade 3 or 4 TEAEs ((≥5% in either treatment arm are presented in Table 20 and Table 21 , respectively.

<div style=\"page-break-after: always\"></div>

Table 20 . Most common (at Least 10% in Either VRd or D-VRd) Treatment-emergent Adverse Events by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3019)

|                                                                   | VRd                    | D-VRd                            |
|-------------------------------------------------------------------|------------------------|----------------------------------|
|                                                                   | n (%)                  | n (%)                            |
| Analysis set: safety                                              | 195                    | 197                              |
| TotalnumberofsubjectswithTEAE                                     | 195 (100.0%)           | 197 (100.0%)                     |
| MedDRA system organ class / Preferred term                        |                        |                                  |
| Infections and infestations                                       | 167 (85.6%)            | 181 (91.9%)                      |
| Upper respiratory tract infection                                 | 64 (32.8%)             | 78 (39.6%)                       |
| COVID-19                                                          | 48 (24.6%)             | 75 (38.1%)                       |
| Pneumonia                                                         | 39 (20.0%)             | 48 (24.4%)                       |
| Urinary tract infection                                           | 29 (14.9%)             | 41 (20.8%)                       |
| Nasopharyngitis                                                   | 22 (11.3%)             | 35 (17.8%)                       |
| Bronchitis                                                        | 19 (9.7%)              | 29 (14.7%)                       |
| Influenza                                                         | 15 (7.7%)              | 27 (13.7%)                       |
| Blood and lymphatic system disorders                              | 126 (64.6%)            | 163 (82.7%)                      |
| Neutropenia                                                       | 76 (39.0%)             | 110 (55.8%)                      |
| Thrombocytopenia                                                  | 66 (33.8%)             | 92 (46.7%)                       |
| Anaemia                                                           | 62 (31.8%)             | 73 (37.1%)                       |
| Lymphopenia                                                       | 34 (17.4%)             | 36 (18.3%)                       |
| Leukopenia                                                        | 19 (9.7%)              | 28 (14.2%)                       |
| Nervous system disorders                                          | 155 (79.5%)            | 161 (81.7%)                      |
| Peripheral sensory neuropathy                                     | 119 (61.0%)            | 110 (55.8%)                      |
| Dizziness                                                         | 41 (21.0%)             | 41 (20.8%)                       |
| Headache                                                          | 16 (8.2%)              | 30 (15.2%)                       |
| Neuralgia                                                         | 30 (15.4%)             | 28 (14.2%)                       |
| Paraesthesia Dysgeusia                                            | 18 (9.2%) 22 (11.3%)   | 25 (12.7%) 19 (9.6%)             |
| Generaldisordersandadministrationsiteconditions Oedema peripheral | 147 (75.4%) 76 (39.0%) | 159 (80.7%) 83 (42.1%)           |
| Fatigue                                                           | 60 (30.8%)             | 63 (32.0%)                       |
| Asthenia                                                          | 40 (20.5%)             | 51 (25.9%)                       |
| Pyrexia                                                           | 30 (15.4%)             | 46 (23.4%)                       |
| Injectionsiteerythema                                             | 10 (5.1%)              | 25 (12.7%)                       |
| Influenzalikeillness                                              | 21 (10.8%)             | 24 (12.2%)                       |
| Malaise Gastrointestinal disorders                                | 20 (10.3%)             | 10 (5.1%) 157 (79.7%)            |
| Diarrhoea                                                         | 159 (81.5%)            | 112 (56.9%)                      |
| Constipation                                                      | 115 (59.0%) 82 (42.1%) | 75 (38.1%)                       |
| Nausea Abdominal pain                                             | 48 (24.6%)             | 49 (24.9%) 31 (15.7%)            |
|                                                                   | 20 (10.3%)             | 26 (13.2%)                       |
| Dyspepsia                                                         | 17 (8.7%)              |                                  |
| Vomiting                                                          | 23 (11.8%)             | 23 (11.7%) 146 (74.1%)           |
| Musculoskeletalandconnectivetissuedisorders Back pain             | 142 (72.8%) 43 (22.1%) | 55 (27.9%)                       |
| Arthralgia                                                        | 39 (20.0%)             | 45 (22.8%)                       |
| Muscular weakness                                                 | 29 (14.9%)             | 38 (19.3%)                       |
| Muscle spasms                                                     | 31 (15.9%)             | 36 (18.3%)                       |
| Paininextremity                                                   | 30 (15.4%)             | 35 (17.8%)                       |
| Musculoskeletal pain                                              | 21 (10.8%)             | 24 (12.2%)                       |
| Metabolismandnutritiondisorders                                   | 105 (53.8%)            | 120 (60.9%)                      |
| Hypokalaemia                                                      | 25 (12.8%)             | 58 (29.4%)                       |
| Decreased appetite                                                | 39 (20.0%)             |                                  |
| Hypocalcaemia                                                     | 18 (9.2%)              | 42 (21.3%) 28 (14.2%)            |
| Hyperglycaemia Hyponatraemia                                      | 19 (9.7%)              | 24 (12.2%) 15 (7.6%)             |
|                                                                   | 20 (10.3%)             | 118 (59.9%)                      |
| Skinandsubcutaneoustissuedisorders Rash                           | 110 (56.4%) 48 (24.6%) |                                  |
| s                                                                 | 22 (11.3%)             | 50 (25.4%) 21 (10.7%)            |
|                                                                   | 86 (44.1%)             | 112 (56.9%)                      |
| Respiratory,thoracicandmediastinal disorders Cough                | 38 (19.5%)             | 53 (26.9%)                       |
| Dyspnoea                                                          | 29 (14.9%)             |                                  |
| Cataract                                                          | 88 (45.1%) 51 (26.2%)  | 35 (17.8%) 92 (46.7%) 55 (27.9%) |
| Eye disorders Visionblurred                                       | 19 (9.7%)              |                                  |
|                                                                   | 96 (49.2%)             | 24 (12.2%) 91 (46.2%)            |
| Psychiatricdisorders Insomnia                                     | 63 (32.3%) 73 (37.4%)  | 63 (32.0%)                       |
|                                                                   |                        | 90 (45.7%)                       |
| Vasculardisorders Hypertension                                    | 14 (7.2%) 23 (11.8%)   | 35 (17.8%)                       |
| Hypotension                                                       | 80 (41.0%)             | 31 (15.7%)                       |
|                                                                   |                        | 79 (40.1%)                       |
| Investigations                                                    | 27 (13.8%)             | 26 (13.2%)                       |
| Alanineaminotransferaseincreased Weightdecreased                  | 22 (11.3%)             | 15 (7.6%)                        |
|                                                                   | 60 (30.8%) 20 (10.3%)  | 74 (37.6%) 14 (7.1%)             |
| Renalandurinarydisorders Renalimpairment                          |                        | 72 (36.5%)                       |
|                                                                   | 58 (29.7%)             |                                  |
| Injury.poisoningandprocedural complications                       | 20 (10.3%)             | 24 (12.2%)                       |
| Contusion Cardiacdisorders                                        | 49 (25.1%)             | 56 (28.4%) 17 (8.6%)             |
| Atrial fibrillation                                               | 20 (10.3%)             |                                  |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone; TEAE =treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 23.0.

Note: Percentages are calculated with the number of subjects in each g groupasdenominator.

<div style=\"page-break-after: always\"></div>

Table 21 .  Most  common  (at  Least  5%  in  Either  VRd  or  D-VRd)  Grade  3  or  4  Treatment-emergent Adverse Events by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3019)

|                                                          | VRd n (%)   | D-VRd n (%)   |
|----------------------------------------------------------|-------------|---------------|
| Analysis set: safety                                     | 195         | 197           |
| Total number of subjects with toxicity grade 3 or 4 TEAE | 167 (85.6%) | 182 (92.4%)   |
| MedDRA system organ class / Preferred term               |             |               |
| Blood and lymphatic system disorders                     | 98 (50.3%)  | 126 (64.0%)   |
| Neutropenia                                              | 58 (29.7%)  | 87 (44.2%)    |
| Thrombocytopenia                                         | 39 (20.0%)  | 56 (28.4%)    |
| Anaemia                                                  | 23 (11.8%)  | 26 (13.2%)    |
| Lymphopenia                                              | 20 (10.3%)  | 24 (12.2%)    |
| Leukopenia                                               | 7 (3.6%)    | 15 (7.6%)     |
| Infections and infestations                              | 62 (31.8%)  | 79 (40.1%)    |
| Pneumonia                                                | 25 (12.8%)  | 28 (14.2%)    |
| COVID-19                                                 | 9 (4.6%)    | 22 (11.2%)    |
| Nervous system disorders                                 | 38 (19.5%)  | 45 (22.8%)    |
| Peripheral sensory neuropathy                            | 16 (8.2%)   | 16 (8.1%)     |
| Syncope                                                  | 10 (5.1%)   | 8 (4.1%)      |
| Metabolism and nutrition disorders                       | 36 (18.5%)  | 44 (22.3%)    |
| Hypokalaemia                                             | 12 (6.2%)   | 24 (12.2%)    |
| Musculoskeletal and connective tissue disorders          | 30 (15.4%)  | 43 (21.8%)    |
| Muscular weakness                                        | 9 (4.6%)    | 17 (8.6%)     |
| Gastrointestinal disorders                               | 40 (20.5%)  | 41 (20.8%)    |
| Diarrhoea                                                | 18 (9.2%)   | 24 (12.2%)    |
| General disorders and administration site conditions     | 28 (14.4%)  | 40 (20.3%)    |
| Fatigue                                                  | 16 (8.2%)   | 18 (9.1%)     |
| Vascular disorders                                       | 22 (11.3%)  | 31 (15.7%)    |
| Hypertension                                             | 4 (2.1%)    | 15 (7.6%)     |
| Respiratory, thoracic and mediastinal disorders          | 14 (7.2%)   | 23 (11.7%)    |
| Pulmonary embolism                                       | 5 (2.6%)    | 10 (5.1%)     |
| Eye disorders                                            | 20 (10.3%)  | 21 (10.7%)    |
| Cataract                                                 | 17 (8.7%)   | 17 (8.6%)     |
| Investigations                                           | 15 (7.7%)   | 19 (9.6%)     |
| Alanine aminotransferaseincreased                        | 4 (2.1%)    | 10 (5.1%)     |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone;

TEAE = treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 23.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

A  review  of  safety  data  in  the  CEPHEUS  study  identified  new  ADR  terms  of  abdominal  pain  and hypokalaemia.

The frequency of the known ADRs associated with daratumumab use were updated with data from Study 54767414MMY3019 study which were combined with other daratumumab monotherapy and combination studies to obtain ADR frequencies from a pooled safety data ( Table 22 ).

<div style=\"page-break-after: always\"></div>

Table 22 . Adverse Reactions in Multiple Myeloma and AL Amyloidosis participants treated with daratumumab IV or daratumumab SC (pooled data including data from study 54767414MMY3019 )

|                                                 | Any Grades   | Any Grades   | Grade 3-4   |
|-------------------------------------------------|--------------|--------------|-------------|
| Infections and infestations                     |              |              |             |
| Upper respiratory tract infectiona              | Very Common  | 45%          | 3%          |
| COVID-19                                        | Very Common  | 39%          | 10%         |
| Pneumoniaa                                      | Very Common  | 19%          | 11%         |
| Bronchitisa                                     | Very Common  | 14%          | 1%          |
| Urinary tract infection                         | Common       | 8%           | 1%          |
| Sepsisa                                         | Common       | 4%           | 4%          |
| Cytomegalovirus infectiona                      | Uncommon     | <1%          | <1%#        |
| Hepatitis B reactivationa                       | Uncommon     | <1%          | <1%         |
| Blood and lymphatic system disorders            |              |              |             |
| Neutropeniaa                                    | Very Common  | 43%          | 37%         |
| Thrombocytopenia                                | Very Common  | 32%          | 19%         |
| Anaemiaa                                        | Very Common  | 27%          | 11%         |
| Lymphopenia?                                    | Very Common  | 13%          | 10%         |
| Leukopeniaa                                     | Very Common  | 11%          | 6%          |
| Immune system disorders                         |              |              |             |
| Hypogammaglobulinaemiaa                         | Common       | 3%           | <1%#        |
| Anaphylactic reactionb                          | Rare         |              |             |
| Metabolism and nutrition disorders              |              |              |             |
| Hypokalaemiaa                                   | Very Common  | 11%          | 3%          |
| Decreased appetite                              | Very Common  | 10%          | 1%          |
| Hyperglycaemia                                  | Common       | 7%           | 3%          |
| Hypocalcaemia                                   | Common       | 6%           | 1%          |
| Dehydration                                     | Common       | 2%           | 1%#         |
| Psychiatric disorders                           |              |              |             |
| Insomnia                                        | Very Common  | 17%          | 1%#         |
| Nervous system disorders                        |              |              |             |
| Peripheral neuropathya                          | Very Common  | 33%          | 4%          |
| Headache                                        | Very Common  | 10%          | <1%#        |
| Dizziness                                       | Common       | 9%           | <1%#        |
| Paraesthesia                                    | Common       | 9%           | <1%         |
| Syncope                                         | Common       | 3%           | 2%#         |
| Cardiac disorders                               |              |              |             |
| Atrial fibrillation                             | Common       | 4%           | 1%          |
| Vascular disorders                              |              |              |             |
| Hypertensiona                                   | Common       | 9%           | 4%          |
| Respiratory, thoracic and mediastinal disorders |              |              |             |
| Cougha                                          | Very Common  | 22%          | <1%#        |
| Dyspnoeaa                                       | Very Common  | 18%          | 2%          |
| Pulmonary oedemaa                               | Common       | 1%           | <1%         |
| Gastrointestinal disorders                      |              |              |             |
| Diarrhoea                                       | Very Common  | 33%          | 5%          |
| Constipation                                    | Very Common  | 29%          | 1%          |
| Nausea                                          | Very Common  | 22%          | 1%#         |
| Abdominal paina                                 | Very Common  | 13%          | 1%          |
| Vomiting                                        | Very Common  | 13%          | 1%#         |
| Pancreatitisa                                   | Common       | 1%           | 1%          |
| Skin and subcutaneous tissue disorders          |              |              |             |
| Rash                                            | Very Common  | 12%          | 1%#         |
| Pruritus                                        | Common       | 6%           | <1%#        |

<div style=\"page-break-after: always\"></div>

|                                                      | Any Grades   | Any Grades   | Grade 3-4   |
|------------------------------------------------------|--------------|--------------|-------------|
| Musculoskeletal and connective tissue disorders      |              |              |             |
| Musculoskeletal pain?                                | Very Common  | 35%          | 3%          |
| Arthralgia                                           | Very Common  | 14%          | 1%          |
| Muscle spasms                                        | Very Common  | 12%          | <1%#        |
| General disorders and administration site conditions |              |              |             |
| Fatigue                                              | Very Common  | 24%          | 4%          |
| Oedema peripherala                                   | Very Common  | 24%          | 1%          |
| Pyrexia                                              | Very Common  | 22%          | 1%          |
| Asthenia                                             | Very Common  | 19%          | 2%          |
| Chills                                               | Common       | 8%           | <1%#        |
| Injection site reactionsdf                           | Common       | 8%           | 0           |
| Injury, poisoning and procedural complications       |              |              |             |
| Infusion related reactionsc                          |              |              |             |
| Daratumumab IVe                                      | Very Common  | 39%          | 5%          |
| Daratumumab SCf                                      | Common       | 7%           | 1%          |

# No grade 4.

b Based on post-marketing adverse feactions.

a Indicates a grouping of terms.

Infusion-related reactions includes terms determined by investigators as related to infusion/injection of daratumumab.

d Injection site reactions includes terms determined by investigators as related to injection of daratumumab.

e Frequency based on daratumumab IV studies only (N=2324).

fFrequency based on daratumumab SC studies only (N=1380).

Frequency based on MMY3014 and MMY3019 studies only (N=548) due to the onset of the pandemic during the studies.

Note: Based on 3704 multiple myeloma and AL amyloidosis patients treated with daratumumab IV or daratumumab SC (daratumumab +rHuPH20).

Note: Studies included are AMY3001, MMY1001, MMY1002, MMY1004, MMY1008, MMY2002, MMY2040, MMY3003,

## Serious adverse event/deaths/other significant events

## Serious Adverse Events

The treatment-emergent SAEs with a frequency ≥2% in either treatment arm are presented in Table 23 .

Table 23 .  Most common (at Least 2% in Either VRd or D-VRd treatment-emergent serious adverse events by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3019)

<div style=\"page-break-after: always\"></div>

|                                                      | VRd         | D-VRd       |
|------------------------------------------------------|-------------|-------------|
| Analysis set: safety                                 | n (%) 195   | n (%) 197   |
| Total number of subjects with serious TEAE           | 131 (67.2%) | 142 (72.1%) |
| MedDRA system organ class / Preferred term           |             |             |
| Infections and infestations                          | 69 (35.4%)  | 78 (39.6%)  |
| Pneumonia                                            | 25 (12.8%)  | 27 (13.7%)  |
| COVID-19                                             | 16 (8.2%)   | 22 (11.2%)  |
| COVID-19 pneumonia                                   | 4 (2.1%)    | 8 (4.1%)    |
| Sepsis                                               | 4 (2.1%)    | 7 (3.6%)    |
| Urinary tract infection                              | 4 (2.1%)    | 7 (3.6%)    |
| Septic shock                                         | 1 (0.5%)    | 6 (3.0%)    |
| Gastroenteritis                                      | 4 (2.1%)    | 4 (2.0%)    |
| Influenza                                            | 1 (0.5%)    | 4 (2.0%)    |
| Gastrointestinal disorders                           | 24 (12.3%)  | 24 (12.2%)  |
| Diarhoea                                             | 6 (3.1%)    | 10 (5.1%)   |
| Cardiac disorders                                    | 17 (8.7%)   | 22 (11.2%)  |
| Atrial fibrillation                                  | 7 (3.6%)    | 7 (3.6%)    |
| General disorders and administration site conditions | 13 (6.7%)   | 21 (10.7%)  |
| Asthenia                                             | 2 (1.0%)    | 6 (3.0%)    |
| Pyrexia                                              | 3 (1.5%)    | 5 (2.5%)    |
| Metabolism and nutrition disorders                   | 17 (8.7%)   | 19 (9.6%)   |
| Hypokalaemia                                         | 3 (1.5%)    | 5 (2.5%)    |
| Hyponatraemia                                        | 1 (0.5%)    | 5 (2.5%)    |
| Dehydration                                          | 5 (2.6%)    | 0           |
| Nervous system disorders                             | 16 (8.2%)   | 18 (9.1%)   |
| Syncope                                              | 6 (3.1%)    | 3 (1.5%)    |
| Respiratory, thoracic and mediastinal disorders      | 12 (6.2%)   | 16 (8.1%)   |
| Pulmonary embolism                                   | 5 (2.6%)    | 11 (5.6%)   |
| Blood and lymphatic system disorders                 | 7 (3.6%)    | 15 (7.6%)   |
| Anaemia                                              | 2 (1.0%)    | 6 (3.0%)    |
| Febrile neutropenia                                  | 4 (2.1%)    | 4 (2.0%)    |
| Thrombocytopenia                                     | 2 (1.0%)    | 4 (2.0%)    |
| Vascular disorders                                   | 17 (8.7%)   | 15 (7.6%)   |
| Deep vein thrombosis                                 | 2 (1.0%)    | 4 (2.0%)    |
| Hypotension                                          | 4 (2.1%)    | 3 (1.5%)    |
| Orthostatic hypotension                              | 5 (2.6%)    | 2 (1.0%)    |
| Renal and urinary disorders                          | 6 (3.1%)    | 8 (4.1%)    |
| Acute kidney injury                                  | 3 (1.5%)    | 6 (3.0%)    |
| Eye disorders                                        | 4 (2.1%)    | 6 (3.0%)    |
| Cataract                                             | 4 (2.1%)    | 5 (2.5%)    |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone;

TEAE = treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 23.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Deaths

Participants in the D-VRd arm and in the VRd arm of the safety analysis set in Study 4767414MMY3019 that had died and cause of death at the time of the clinical cut-off date (07 May 2024) is summarised in Table 24 .

<div style=\"page-break-after: always\"></div>

Table 24 . Summary of death and cause of death; Safety Analysis Set (Study 54767414MMY3019)

|                                                                               | n (%)      | n (%)      | n (%)       |
|-------------------------------------------------------------------------------|------------|------------|-------------|
| Analysis set: safety                                                          | 195        | 197        | 392         |
| Total number of subjects who died during study                                | 59 (30.3%) | 51 (25.9%) | 110 (28.1%) |
| Primary cause of death                                                        |            |            |             |
| Adverse event                                                                 | 25 (12.8%) | 37 (18.8%) | 62 (15.8%)  |
| At least one related a                                                        | 6 (3.1%)   | 5 (2.5%)   | 11 (2.8%)   |
| AE(s) unrelated                                                               | 19 (9.7%)  | 32 (16.2%) | 51 (13.0%)  |
| Adverse event (COVID-19)                                                      | 6 (3.1%)   | 13 (6.6%)  | 19 (4.8%)   |
| Progressive disease                                                           | 16 (8.2%)  | 8 (4.1%)   | 24 (6.1%)   |
| Other                                                                         | 18 (9.2%)  | 6 (3.0%)   | 24 (6.1%)   |
| COVID-19                                                                      | 3 (1.5%)   | 2 (1.0%)   | 5 (1.3%)    |
| Total number of subjects who died within 30 days of last study treatment dose | 16 (8.2%)  | 28 (14.2%) | 44 (11.2%)  |
| Primary cause of death                                                        |            |            |             |
| Adverse event                                                                 | 16 (8.2%)  | 28 (14.2%) | 44 (11.2%)  |
| At least one related a                                                        | 3 (1.5%)   | 5 (2.5%)   | 8 (2.0%)    |
| AE(s) unrelated                                                               | 13 (6.7%)  | 23 (11.7%) | 36 (9.2%)   |
| Adverse event (COVID-19)                                                      | 5 (2.6%)   | 9 (4.6%)   | 14 (3.6%)   |
| Total number of subjects who died within 60 days of first studytreatmentdose  | 3 (1.5%)   | 3 (1.5%)   | 6 (1.5%)    |
| Primary cause of death                                                        |            |            |             |
| Adverse event                                                                 | 3 (1.5%)   | 3 (1.5%)   | 6 (1.5%)    |
| At least one related a                                                        | 0          | 1 (0.5%)   | 1 (0.3%)    |
| AE(s) unrelated                                                               | 3 (1.5%)   | 2 (1.0%)   | 5 (1.3%)    |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone; COVID-19 = Coronavirus Disease 2019.

a Includes adverse events that were related to at least 1 of the 4 components of study treatment: bortezomib, lenalidomide, dexamethasone or daratumumab.

The majority of Grade 5 TEAEs occurred during Cycle 9 and onward, after the participants in both arms had completed the 8 cycles of bortezomib per study protocol. Of the 33 participants who experienced Grade 5 TEAEs in the D-VRd arm, 9 died during the first 8 cycles and 24 during Cycle 9 and onward; of the 21 participants who experienced Grade 5 TEAEs in the VRd arm, 6 died during the first 8 cycles and 15 during Cycle 9 and onward. The post Cycle 8 (ie, after bortezomib was completed) incidence of Grade 5 TEAEs was 13.7% and 9% in the D-VRd and VRd arms, respectively.

TEAEs with an outcome of death reported for &gt;2 participants in either treatment arm were:

- COVID-19 (D-VRd: 3.6%; VRd: 2.6%)
- COVID-19 pneumonia (D-VRd: 2.5%; VRd: 0.5%)
- Pneumonia (D-VRd: 1.5%; VRd: 2.1%)

There was also substantial regional variation in the incidences of COVID-19 deaths and SAEs, with 54.2% of the total COVID-19 deaths and 44.0% of the COVID-19 SAEs reported in Brazil. Eleven of the 15 (73.3%) COVID-19 deaths in the D-VRd arm and 2 of the 9 (22.2%) COVID 19 deaths in the VRd arm occurred in Brazil. The country with the next highest COVID 19 incidence was Poland, with 16.7% of the total COVID-19 deaths and 14% of the total COVID 19 SAEs.

## Adverse Events of Special Interest

Infusion-related reactions (IRRs=Systemic Administration-related Reactions)

<div style=\"page-break-after: always\"></div>

There was a low proportion of participants with sARRs reported in the D-VRd arm (7 [3.6%] participants), and the majority were Grade 1 or 2 events. The most frequently reported (≥1%) sARRs were Chills and Pyrexia in 2 (1.0%) participants each. A Grade 3 sARR of Hypertension was reported in 1 participant. Daratumumab was not discontinued in any participant due to sARRs.

sARRs were reported with the first administration of daratumumab in 5 of the 7 participants, with the second administration in 1 participant, and with subsequent administrations in 2 participants. Recurrent low grade sARRs were reported in 1 participant.

## Local Injection-site Reactions

Local ISRs were reported in 24 (12.2%) participants in the D-VRd arm. All ISRs were Grade 1 or 2. ISRs led to interruption of study treatment in 2 participants. The most frequently reported ( ≥ 2 participants) ISRs were Injection site erythema in 10 (5.1%) participants, Rash in 5 (2.5%) participants, and Injection site bruising and Injection site reaction in 2 (1.0%) participants each.

## Cytopenia

The incidence of treatment-emergent cytopenia is provided in Table 25 and a summary of growth factor use in

## Table 26.

Table 25 . Treatment-emergent Cytopenia by MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3019)

|                                                           | VRd                  | VRd                | D-VRd                | D-VRd              |
|-----------------------------------------------------------|----------------------|--------------------|----------------------|--------------------|
| Analysis set: safety                                      | All Grades n (%) 195 | Grade 3 or 4 n (%) | All Grades n (%) 197 | Grade 3 or 4 n (%) |
| Total number of subjectswith treatment-emergent Cytopenia | 124 (63.6%)          | 98 (50.3%)         | 156 (79.2%)          | 126 (64.0%)        |
| Neutropenia a                                             | 76 (39.0%)           | 58 (29.7%)         | 112 (56.9%)          | 89 (45.2%)         |
| Neutropenia                                               | 76 (39.0%)           | 58 (29.7%)         | 110 (55.8%)          | 87 (44.2%)         |
| Febrile neutropenia                                       | 4 (2.1%)             | 4 (2.1%)           | 7 (3.6%)             | 7 (3.6%)           |
| Granulocytopenia                                          | 1 (0.5%)             | 1 (0.5%)           | 0                    | 0                  |
| Neutrophilcountdecreased                                  | 1 (0.5%)             | 0                  | 0                    | 0                  |
| Anaemia a                                                 | 64 (32.8%)           | 23 (11.8%)         | 73 (37.1%)           | 26 (13.2%)         |
| Anaemia                                                   | 62 (31.8%)           | 23 (11.8%)         | 73 (37.1%)           | 26 (13.2%)         |
| Anaemiamacrocytic                                         | 2 (1.0%)             | 0                  | 0                    | 0                  |
| Thrombocytopenia a                                        | 66 (33.8%)           | 39 (20.0%)         | 92 (46.7%)           | 56 (28.4%)         |
| Thrombocytopenia                                          | 66 (33.8%)           | 39 (20.0%)         | 92 (46.7%)           | 56 (28.4%)         |
| Lymphopenia a                                             | 34 (17.4%)           | 20 (10.3%)         | 36 (18.3%)           | 24 (12.2%)         |
| Lymphopenia                                               | 34 (17.4%)           | 20 (10.3%)         | 36 (18.3%)           | 24 (12.2%)         |

Key:VRd =bortezomib-lenalidomide-dexamethasone;D-VRd=daratumumab-bortezomib-lenalidomide-dexamethasone;

a Preferred term grouping.

TEAE=treatment-emergent adverseevent.

Note:Adveise eventsarereported usingMedDRAveision 23.0.

Note:Percentagcsarecalculatedwiththenumberofsubjectsincachgroupasdenominator.

Table 26. Summary of Growth Factor Use by Therapeutic Class, Pharmacologic Class and Drug; Intent-to-treat Analysis Set (Study 54767414MMY3019)

<div style=\"page-break-after: always\"></div>

| Analysis set: intent-to-treat                             | VRd n (%) 198   | D-VRd n (%) 197   | Total n (%) 395   |
|-----------------------------------------------------------|-----------------|-------------------|-------------------|
| Total number of subjects with 1 or more growth factor use | 49 (24.7%)      | 86 (43.7%)        | 135 (34.2%)       |
| Therapeutic class/pharmacologic class/drug                |                 |                   |                   |
| Immunostimulants                                          | 49 (24.7%)      | 86 (43.7%)        | 135 (34.2%)       |
| Immunostimulants                                          | 49 (24.7%)      | 86 (43.7%)        | 135 (34.2%)       |
| Filgrastim                                                | 38 (19.2%)      | 71 (36.0%)        | 109 (27.6%)       |
| Granulocyte colony stimulating factor                     | 14 (7.1%)       | 15 (7.6%)         | 29 (7.3%)         |
| Lenograstim                                               | 1 (0.5%)        | 7 (3.6%)          | 8 (2.0%)          |
| Pegfilgrastim                                             | 3 (1.5%)        | 3 (1.5%)          | 6 (1.5%)          |
| Lipegfilgrastim                                           | 3 (1.5%)        | 1 (0.5%)          | 4 (1.0%)          |
| Filgrastim sndz                                           | 1 (0.5%)        | 1 (0.5%)          | 2 (0.5%)          |
| Filgrastim aafi                                           | 0               | 1 (0.5%)          | 1 (0.3%)          |
| Filgrastim biosimilar 1                                   | 0               | 1 (0.5%)          | 1 (0.3%)          |
| Pegfilgrastim cbqv                                        | 1 (0.5%)        | 0                 | 1 (0.3%)          |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone.

Note: Percentages calculated with the number of subjects in each treatment group as denominator.

Note: WHO drug dictionary, September 2020 version.

## Haemorrhage

The overall incidence of haemorrhagic events (SMQ, excluding injection site reactions) was 31.0% in the D-VRd arm and 26.2% in the VRd arm. The incidence of Grade 3 or 4 hemorrhagic events was low and similar  in  both  treatment  arms  (D-VRd:  3.0%;  VRd:  1.5%).  The  treatment-emergent  hemorrhagic events at a ≥ 5% frequency in either treatment arm were:

- Contusion (D-VRd: 12.2%; VRd: 10.3%)
- Hematoma (D-VRd: 6.1%; VRd: 0.5%)

## Infections and Infestations

The incidences of Infections and Infestations (SOC), including overall (D-VRd: 91.9%; VRd: 85.6%), Grade 3 or 4 (D-VRd: 40.1%; VRd: 31.8%), and SAEs (D-VRd: 39.6%; VRd: 35.4%), were all higher in the D-VRd arm compared with the VRd arm.

The most common TEAEs of Infections and Infestations (frequency ≥ 10% in either treatment arm) were:

- Upper respiratory tract infection (D-VRd: 39.6%; VRd: 32.8%)
- COVID-19 (D-VRd: 38.1%; VRd: 24.6%)
- Pneumonia (D-VRd: 24.4%; VRd: 20.0%)
- Urinary tract infection (D-VRd: 20.8%; VRd: 14.9%)
- Nasopharyngitis (D-VRd: 17.8%; VRd: 11.3%)
- Bronchitis (D-VRd: 14.7%; VRd: 9.7%)
- Influenza (D-VRd: 13.7%; VRd: 7.7%)

The most common Grade 3 or 4 Infections and Infestations (frequency ≥5% in either treatment arm) were Pneumonia (D-VRd: 14.2%; VRd: 12.8%) and COVID-19 (D-VRd: 11.2%; VRd: 4.6%).

<div style=\"page-break-after: always\"></div>

## Hepatitis B Reactivation

Four (2%) participants in the D-VRd arm and 7 (3.5%) participants in the VRd arm had a medical history of Hepatitis B. Two (1.0%) participants in the D-VRd arm and none of the participants in the VRd arm had events of Hepatitis B virus reactivation. Neither participant discontinued study treatment due to Hepatitis B virus reactivation.

## Opportunistic Infections

The incidences of treatment-emergent opportunistic infections (SMQ), both overall (D VRd: 2.5%; VRd: 3.1%) and Grade 3 or 4 (D-VRd: 2.0%; VRd: 1.0%), were low and similar in both treatment arms. There were no opportunistic infections by PT reported in ≥ 2% of participants in either treatment arm. No fatal treatment emergent opportunistic infections were reported in either treatment arm.

## New Malignancies

The  overall  incidence  of  new  malignancies,  previously  known  as  second  primary  malignancies,  was numerically  lower  in  the  D-VRd  arm  compared  with  the  VRd  arm,  despite  much  longer  treatment exposure in the D-VRd arm (D VRd: 7.6%; VRd: 9.2%).

## Treatment-emergent Interferences for Blood Typing

No treatment-emergent events related to interference with blood typing were reported.

## Peripheral Neuropathy

The overall incidence of treatment-emergent peripheral neuropathies (High Level Term) was similar in both treatment arms (D-VRd: 61.9%; VRd: 66.2%). The incidence of Grade 2 peripheral neuropathies was lower in the D-VRd arm compared with the VRd arm (D-VRd: 31.5%; VRd: 36.9%) and the incidence of  Grade  3  or  4  peripheral  neuropathies  was  similar  in  both  treatment  arms  (D  VRd:  11.2%;  VRd: 10.8%).

In  addition,  the  overall  incidences  of  treatment  discontinuation  (all  study  treatment  and  bortezomib alone) and dose modification (any study treatment and bortezomib alone) due to treatment emergent peripheral neuropathies were similar in both treatment arms.

## Laboratory findings

Overall, the data showed no clinically meaningful changes for any chemistry parameter and the results were consistent between treatment arms (data not shown).

The  only  Grade  3  or  4  chemistry  laboratory  abnormalities  reported  at  a  frequency  ≥10%  in  either treatment arm were hyponatremia (D-VRd 18.0% and VRd 12.9%) and hypokalaemia (D-VRd 19.1% and VRd 12.4%).

## Safety in special populations

## Age

The distribution of participants in the &lt;65 years, 65 to &lt;70 years and ≥ 70 years subgroups was as follows:

- &lt;65 years: D-VRd: 18.3%; VRd: 17.7%
- 65 years to &lt;70 years: D-VRd: 26.4%; VRd: 26.8%
- ≥70 years: D-VRd: 55.3%; VRd: 55.6%

No increased safety concerns were observed in the 65 to &lt;70 years and ≥ 70 years subgroups.

<div style=\"page-break-after: always\"></div>

The incidence of Grade 3 or 4 TEAEs was not increased in the 2 older subgroups (65 to &lt;70 years and ≥ 70 years) compared with the &lt;65 years age subgroup in the D-VRd arm and was similar in the 2 older subgroups and higher than the &lt;65 years age subgroup in the VRd arm:

The  most  frequently  reported  TEAE  Grade  3  or  4  (at  least  10%  in  one  subgroup)  by  Age  group  is summarised in Table 27.

Table 27 . Number of subjects with 1 or more Grade 3 or 4 ( at least 10%) Treatment-emergent Adverse Events by Age MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3019)

|                                                         | VRd n (%)   | VRd n (%)    | VRd n (%)         | VRd n (%)     | D-VRd n (%)   | D-VRd n (%)   | D-VRd n (%)       | D-VRd n (%)   |
|---------------------------------------------------------|-------------|--------------|-------------------|---------------|---------------|---------------|-------------------|---------------|
| Analysis set: safety                                    | Total 195   | <65 years 35 | 65 -< 70 years 53 | ≥70 years 107 | Total 197     | <65 years 36  | 65 -< 70 years 52 | ≥70 years 109 |
| Total number of subjectswith toxicity grade 3 or 4 TEAE | 167 (85.6%) | 25 (71.4%)   | 46 (86.8%)        | 96 (89.7%)    | 182 (92.4%)   | 33 (91.7%)    | 46 (88.5%)        | 103 (94.5%)   |
| MedDRA system organ class/ Preferred term               |             |              |                   |               |               |               |                   |               |
| Blood andlymphatic system                               |             |              |                   |               |               |               |                   |               |
| disorders                                               | 98 (50.3%)  | 16 (45.7%)   | 23 (43.4%)        | 59 (55.1%)    | 126 (64.0%)   | 21 (58.3%)    | 32 (61.5%)        | 73 (67.0%)    |
| Neutropenia                                             | 58 (29.7%)  | 10 (28.6%)   | 14 (26.4%)        | 34 (31.8%)    | 87 (44.2%)    | 14 (38.9%)    | 25 (48.1%)        | 48 (44.0%)    |
| Thrombocytopenia                                        | 39 (20.0%)  | 5 (14.3%)    | 6 (11.3%)         | 28 (26.2%)    | 56 (28.4%)    | 8 (22.2%)     | 10 (19.2%)        | 38 (34.9%)    |
| Anaemia                                                 | 23 (11.8%)  | 5 (14.3%)    | 6 (11.3%)         | 12 (11.2%)    | 26 (13.2%)    | 7 (19.4%)     | 4 (7.7%)          | 15 (13.8%)    |
| Lymphopenia                                             | 20 (10.3%)  | 4 (11.4%)    | 6 (11.3%)         | 10 (9.3%)     | 24 (12.2%)    | 6 (16.7%)     | 7 (13.5%)         | 11 (10.1%)    |
| Infections and infestations                             | 62 (31.8%)  | 10 (28.6%)   | 22 (41.5%)        | 30 (28.0%)    | 79 (40.1%)    | 16 (44.4%)    | 16 (30.8%)        | 47 (43.1%)    |
| Pneumonia                                               | 25 (12.8%)  | 4 (11.4%)    | 8 (15.1%)         | 13 (12.1%)    | 28 (14.2%)    | 5 (13.9%)     | 6 (11.5%)         | 17 (15.6%)    |
| COVID-19                                                | 9 (4.6%)    | 3 (8.6%)     | 3 (5.7%)          | 3 (2.8%)      | 22 (11.2%)    | 7 (19.4%)     | 4 (7.7%)          | 11 (10.1%)    |
| Nervous system disorders                                | 38 (19.5%)  | 5 (14.3%)    | 8 (15.1%)         | 25 (23.4%)    | 45 (22.8%)    | 2 (5.6%)      | 15 (28.8%)        | 28 (25.7%)    |
| Metabolism and nutrition disorders                      | 36 (18.5%)  | 7 (20.0%)    | 5 (9.4%)          | 24 (22.4%)    | 44 (22.3%)    | 6 (16.7%)     | 11 (21.2%)        | 27 (24.8%)    |
| Hypokalaemia                                            | 12 (6.2%)   | 0            | 2 (3.8%)          | 10 (9.3%)     | 24 (12.2%)    | 2 (5.6%)      | 5 (9.6%)          | 17 (15.6%)    |
| Musculoskeletalandconnective                            |             |              |                   |               |               |               |                   |               |
| tissue disorders                                        | 30 (15.4%)  | 6 (17.1%)    | 7 (13.2%)         | 17 (15.9%)    | 43 (21.8%)    | 9 (25.0%)     | 10 (19.2%)        | 24 (22.0%)    |
| Gastrointestinal disorders                              | 40 (20.5%)  | 8 (22.9%)    | 13 (24.5%)        | 19 (17.8%)    | 41 (20.8%)    | 9 (25.0%)     | 11 (21.2%)        | 21 (19.3%)    |
| Diarrhoea                                               | 18 (9.2%)   | 3 (8.6%)     | 5 (9.4%)          | 10 (9.3%)     | 24 (12.2%)    | 5 (13.9%)     | 6 (11.5%)         | 13 (11.9%)    |
| General disorders and                                   |             |              |                   |               |               |               |                   |               |
| administrationsite conditions                           | 28 (14.4%)  | 2 (5.7%)     | 7 (13.2%)         | 19 (17.8%)    | 40 (20.3%)    | 3 (8.3%)      | 9 (17.3%)         | 28 (25.7%)    |
| Vascular disorders                                      | 22 (11.3%)  | 3 (8.6%)     | 8 (15.1%)         | 11 (10.3%)    | 31 (15.7%)    | 3 (8.3%)      | 9 (17.3%)         | 19 (17.4%)    |
| Respiratory, thoracic and mediastinal disorders         | 14 (7.2%)   | 1 (2.9%)     | 5 (9.4%)          | 8 (7.5%)      | 23 (11.7%)    | 1 (2.8%)      | 8 (15.4%)         | 14 (12.8%)    |
| Eye disorders                                           | 20 (10.3%)  | 5 (14.3%)    | 6 (11.3%)         | 9 (8.4%)      | 21 (10.7%)    | 4 (11.1%)     | 8 (15.4%)         | 9 (8.3%)      |

Key: VRd = bortezomib-lenalidomide-dexamethasone; D-VRd = daratumumab-bortezomib-lenalidomide-dexamethasone; TEAE = treatment-emergent adverse event. Note: Adverse events are reported using MedDRA 23.0.

ofsubjectsineachsubgroupasdenominator.

The incidence of SAEs was higher in the ≥70 years age subgroup compared with the other subgroups in the D-VRd arm and was higher in the 2 older subgroups compared with the youngest subgroup in the VRd arm ( Table 28 ).

Table 28 . Number of subjects Treatment-emergent Serious Adverse Events (at least 5%) by Age MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3019)

<div style=\"page-break-after: always\"></div>

|                                                                     | VRd n (%)   | VRd n (%)    | VRd n (%)        | VRd n (%)     | D-VRd n (%)   | D-VRd n (%)   | D-VRd n (%)      | D-VRd n (%)    |
|---------------------------------------------------------------------|-------------|--------------|------------------|---------------|---------------|---------------|------------------|----------------|
| Analysis set: safety                                                | Total 195   | <65 years 35 | 65 -<70 years 53 | ≥70 years 107 | Total 197     | <65 years 36  | 65 -<70 years 52 | ≥ 70 years 109 |
| Total number of subjectswithserious TEAE                            | 131 (67.2%) | 20 (57.1%)   | 37 (69.8%)       | 74 (69.2%)    | 142 (72.1%)   | 24 (66.7%)    | 35 (67.3%)       | 83 (76.1%)     |
| MedDRA system organ class /                                         |             |              |                  |               |               |               |                  |                |
| Preferredterm                                                       |             |              |                  |               |               |               |                  |                |
| Infections and infestations                                         | 69 (35.4%)  | 17 (48.6%)   | 23 (43.4%)       | 29 (27.1%)    | 78 (39.6%)    | 17 (47.2%)    | 14 (26.9%)       | 47 (43.1%)     |
| Pneumonia                                                           | 25 (12.8%)  | 4 (11.4%)    | 8 (15.1%)        | 13 (12.1%)    | 27 (13.7%)    | 5 (13.9%)     | 7 (13.5%)        | 15 (13.8%)     |
| COVID-19                                                            | 16 (8.2%)   | 9 (25.7%)    | 4 (7.5%)         | 3 (2.8%)      | 22 (11.2%)    | 7 (19.4%)     | 3 (5.8%)         | 12 (11.0%)     |
| Gastrointestinal disorders                                          | 24 (12.3%)  | 2 (5.7%)     | 11 (20.8%)       | 11 (10.3%)    | 24 (12.2%)    | 6 (16.7%)     | 2 (3.8%)         | 16 (14.7%)     |
| Diarrhoea                                                           | 6 (3.1%)    | 0            | 2 (3.8%)         | 4 (3.7%)      | 10 (5.1%)     | 2 (5.6%)      | 0                | 8 (7.3%)       |
| Cardiac disorders                                                   | 17 (8.7%)   | 0            | 7 (13.2%)        | 10 (9.3%)     | 22 (11.2%)    | 3 (8.3%)      | 5 (9.6%)         | 14 (12.8%)     |
| General disorders and administration site conditions                | 13 (6.7%)   | 1 (2.9%)     | 3 (5.7%)         | 9 (8.4%)      | 21 (10.7%)    | 3 (8.3%)      | 4 (7.7%)         | 14 (12.8%)     |
| Metabolismandnutritiondisorders                                     | 17 (8.7%)   | 3 (8.6%)     | 4 (7.5%)         | 10 (9.3%)     | 19 (9.6%)     | 4 (11.1%)     | 6 (11.5%)        | 9 (8.3%)       |
| Nervoussystemdisorders                                              | 16 (8.2%)   | 1 (2.9%)     | 3 (5.7%)         | 12 (11.2%)    | 18 (9.1%)     | 1 (2.8%)      | 9 (17.3%)        | 8 (7.3%)       |
| Musculoskeletalandconnective tissue disorders                       | 16 (8.2%)   | 4 (11.4%)    | 5 (9.4%)         | 7 (6.5%)      | 17 (8.6%)     | 1 (2.8%)      | 1 (1.9%)         | 15 (13.8%)     |
| Respiratory, thoracic and mediastinaldisorders                      | 12 (6.2%)   | 0            | 5 (9.4%)         | 7 (6.5%)      | 16 (8.1%)     | 0             | 6 (11.5%)        | 10 (9.2%)      |
| Pulmonary embolism                                                  | 5 (2.6%)    | 0            | 3 (5.7%)         | 2 (1.9%)      | 11 (5.6%)     | 0             | 4 (7.7%)         | 7 (6.4%)       |
| Blood andlymphatic system disorders                                 | 7 (3.6%)    | 1 (2.9%)     | 4 (7.5%)         | 2 (1.9%)      | 15 (7.6%)     | 4 (11.1%)     | 1 (1.9%)         | 10 (9.2%)      |
| Vascular disorders                                                  | 17 (8.7%)   | 0            | 7 (13.2%)        | 10 (9.3%)     | 15 (7.6%)     | 3 (8.3%)      | 1 (1.9%)         | 11 (10.1%)     |
| Injury, poisoning and procedural complications                      | 12 (6.2%)   | 2 (5.7%)     | 2 (3.8%)         | 8 (7.5%)      | 10 (5.1%)     | 0             | 3 (5.8%)         | 7 (6.4%)       |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 10 (5.1%)   | 1 (2.9%)     | 0                | 9 (8.4%)      | 10 (5.1%)     | 1 (2.8%)      | 1 (1.9%)         | 8 (7.3%)       |

Key:VRd=bortezomib-lenalidomide-dexamethasone;D-VRd=daratumumab-bortezomib-lenalidomide-dexamethasone;TEAE=treatment-emergentadverseevent. Note:Adverseevents arereportedusingMedDRA 23.0.

Note:Percentages in the total column were calculatedwith thenumber of subjects ineach group as denominator.Percentages of subgroupswere calculated with the number ofsubjectsineachsubgroupasdenominator.

The incidence of COVID-19 (PT) SAEs was higher in the youngest subgroup (&lt;65 years age) compared with the older subgroups (65 to &lt;70 years and ≥70 years) in both treatment arms.

The proportion of participants with TEAEs leading to discontinuation of all study treatment was higher in the 2 older subgroups (65 to &lt;70 years and ≥70 years) compared with the &lt;65 years subgroup in both treatment arms:

- D-VRd: &lt;65 years, 2.8%; 65 to &lt;70 years, 7.7%; ≥70 years, 9.2%
- VRd: &lt;65 years, 2.9%; 65 to &lt;70 years, 17.0%; ≥ 70 years, 19.6%

The proportion of participants with TEAEs leading to discontinuation of lenalidomide in the &lt;65 years subgroup was higher in the D-VRd arm compared with the VRd arm (D VRd: 33.3%; VRd: 14.3%).

The  incidence  of  Grade  5  TEAEs  was  higher  in  the  youngest  subgroup  compared  with  the  2  older subgroups in both treatment arms.

- -D-VRd: &lt;65 years, 30.6%; 65 to &lt;70 years, 13.5%; ≥70 years, 13.8%
- -VRd: &lt;65 years, 17.1%; 65 to &lt;70 years, 11.3%; ≥ 70 years, 8.4%

The incidence of Grade 5 TEAEs in the &lt;65 years age group was higher in the D-VRd arm than in the VRd arm. This is likely due to the higher number of COVID 19 deaths in the D VRd arm in the &lt;65 years age group compared with the VRd arm. The incidence of Grade 5 COVID-19 TEAEs was higher in the youngest subgroup compared with the 2 older subgroups in both treatment arms.

- -D-VRd: &lt;65 years, 11.1%; 65 to &lt;70 years, 3.8%; ≥70 years, 5.5%
- -VRd: &lt;65 years, 8.6%; 65 to &lt;70 years, 3.8%; ≥ 70 years, 0.9%

<div style=\"page-break-after: always\"></div>

## Baseline Renal Function

The distribution of participants by baseline renal function (creatinine clearance of &lt;30, 30 to &lt;60, 60 to &lt;90, or ≥90 mL/min/1.73 m 2 ) was as follows:

- &lt;30 mL/min/1.73 m 2 : D-VRd: 3/197 (1.5%) participants; VRd: 3/195 (1.5%) participants
- 30  to  &lt;60  mL/min/1.73  m 2 :  D-VRd: 56/197  (28.4%)  participants;  VRd: 56/195  (28.7%) participants
- 60  to  &lt;90  mL/min/1.73  m 2 :  D-VRd: 91/197  (46.2%)  participants;  VRd: 97/195  (49.7%) participants
- ≥90 mL/min/1.73 m 2 : D-VRd: 47/197 (23.9%) participants; VRd: 39/195 (20.0%) participants

Interpretation of the subgroup analysis by baseline renal function is limited due to the small number of participants enrolled in the &lt;30 mL/min/1.73 m 2  subgroup compared with the other subgroups in both treatment arms. There was a higher incidence of Grade 3 or 4 TEAEs and SAEs in the 60 to &lt;90 mL/min and ≥90 mL/min subgroups in the D-VRd arm compared with the VRd arm.

## Baseline Hepatic Function

Interpretation of the subgroup analysis by baseline hepatic function is limited due to the small number of participants with impaired hepatic function enrolled in the study.

## Transplant eligibility

Eligibility  for  transplant  in  NDMM  is  based  on  age,  fitness,  and  co-morbidities.  However,  in  clinical practice, many patients who are transplant-eligible choose to defer/delay transplant to the first salvage therapy after relapse from frontline therapy. The CEPHEUS study was designed and powered based on the ITT study population that included participants who were either TIE (transplant ineligible) or TD (transplant deferred).

The main difference between the TIE and the TD subgroups is seen in the countries of enrollment. Brazil (38.7%) and Poland (32.1%) recruited 70.8% of the TD participants.

Safety results and most commonly reported TEAEs in these two subgroups are summarised in Table 29 and Table 30 respectively.

<div style=\"page-break-after: always\"></div>

Table 29 . Key safety results by transplant eligibility status, Safety Analysis Set (Study 54767414MMY3019)

|                                                       | TIE Subgroup       | TIE Subgroup       | TD Subgroup        | TD Subgroup        |
|-------------------------------------------------------|--------------------|--------------------|--------------------|--------------------|
| Event, n (%)                                          | VRd (n=142)        | D-VRd (n=144)      | VRd(n=53)          | D-VRd(n=53)        |
| Any TEAE                                              | 142 (100)          | 144 (100)          | 53 (100)           | 53 (100)           |
| MaximumToxicityGrade                                  |                    |                    |                    |                    |
| Grade1-2 TEAE                                         | 16 (11.3)          | 10 (6.9)           | 11 (20.8)          | 5 (9.4)            |
| Grade 3 TEAE                                          | 81 (57.0)          | 68 (47.2)          | 32 (60.4)          | 20 (37.7)          |
| Grade 4 TEAE                                          | 32 (22.5)          | 47 (32.6)          | 2 (3.8)            | 14 (26.4)          |
| Grade 5 TEAE                                          | 13 (9.2)           | 19 (13.2)          | 8 (15.1)           | 14 (26.4)          |
| COVID-19 Related                                      | 1 (0.7)            | 6 (4.2)            | 5 (9.4)            | 6 (11.3)           |
| Non COVID-19 Related                                  | 12 (8.5)           | 13 (9.0)           | 3 (5.7)            | 8 (15.1)           |
| Cycles 1 -8                                           | 6 (4.2)            | 3 (2.1)            | 0 (0.0)            | 6 (11.3)           |
| Cycles 9+                                             | 7 (4.9)            | 16 (11.1)          | 8 (15.1)           | 8 (15.1)           |
| Exposure-Adjusted                                     | 0.27/100 pt months | 0.31/100 pt months | 0.40/100 pt months | 0.62/100 pt months |
| Grade 5 TEAEs > 2 subjects in either arm              |                    |                    |                    |                    |
| COVID-19                                              | 1 (0.7)            | 3 (2.1)            | 4 (7.5)            | 4 (7.5)            |
| COVID-19 Pneumonia                                    | 0 (0.0)            | 3 (2.1)            | 1 (1.9)            | 2 (3.8)            |
| Pneumonia                                             | 3 (2.1)            | 1 (0.7)            | 1 (1.9)            | 2 (3.8)            |
| Any SeriousTEAE                                       | 99 (69.7)          | 104 (72.2)         | 32 (60.4)          | 38 (71.1)          |
| TEAE leading todiscontinuation of all study treatment | 27 (19.0)          | 11 (7.6)           | 4 (7.5)            | 4 (7.5)            |

Table 30. Most commonly reported TEAEs by transplant eligibility status, Safety Analysis Set (Study 54767414MMY3019)

|                                   | TIE Subgroup   | TIE Subgroup   | TIE Subgroup    | TIE Subgroup    | TD Subgroup   | TD Subgroup   | TD Subgroup   | TD Subgroup   |
|-----------------------------------|----------------|----------------|-----------------|-----------------|---------------|---------------|---------------|---------------|
|                                   | VRd (n=142)    | VRd (n=142)    | D-VRd (n = 144) | D-VRd (n = 144) | VRd(n= 53)    | VRd(n= 53)    | D-VRd (n= 53) | D-VRd (n= 53) |
| Event, n (%)                      | Any Grade      | Grade 3or4     | Any Grade       | Grade 3 or4     | Any Grade     | Grade3or4     | Any Grade     | Grade 3 or 4  |
| HEMATOLOGIC                       |                |                |                 |                 |               |               |               |               |
| Neutropenia                       | 57 (40.1)      | 45 (31.7)      | 81 (56.3)       | 63 (43.8)       | 19 (35.8)     | 13 (24.5)     | 29 (54.7)     | 24 (45.3)     |
| Thrombocytopenia                  | 51 (35.9)      | 33 (23.2)      | 70 (48.6)       | 44 (30.6)       | 15 (28.3)     | 6 (11.3)      | 22 (41.5)     | 12 (22.6)     |
| Anemia                            | 46 (32.4)      | 18 (12.7)      | 52 (36.1)       | 18 (12.5)       | 16 (30.2)     | 5 (9.4)       | 21 (39.6)     | 8 (15.1)      |
| NON-HEMATOLOGIC                   |                |                |                 |                 |               |               |               |               |
| Diarrhea                          | 87 (61.3)      | 14 (9.9)       | 87 (60.4)       | 17 (11.8)       | 28 (52.8)     | 4 (7.5)       | 25 (47.2)     | 7 (13.2)      |
| Constipation                      | 65 (45.8)      | 2 (1.4)        | 57 (39.6)       | 3 (2.1)         | 17 (32.1)     | 3 (5.7)       | 18 (34.0)     | 1 (1.9)       |
| Fatigue                           | 54 (38.0)      | 15 (10.6)      | 48 (33.3)       | 13 (9.0)        | 6 (11.3)      | 1 (1.9)       | 15 (28.3)     | 5 (9.4)       |
| Peripheral edema                  | 59 (41.5)      | 0              | 63 (43.8)       | 4 (2.8)         | 17 (32.1)     | 1 (1.9)       | 20 (37.7)     | 0             |
| Insomnia                          | 47 (33.1)      | 2 (1.4)        | 51 (35.4)       | 3 (2.1)         | 16 (30.2)     | 0             | 12 (22.6)     | 1 (1.9)       |
| Hypokalemia                       | 22 (15.5)      | 12 (8.5)       | 49 (34.0)       | 21 (14.6)       | 3 (5.7)       | 0             | 9 (17.0)      | 3 (5.7)       |
| Cataract                          | 31 (21.8)      | 9 (6.3)        | 38 (26.4)       | 14 (9.7)        | 20 (37.7)     | 8 (15.1)      | 17 (32.1)     | 3 (5.7)       |
| Cough                             | 32 (22.5)      | 2 (1.4)        | 37 (25.7)       | 0               | 6 (11.3)      | 0             | 16 (30.2)     | 1 (1.9)       |
| INFECTION                         |                |                |                 |                 |               |               |               |               |
| COVID-19 (Group term)             | 26 (18.3)      | 5 (3.5)        | 52 (36.1)       | 14 (9.7)        | 22 (41.5)     | 4 (7.5)       | 23 (43.4)     | 8 (15.1)      |
| Upper respiratory tract infection | 38 (26.8)      | 1 (0.7)        | 49 (34.0)       | 1 (0.7)         | 26 (49.1)     | 1 (1.9)       | 29 (54.7)     | 0             |
| PERIPHERAL NEUROPATHY(Group term) | 96 (67.6)      | 16 (11.3)      | 95 (66.0)       | 18 (12.5)       | 33 (62.3)     | 5 (9.4)       | 27 (50.9)     | 4 (7.5)       |

## Safety related to drug-drug interactions and other interactions

No dedicated drug-drug interaction studies were performed for daratumumab SC.

## Discontinuation due to adverse events

Adverse Events Leading to Daratumumab Discontinuation

<div style=\"page-break-after: always\"></div>

The proportion of participants with TEAEs leading to discontinuation of daratumumab was 17.3%. This included  5.1%  of  participants  with  Grade  3  or  4  TEAEs.  TEAEs  resulting  in  discontinuation  of daratumumab which occurred in &gt;2 participants were:

- Pneumonia (2.0%)
- COVID-19 (1.5%)
- General physical health deterioration (1.5%)

## Adverse Events Leading to Bortezomib Discontinuation

The proportion of participants with TEAEs leading to discontinuation of bortezomib was similar in both treatment arms (D-VRd: 12.7%; VRd: 16.4%). TEAEs resulting in discontinuation of bortezomib which occurred in &gt;2 participants in either treatment arm were:

- Peripheral sensory neuropathy (D-VRd: 5.1%; VRd: 7.2%)
- Peripheral sensorimotor neuropathy (D-VRd: 1.5%; VRd: 1.0%)
- Pneumonia (D-VRd: 1.5%; VRd: 0%)
- Neuralgia (D-VRd: 1.0%; VRd: 1.5%)

## Adverse Events Leading to Lenalidomide Discontinuation

The proportion of participants with TEAEs leading to discontinuation of lenalidomide was higher in the D-VRd arm compared with the VRd arm (D-VRd: 32.0%; VRd: 24.6%). TEAEs leading to discontinuation of lenalidomide which occurred in &gt;2 participants in either treatment arm were:

- Peripheral sensory neuropathy (D-VRd: 3.0%; VRd: 2.6%)
- Diarrhoea (D-VRd: 3.0%; VRd: 2.1%)
- Pneumonia (D-VRd: 2.5%; VRd: 1.5%)
- COVID-19 (D-VRd: 2.0%; VRd: 1.5%)
- COVID-19 pneumonia (D-VRd: 1.5%; VRd: 1.0%)
- Rash (D-VRd: 1.5%; VRd: 1.0%)
- General physical health deterioration (D-VRd: 1.5%; VRd: 0%)
- Pulmonary embolism (D-VRd: 1.5%; VRd: 0%)
- Peripheral sensorimotor neuropathy (D-VRd: 0%; VRd: 1.5%)

## Adverse Events Leading to Dexamethasone Discontinuation

The proportion of participants with TEAEs leading to discontinuation of dexamethasone was lower in the D-VRd arm compared with the VRd arm (D-VRd: 23.9%; VRd: 35.4%). TEAEs leading to discontinuation of dexamethasone which occurred in &gt;2 participants in either treatment arm were:

- Insomnia (D-VRd: 2.0%; VRd: 2.1%)
- COVID-19 (D-VRd: 2.0%; VRd: 1.0%)
- Pneumonia (D-VRd: 2.0%; VRd: 0.5%)
- General physical health deterioration (D-VRd: 1.5%; VRd: 0.5%)
- Cataract (D-VRd: 1.0%; VRd: 2.6%)
- Muscular weakness (D-VRd: 0.5%; VRd: 2.6%)

<div style=\"page-break-after: always\"></div>

- Fatigue (D-VRd: 0%; VRd: 2.1%)
- Oedema peripheral (D-VRd: 0%; VRd: 2.1%)

## Adverse Events Leading to Cycle Delays or Dose Modification

TEAEs leading to treatment cycle delays or dose modifications that occurred at a frequency ≥20% in either treatment arm were:

- Neutropenia (D-VRd: 39.6%; VRd: 28.7%)
- Peripheral sensory neuropathy (D-VRd: 36.5%; VRd: 43.6%)
- Diarrhea (D-VRd: 31.0%; VRd: 20.5%)
- COVID-19 (D-VRd: 30.5%; VRd: 20.5%)
- Upper respiratory tract infection (D-VRd: 24.9%; VRd: 17.4%)
- Thrombocytopenia (D-VRd: 21.3%; VRd: 10.3%)

The Grade 3 or 4 TEAEs leading to treatment cycle delays or dose modifications that occurred at a frequency ≥5% in either treatment arm were:

- Neutropenia (D-VRd: 37.6%; VRd: 28.2%)
- Thrombocytopenia (D-VRd: 15.7%; VRd: 8.7%)
- Pneumonia (D-VRd: 10.7%; VRd: 8.2%)
- Diarrhea (D-VRd: 8.6%; VRd: 5.6%)
- Peripheral sensory neuropathy (D-VRd: 8.1%; VRd: 6.7%)
- COVID-19 (D-VRd: 7.6%; VRd: 3.1%)
- Fatigue (D-VRd: 7.6%; VRd: 7.7%)
- Muscular weakness (D-VRd: 7.1%; VRd: 4.6%)

## Post marketing experience

Post-marketing safety information is available for both daratumumab SC and daratumumab IV.

A  cumulative  review  was  performed  for  all  medically  confirmed  spontaneous  cases  (serious  and nonserious)  of  daratumumab  received  in  the  global  safety  database  through  01  February  2024.  A separate cumulative review of cases reporting SC administration was also performed.

Of  the  7,838  serious  cases,  960  (12.2%)  reported  1,445  serious  events  with  SC  administration  of daratumumab. The most frequently reported serious PTs ( ≥ 2% of the reported serious events) involving the  SC  administration  of  daratumumab  were  Neutropenia  (5.0%;  72/1,445),  Plasma  cell  myeloma (4.7%; 68/1,445), Pneumonia (3.0%; 43/1,445), Thrombocytopenia (2.8%; 41/1,445), Infusion related reaction (2.5%; 36/1,445), and Neuropathy peripheral (2.4%; 34/1,445).

The cumulative review of the post-marketing spontaneous cases through 01 February 2024 revealed that based on the most commonly reported events, serious events, and fatal events, the post-marketing experience  of  daratumumab  SC  remained  generally  consistent  with  the  overall  post-marketing experience.

No new safety signals were identified from the cumulative review of post-marketing spontaneous cases, both overall and separately for SC daratumumab. The post-marketing experience was consistent with the known safety profile of daratumumab or clinical experience of the population under treatment.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

The Safety Analysis Set includes all patients that received at least one dose of any study treatment in study MMY3019 (Cepheus) corresponding to a total of 392 participants (D-VRd: 197; VRd: 195). It also includes patients that were eligible for ASCT but opted out (n=53 in each arm corresponding to 27%).

Generally, demographic and baseline characteristics were balanced between the two treatment arms and did not favour the D-VRD arm. In the D-VRd the median number of treatment cycles was 59 (1-71) and the median duration of treatment was 56 months, whereas in the VRd arm the median number of treatment cycles was 37 (1-70) and the median duration of treatment was 34 months corresponding to a difference of 22 months for the median duration of treatment. Bortezomib was given for 8 3-week cycles and daratumumab (in the D-VRd arm), lenalidomide and dexamethasone continued until disease progression or unacceptable toxicity.

## Adverse events

Several of the most frequent TEAEs are considered related to one of the VRd components (diarrhoea, sensory  neuropathy,  oedema  peripheral,  constipation,  insomnia,  fatigue)  and  also  the  disease  itself (infections), whereas cytopenias are considered related both to VRd and to daratumumab as there is a higher  frequency  in  the  D-VRD  arm  compared  to  the  VRd  arm  [(neutropenia  55.8%  and  39.0%, respectively and for thrombocytopenia (46.7% and 33.8%, respectively)].

The  most  pronounced  differences  between  the  two  arms  in  relation  to  Grade  3-4  TEAEs  were  for Neutropenia  (D-VRd:  44.2%;  VRd:  29.7%),  Thrombocytopenia  (D-VRd:  28.4%;  VRd:  20.0%), Hypokalaemia (D-VRd: 12.2%; VRd: 6.2%), and COVID-19 (D-VRd: 11.2%; VRd: 4.6%).

The incidence of Grade 5 AEs was higher in the D-VRd arm compared with the VRd arm (D-VRd: 16.8%; VRd: 10.8%). Longer exposure in D-VRd arm compared to the VRd arm (+22 months) as well as longer time during the COVID-19 epidemic for the D-VRd arm due to this longer exposure, is considered to account for a major part of this difference.

The main differences in the frequency of SAEs by SOC were seen in the SOCs Infections and infestations (D-VRd; 39.6% vs VRd; 35.4%) with COVID-19 (including COVID-19 pneumonia) being more frequent in the D-VRd arm; 15.3% vs 10.3%.

A  review  of  safety  data  in  the  CEPHEUS  study  identified  new  ADR  terms  of  abdominal  pain  and hypokalaemia which are now included in Section 4.8 of the SmPC.

Abdominal  pain  was  higher  in  the  D-VRD  arm  compared  to  the  VRD  arm  (15.7%  and  10.3%, respectively). The corresponding frequencies of Grade 3-4 AE (1.0% and 1.5%, respectively) and SAE (0.5% and 1.5%, respectively) were low and comparable between the two arms. No patients in either arm discontinued due to abdominal pain.

Hypokalaemia was higher in the D-VRD arm compared to the VRD arm (29.4% and 12.8%, respectively). These events could be secondary to gastrointestinal ADRs of daratumumab (e.g., vomiting, diarrhoea). The  corresponding  Grade  3-4  AE  frequencies  were  12.2%  and  6.2%.  Serious  hypokalaemia  was comparable between the two arms; D-VRD 2.5% and VRd: 1.5%.

## Adverse Events of Special Interest

Systemic Administration-related Reactions (sARR=IRR) occurred with a relatively low frequency of 3.6% with the highest grade being grade 3 occurring in one patient.

Local injection site reactions were reported in 12.2% of patients in the D-VRd arm and were grade ≤2.

Cytopenia were seen more frequently in the D-VRd arm. The use of G-CSF was almost twice as high in the D-VRd arm compared to the VRd arm (43.7 vs 24.7%, respectively). Despite a frequency of 28.4%

<div style=\"page-break-after: always\"></div>

of thrombocytopenia in the D-VRd arm (20.0% in the VRd arm) grade 3-4 haemorraghe was low: 3.0% vs 1.5%.

Infections and Infestations by SOC were observed with a higher frequency in the D-VRd arm compared to the VRd arm (Grade 3-4; 40.1% and 31.8%, respectively). Particularly COVID-19 was more frequent in the D-VRd arm. Longer exposure in D-VRd arm compared to the VRd arm (+22 months) as well as longer time during the COVID-19 epidemic for the D-VRd arm due to this longer exposure, is expected to account for a major part of this difference. The frequencies of opportunistic infections were low and comparable.

Peripheral sensory neuropathy was comparable between the arms and is considered due to bortezomib.

The  only  Grade  3  or  4  chemistry  laboratory  abnormalities  reported  at  a  frequency ≥ 10% in  either treatment arm were hyponatremia (D-VRd 18.0% and VRd 12.9%) and hypokalaemia (D-VRd 19.1% and VRd 12.4%). Hypokalaemia (in the SOC Metabolism and nutrition disorders) has been added as a new ADR.

## Safety in special populations

The incidence of Grade 3 or 4 TEAEs was not increased in the 2 older subgroups (65 to &lt;70 years and ≥ 70 years) compared with the &lt;65 years age subgroup in the D-VRd arm and was similar in the 2 older subgroups and higher than the &lt;65 years age subgroup in the VRd arm.

The incidence of SAEs was higher in the ≥70 years age subgroup compared with the other subgroups in the D-VRd arm and was higher in the 2 older subgroups compared with the youngest subgroup in the VRd arm.

In the context of the current indication (ASCT ineligible) it is important to be able to evaluate adverse events in the various age groups given that 27% of the patients (in each arm) were eligible for transplant, and age is one of the main modifiers of eligibility for ASCT. A post-hoc analysis of safety in the two treatment arms in true ASCT-ineligible patients revealed no new concerns compared to the overall safety population.

AEs leading to discontinuation of all study treatment were higher in the VRd arm compared to the D-VRd arm (all grades 15.9% and 7.6%, and grade 3-4 9.7% and 4.6%, respectively). The difference was especially pronounced with regards to peripheral neuropathy (sensory and sensorimotor) with 4.1% of events in the VRd arm and 0.5% in the D-VRd arm regards to peripheral neuropathy are based on small numbers and are not considered clinically meaningful.

## 2.5.2. Conclusions on clinical safety

The safety profile of daratumumab in study MMY3019 is considered to be consistent with the known safety profile for SC daratumumab in combination with VRd and manageable also in patients with NDMM ineligible for treatment with ASCT. Review of the safety data from this study identified new ADR terms of abdominal pain and hypokalaemia, which are now included in the product information.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

The MAH submitted to submit an updated RMP version 11.1 with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 11.1 is acceptable.

The CHMP endorsed the Risk Management Plan version 11.1 with the following content:

## Safety concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                                                            |
|------------------------------|---------------------------------------------------------------------------------------|
| Important identified risks   | Interference for blood typing (minor antigen) (positive indirect Coombs' test)        |
| Important identified risks   | Hepatitis B virus reactivation                                                        |
| Important potential risks    | None                                                                                  |
| Missing information          | Use in patients with AL amyloidosis who have pre-existing serious cardiac involvement |

## Pharmacovigilance plan

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                           | Summary of Objectives                                                                                                                                                                                                                                        | Safety Concerns Addressed                                                             | Milestones                                                    | Due Dates                                                     |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                          | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                | Category 3 - Required additional pharmacovigilance activities                         | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| A multicenter prospective study of daratumumab- based therapy in patients with newly diagnosed AL amyloidosis. Ongoing | Primary objective is to further characterize cardiac adverse events in patients with newly diagnosed AL amyloidosis treated with subcutaneous daratumumab-based therapy in terms of the incidence, severity, clinical presentation, management, and outcome. | Use in patients with AL amyloidosis who have pre-existing serious cardiac involvement | Draft Protocol: Interim report: Final report:                 | Aug 2021 2 nd Quarter 2024 1 st Quarter 2026                  |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

## Summary Table of Risk Minimisation Activities

| Safety Concern                                                                        | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Interference for blood typing (minor antigen) (positive indirect Coombs' test)        | Routine risk minimization measures: • SmPC Section 4.4, which advises that patients should be typed and screened, and phenotyping or genotyping be considered prior to starting daratumumab treatment; • SmPC Sections 4.4, which advises HCPs to notify blood transfusion centers of this interference with indirect antiglobulin tests in the event of a planned transfusion; • SmPC Section 4.4, which recommend that if an emergency transfusion is required, non-cross-matched ABO/RhD compatible RBCs can be given per local blood bank practices; • SmPC Section 4.5, which recommend mitigating daratumumab interference by treating reagent RBCs with DTT to disrupt daratumumab binding or other locally validated methods, and that Kell negative units should be supplied after ruling out or identifying alloantibodies using DTT treated RBCs; • PL Section 2, which instructs patients to inform the person doing the blood test to match blood type that they are receiving treatment with daratumumab. Additional risk minimization measures: • Distribution of educational materials and Patient Alert Cards to HCPs and blood banks as described in the PL, in Annex II, D. |
| Hepatitis B virus reactivation                                                        | Routine risk minimization measures: • SmPC Section 4.8 and PL Section 4; • SmPC Section 4.4 and PL Section 2, which advise HBV screening before initiation of treatment with daratumumab and to monitor for clinical and laboratory signs of HBV reactivation during and for at least 6 months following the end of daratumumab treatment for patients with evidence of positive HBV serology; • SmPC Section 4.4, which advises to manage patients according to current clinical guidelines, and to consider consulting a hepatitis disease expert as clinically indicated; • SmPC Section 4.4, which advises to suspend treatment with daratumumab and to institute appropriate treatment in patients who develop reactivation of HBV while on daratumumab. Resumption of daratumumab treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV; • PL Section 2, which includes a warning to patients with history or current HBV infection; Additional risk minimization measures: • Distribution of a DHPC to HCPs who prescribe daratumumab was issued in the EU member states in June 2019.               |
| Use in patients with AL amyloidosis who have pre-existing serious cardiac involvement | Routine risk minimization measures: • SmPC Section 5.1. Additional risk minimization measures: • None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

Key: AL amyloidosis = light chain amyloidosis; DHPC = Direct Healthcare Professional Communication; DTT = dithiothreitol; HBC = hepatitis B virus; HCP = healthcare professional; PL = package leaflet; RBC = red blood cell; SmPC = Summary of Product Characteristics.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

In addition, the list of local representatives in the PL has been revised to amend contact details for the representative(s) of Germany and Slovenia.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and was found acceptable for the following reasons:

With the currently proposed indication extension, minimal changes have been introduced to the package leaflet  and  the  proposed  changes  reflect  language  and  a  format  that  is  consistent  with  that  in  the currently approved leaflet. The use of lay language for additional symptoms and side effects is consistent with the current approved leaflet.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Multiple  myeloma  is  a  malignant  disorder  of  the  plasma  cells,  characterized  by  uncontrolled  and progressive proliferation of a plasma cell clone. The clinical presentation is characterized by osteolytic lesions, usually in the pelvis, spine, ribs, and skull. Lesions are caused by expanding plasmacytomas or by cytokines secreted by myeloma cells that activate osteoclasts and suppress osteoblasts. Increased bone loss may also lead to hypercalcemia. Solitary extraosseous plasmacytomas are unusual but may occur in any tissue. In many patients, renal failure is present at diagnosis or develops during the course of the disorder and is caused by the deposition of light chains in the distal tubules or by hypercalcemia. Patients also often develop anaemia due to kidney disease or suppression of erythropoiesis by cancer cells. These signs and symptoms are commonly denoted by the mnemonic acronym CRAB (Calcemia, Renal damage, Anaemia, Bone lesions).

The  MAH submitted an application  to  remove  the  transplant  eligibility  requirement  in  the  approved indication of DARZALEX 1800 mg solution for injection in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (SCT).

The proposed modified indication for multiple myeloma is:

DARZALEX  is  indicated  in  combination  with  bortezomib,  lenalidomide  and  dexamethasone  for  the treatment of adult patients with newly diagnosed multiple myeloma.

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Patients with NDMM are typically categorized as 'transplant-eligible' or 'transplant-ineligible' (TIE). For patients not considered eligible for high-dose chemotherapy and ASCT (TIE) or for whom transplant was not  planned  as  initial  therapy,  the  current  standard  of  care  is  longer-term  treatment  with  triplet  or quadruplet combinations. Current frontline standards of care recommended for these patients in the EHA-ESMO Guideline include D-Rd, VRd, D-VMP, VMP, and Rd, commonly on a treat-to-progression or unacceptable toxicity basis (Dimopoulos 2021).

Over the past two decades, the introduction of new classes of drugs, such as PIs, IMiDs and anti-CD38 antibodies, have changed the management of frontline treatment in both transplant eligible and ineligible candidates.  Despite  the  significant  progress  that  has  been  made  in  the  management  of  multiple myeloma,  the  disease  relapses  and  it  remains  an  incurable  malignancy.  Therefore,  new  treatment options and combinations directed at alternative mechanisms of action are needed for these patients.

## 3.1.3. Main clinical studies

Study MMY3019 (CEPHEUS) is a randomised (1:1), open-label, multicentre, Phase 3 study that evaluated the efficacy and safety of daratumumab SC in combination with D-VRd vs VRd in participants with NDMM for whom ASCT was not planned as initial therapy.

The primary endpoint was overall MRD negativity rate defined as the proportion of ITT subjects who have achieved MRD negative status (at 10-5) by bone marrow aspirate after randomization and prior to progressive disease (PD) or subsequent anti-myeloma therapy. The key secondary endpoints were PFS by computerised algorithm (assessed by 2011 IMWG criteria), overall CR or better rate and sustained MRD negativity rate.

At randomization, participants were stratified by ISS stage (I, II, or III) and age/transplant eligibility (&lt;70 years ineligible, or &lt;70 years and refusal to transplant [meaning transplant was not planned as initial therapy], or ≥70 years).

## 3.2. Favourable effects

At the primary MRD analysis (08 April 2021), with a median follow-up of 22.3 months, the addition of daratumumab SC to VRd resulted in a statistically significant  improvement  in  the  primary  endpoint overall MRD negativity rate as measured by NGS for participants achieving CR or better compared with VRd  alone,  with  an  absolute  increase  of  17.9%  favouring  D-VRd  (D-VRd:  105  (53.3%);  VRd:  70 (35.4%); OR=2.07 with 95% CI: 1.38, 3.10; 2-sided p=0.0004).

The primary endpoint was supported by key secondary endpoint PFS. As of the interim PFS analysis cutoff date (08 SEP 2022), with a median follow-up of 39.0 months, a total of 113 PFS events were observed (D-VRd: 46 [23.4%]; VRd: 67 [33.8%]) corresponding to a maturity of 28.6% PFS events (113/395). The addition of daratumumab to VRd resulted in a statistically significant improvement in the key secondary endpoint of PFS with a HR of 0.61 (95% CI: 0.42, 0.90; 2-sided p=0.0104) crossing the prespecified 2-sided stopping boundary of 0.0145 in favor of the D-VRd arm). Efficacy in the claimed indication was further supported by two other key secondary endpoints: Overall CR rate or better and sustained MRD negativity rate. Both endpoints favoured D-VRd treatment over VRd treatment. With a total of 111 deaths (D-VRd: 51; VRd: 60), the median OS was not reached for either treatment arm.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

Whether MRD negativity can be considered a validated trial level surrogate marker for PFS in NDMM is yet to be robustly confirmed (Landgren, Blood, 2024; Paiva, Blood Adv, 2023; Ficek, Clin lymp myel leuk, 2023). Currently, MRD negative CR is not considered a clinical benefit per se but a mechanistic endpoint which has individual prognostic value based on different meta-analyses. This uncertainty however is negated by the improvement in PFS, a time-to-event endpoint.

OS data are immature. Furthermore, whether the PFS benefit will translate into OS superiority from DVRd vs VRd is also doubtful, since it is likely that many patients randomised to the VRd arm will receive daratumumab  in  subsequent  treatment  lines,  confounding  OS  analysis.  The  CHMP  nevertheless recommended that the MAH submits the final OS analysis when available.

## 3.4. Unfavourable effects

The main safety concerns associated with daratumumab use are cytopenias and infections.

The  most  pronounced  differences  between  the  two  arms  in  relation  to  Grade  3-4  TEAEs  were  for Neutropenia  (D-VRd:  44.2%;  VRd:  29.7%),  Thrombocytopenia  (D-VRd:  28.4%;  VRd:  20.0%), Hypokalemia (D-VRd: 12.2%; VRd: 6.2%), and COVID-19 (D-VRd: 11.2%; VRd: 4.6%).

The incidence of Grade 5 AEs was higher in the D-VRd arm compared with the VRd arm (D-VRd: 16.8%; VRd: 10.8%). Longer exposure in D-VRd arm compared to the VRd arm (+22 months) as well as longer time during the COVID-19 epidemic for the D-VRd arm due to this longer exposure, is considered to account for a major part of this difference.

The main differences in the frequency of SAEs by SOC were seen in the SOCs Infections and infestations (D-VRd; 39.6% vs VRd; 35.4%) with COVID-19 (including COVID-19 pneumonia) being more frequent in the D-VRd arm; 15.3% vs 10.3%.

## 3.5. Uncertainties and limitations about unfavourable effects

The AEs related to non-ASCT eligibility are diluted by the fact that 27% of patients in each arm were considered eligible for ASCT, for which the D-VRd regimen already is approved. However, a post-hoc analysis of safety in the two treatment arms in true ASCT-ineligible patients revealed no new concerns compared to the overall safety population.

The COVID-19 epidemic had a negative impact on safety, which possibly impacted more the D-VRd arm due to the longer exposure of treatment compared to the control arm.

## 3.6. Effects Table

Table 1. Effects Table for Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the treatment of NDMM (data cut-off: 07 May 2024).

| Effect             | Short description                                                       | Unit               | D-VRd n=197        | VRd n=198          | Uncertainties / Strength of evidence                                                  | References         |
|--------------------|-------------------------------------------------------------------------|--------------------|--------------------|--------------------|---------------------------------------------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects                                                      | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                                                                    | Favourable Effects |
| PFS                | Time from randomisati on to first disease progression (according to the | N %                | 46 23.4%           | 67 33.8%           | SoE: HR 0.61 95% CI: 0.42, 0.90 MRD negativity 10 -5 : OR: 2.07%; 95% CI: 1.38, 3.10. | CEPHEUS            |

<div style=\"page-break-after: always\"></div>

| Effect             | Short description          | Unit   | D-VRd n=197   | VRd n=198   | Uncertainties / Strength of evidence           | References   |
|--------------------|----------------------------|--------|---------------|-------------|------------------------------------------------|--------------|
|                    | IMWG response criteria) or |        |               |             |                                                |              |
| Unfavourable       | death                      |        | D-VRd         | VRd         |                                                |              |
|                    | Effects                    |        |               | n=195       |                                                |              |
|                    |                            |        | n=197         |             |                                                |              |
| Death              | Due to AE                  | %      | 18.8          | 12.8        |                                                |              |
| Neutropenia        | Any AE Grade 3-4           | % %    | 56.9 45.2     | 39.0 29.7   | Growth factor use: 43.7% (D-VRd) 24.7% (VRd)   | CEPHEUS      |
| Thrombo- cytopenia | Any AE Grade 3-4           | % %    | 46.7 28.4     | 33.8 20.0   | Grade haemorrhage: 3.0% (D-VRd) and 1.5% (VRd) |              |
| SOC Infections     | Grade 3-4                  | %      | 40.1          | 31.8        | +22 months exposure in the D-VRd arm.          |              |

Abbreviations: D= daratumumab; VRd= bortezomib, lenalidomide and dexamethasone; PFS = Progression free survival; IMWG= International Myeloma Working Group; HR = Hazard ratio; OR = Odds ratio; CI = Confidence Interval, CR: Complete response; MRD: Minimal residual disease

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Results showed that the addition of daratumumab to VRd treatment in patients with newly diagnosed multiple myeloma who are not eligible for treatment with ASCT resulted in a statistically significant improvement in PFS.  This is further supported by the primary endpoint of the study which also showed a statistically significant improvement in overall MRD negativity as well as in overall CR or better rate and sustained MRD negativity rate. These improvements are considered clinically meaningful. OS data are immature but do not show any sign of detriment in the experimental arm.

The safety profile is in general as expected in the context of the patient population, the backbone therapy and the known safety profile of daratumumab SC. New ADRs which were identified in patients with NDMM ineligible for treatment with ASCT have been added to the product information. Existing warnings in the product information and additional risk minimisation measures are considered adequate to manage the knowns risks associated with daratumumab use in the new target population.

## 3.7.2. Balance of benefits and risks

The benefit-risk balance of D-VRd in the proposed patient population is positive, since the demonstrated clinically relevant benefits of D-VRd for the treatment of adult patients with newly diagnosed multiple myeloma that are not eligible for autologous stem cell transplant are considered to outweigh the toxicity of  the  combination, which is considered generally acceptable and manageable in the current clinical setting.

## 3.8. Conclusions

The overall B/R of Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the

<div style=\"page-break-after: always\"></div>

treatment of adult patients with newly diagnosed multiple myeloma is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Darzalex in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma and who are ineligible for stem cell transplant (SCT), based on the results from Study CEPHEUS (54767414MMY3019), a randomised, open-label, active-controlled, multi-centre phase 3 study.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Darzalex is not similar to Talvey, Carvykti, Abecma, Farydak, Ninlaro and Kyprolis within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Darzalex-EMEA/H/C/004077/II/76'.